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Acute traumatic coagulopathy (ATC) is seen in 30% to 40% of severely 
injured civilian and military casualties.  Early use of blood products 
attenuates ATC, but the timing for optimal effect is unknown.  Emergent 
clinical practice has started pre-hospital deployment of blood components 
(combined packed red blood cells [PRBC] and fresh frozen plasma [FFP]), 
but this is associated with significant logistical burden and some clinical risk.  
It is therefore imperative to establish whether pre-hospital use of blood 
products is likely to confer benefit.  This study compared the potential 
impact of pre-hospital resuscitation with blood components versus 0.9% 
saline in a model of severe injury.  
 
Terminally anaesthetised Large White pigs received controlled soft tissue 
blunt injury, controlled haemorrhage (35% blood volume) with or without a 
primary blast injury followed by a 30-min shock phase.  The animals were 
allocated randomly to one of the two injury arms (blast or sham blast).  
Within each injury arm the animals were allocated randomly to one of two 
treatment groups as follows: the shock phase was followed by a 60-min pre-
hospital evacuation phase; comprising hypotensive resuscitation (target 
systolic arterial pressure 80 mmHg) using either 0.9% saline or blood 
components (PRBCs:FFP in a 1:1 ratio).  Following this phase, an in-
hospital phase involving resuscitation to a normotensive target (110 mmHg 
systolic arterial blood pressure) using PRBCs:FFP was performed in all four 
groups.  A coagulopathy developed in both pre-hospital saline groups 
(increase in TEG [thromboelastography] R and K times and aPTT [activated 
partial thromboplastin time]) that persisted for 60 to 90 minutes into the in-
hospital phase.  The coagulopathy was attenuated in the pre-hospital blood 
component groups.  Pre-hospital blood component resuscitation may 






Table of Contents 
 
 
Abstract         i 
Table of Contents        ii 
Declaration         x 
Statement of Copyright       x 
Acknowledgments        xi 
Dedications         xii 
Publications and Presentations      xiii 
 Publications        xiii 
 Presentations        xiv 
List of Abbreviations         xv 
Chapter 1.  Introduction       1 
Chapter 2. Military Resuscitation Strategies    6 
 2.1 Counterterrorism Campaign     6 
 2.2 Military Trauma Care      6 
  2.2.1 Damage Control Resuscitation    8 
  2.2.2 Hypotensive Resuscitation    9 
  2.2.3 Haemostatic Resuscitation    15 
  2.2.4 Coagulation Support     16 
  2.2.5 Restoration of Tissue Perfusion    18 
 2.3 Military Pre-Hospital Trauma Care    19 
 2.4 Military Pre-Hospital Resuscitation    20 
  2.4.1 Pre-hospital Blood Components    22 
Chapter 3. Ballistic and Civilian Injuries     27 
 3.1 Introduction       27 
 3.2 Civilian Terrorist Injuries     29 
 3.3 Civilian Trauma Injuries      30 
 3.4 Physical Impact of Penetrating Injury    31 
 3.5 Physical Impact of Ballistic Injuries    31 
	
iii	
 3.6 Physical Impact of Explosions     34 
3.6.1 The Physics of Explosions    34 
3.6.2 Primary Blast Injury     37 
3.6.3 Primary Blast Injury - Blast Lung    38 
3.6.4 Primary Blast Injury - Cardio-respiratory  
Response to Blast  39 
3.6.5 Secondary Blast Injuries    39 
3.6.6 Tertiary Blast Injuries      39 
3.6.7 Quaternary Blast Injuries    40 
3.7 Physical Impact of Blunt Injury     40 
3.8 Cardiovascular Response to Haemorrhage   41 
3.8.1 Simple Haemorrhage     41 
3.8.2 Delayed Cardiovascular Response to Haemorrhage 43 
3.8.3 Experimental Studies     44 
3.9 Cardiovascular Response to Haemorrhage and Injury  46 
3.10 Cardiovascular Response to Haemorrhage and Blast  47 
3.11 Helmand Casualties      48 
Chapter 4. Haemostasis       51 
4.1 Introduction       51 
4.2 Vasoconstriction      52 
4.3 Platelets       52 
4.3.1 Platelet Adhesion     53 
4.3.2 Platelet Activation     54 
4.3.3  Platelet Aggregation     55 
4.4 Coagulation Cascade      55 
4.4.1 Tissue Factor       55 
4.4.2  Classic Clotting Cascade    55 
4.5 Cell Based Coagulation      57 
4.5.1 Thrombin      58 
4.5.2 Initiation      58 
	
	 iv	
4.5.3  Amplification      58 
4.5.4 Propagation        59 
4.6 Anti-coagulation      60 
4.6.1 Tissue Factor Pathway Inhibitor    61 
4.6.2 Antithrombin      61 
4.6.3 Protein C and S      61 
4.7 Fibrinolysis       63 
4.7.1 Fibrinolysis Inhibition     63 
4.8 Coagulopathy       65 
4.9 Trauma Induced Coagulopathy     66 
4.10 Acute Traumatic Coagulopathy     69 
4.10.1 Pathophysiology of ATC    70 
4.10.2 Endothelial Glycocalyx     71 
4.10.3 Hypoperfusion and the Role of APC   74 
4.10.4 Fibrinolysis      76 
4.10.5 Platelet Dysfunction     79 
4.11 Resuscitation Associated Coagulopathy    81 
4.11.1 Consumption      81 
4.11.2 Haemodilution      82 
4.11.3 Anaemia      83 
4.11.4 Hypothermia      83 
4.11.5 Acidosis       85 
4.11.6  Immune System Activation       87 
4.12 Coagulation Summary       89 
Chapter 5. Diagnostic Equipment      90 
5.1 Introduction       90 
5.2 Acid Base Balance      91 
5.3 Assessment of Coagulation      92 
5.4 Routine Laboratory Testing     93 
5.5 Whole Blood Tests      93 
	
v	
5.5.1 Bleeding Time      93 
5.5.2 Activated Clotting Time (ACT)        94 
5.6 Plasma Tests       95 
5.6.1 Activated Partial Thromboplastin Time (aPTT)  95 
5.6.2 Prothrombin Time (PT)     96 
5.7 Platelet Tests       97 
5.7.1 Platelet Count      97 
5.7.2 Platelet Function     97 
5.8 Fibrinogen Tests       100 
5.8.1 Fibrinolysis      100 
5.8.2 Fibrinogen Levels     100 
5.9 Coagulation Tests in Trauma Management   102 
5.10 Modern Whole Blood Testing     103 
5.11 Viscoelastic Coagulation Testing    104 
5.11.1 TEG® 5000 Thromboelastograph® Haemostasis  
Analyzer System 105 
5.11.2 ROTEM® delta Haemostasis Analyser    108 
5.11.3 ROTEM Assays     112 
5.12 Viscoelastic Interpretation      114 
5.12.1 Abnormal Temograms     115 
5.12.2 Prolonged Clotting Time    115 
5.12.3 Maximum Clot Firmness    117 
5.12.4 Fibrinolysis      118 
5.13 Limitations to Visco-elastic Testing      119 
5.13.1 Initiators      119 
5.13.2 Clinical       119 
5.13.3 Experimental      120 
5.14 Use of ROTEM and TEG in Trauma    120 
5.15 Viscoelastic Equipment Development    123 
5.16 Equipment Summary      124 
	
	 vi	
Chapter 6. Resuscitation Fluids      125 
 6.1 Introduction       125 
6.2 Non-Blood Component Fluids     125 
6.2.1 Crystalloids       126 
6.2.2 Colloids      129 
6.2.3 Hypertonic Saline      133 
6.2.4 Hypertonic Saline Dextran    137 
6.3 Blood and Blood Components     138 
6.3.1 Packed Red Blood Cells    139 
6.3.2 Fresh Frozen Plasma     141 
6.3.3 Packed Blood Red Cell: Fresh Frozen Plasma Ratios 144 
6.3.4 Platelets      151 
6.3.5 Cryoprecipitate      154 
6.3.6 Fibrinogen Concentrate     157 
6.3.7 Freeze Dried Plasma     160 
6.3.8 Whole Blood      163 
6.4 Transfusion Adjuncts      164 
6.4.1 Tranexamic Acid     164 
6.4.2 Recombinant Activated Factor Seven   167 
6.5 Resuscitation Fluid Summary     168 
Chapter 7. Hypothesis, Aims and Methods    170 
7.1 Introduction       170 
7.1.1 Animal Models of Haemorrhage and Coagulopathy 170 
7.1.2 Requirements of Model     172 
7.1.3 Dstl Animal Model     173 
7.1.4 Animal Model for Shock, Haemorrhage and     
Acute Coagulopathy of Trauma  174 
7.2 Hypothesis        175 
7.3 Outcomes       176 
7.3.1 Primary Outcome     176 
	
vii	
7.3.2 Secondary Outcomes     176 
  7.3.3 Tertiary Outcome     176 
7.4 Study Design       176 
7.5 Experimental Protocol      178 
7.6 Licensing and Animal Husbandry    179 
7.7 Blood bank        179 
7.8 Initial Anaesthesia and Surgical Preparation    182 
7.8.1 Anaesthesia      182 
7.8.2 Surgical Preparation     183 
7.9 Animal Assessment Methods     186 
7.9.1 Cardiovascular Measurements    186 
7.9.2 Blood Gas Analysis     187 
7.9.3 Coagulation and Haematology     188 
7.9.4 Pre-injury Baseline Measurements   188 
7.10 Wounding Phase      189 
7.10.1 Blast Arena      189 
7.10.2 Blast Exposure      190 
7.10.3 Post-blast      191 
7.10.4 Tissue Blunt Injury      191 
7.10.5 Controlled Haemorrhage    193 
7.11 Shock Phase        193 
7.12 Pre-Hospital Phase       193 
7.13 Early In-Hospital Phase.      194 
7.14 Late In-Hospital Phase      194 
7.15 Study End       195 
7.15.1 Post-Mortem Examination    195 
7.16 Statistics       196 
Chapter 8. Results       198 
8.1 Introduction       198 
8.2 Baseline Results – Sham Blast Groups    198 
	
	 viii	
8.3 Injury Period – Sham Blast Groups    201 
8.3.1 Coagulation      201 
8.3.2 Physiology      201 
8.3.3 Haematology      207 
8.3.4 Fluids       207 
8.3.5 Biochemistry       208 
8.4 Primary Treatment Period – Sham Blast Groups   209 
8.4.1 Coagulation       210 
8.4.2 Physiology      214 
8.4.3 Haematology      218 
8.4.4 Fluids       219 
8.4.5 Biochemistry      221 
8.5 Final Treatment Period – Sham Blast Groups   222 
8.5.1 Coagulation       222 
8.5.2 Physiology      230 
8.5.3 Haematology      234 
8.5.4 Fluids       235 
8.5.5 Biochemistry      237 
8.6 Baseline Results – Blast Groups    238 
8.7 Injury Period – Blast Groups     238 
8.7.1 Coagulation      238 
8.7.2 Physiology      242 
8.7.3 Haematology      245 
8.7.4 Fluids       246 
8.7.5 Biochemistry       246 
8.8 Primary Treatment Period – Blast Groups   247 
8.8.1 Coagulation       247 
8.8.2 Physiology      253 
8.8.3 Haematology      257 
8.8.4 Fluids       258 
	
ix	
8.8.5 Biochemistry      260 
8.9 Final Treatment Period – Blast Groups    261 
8.9.1 Coagulation       262 
8.9.2 Physiology      268 
8.9.3 Haematology      273 
8.9.4 Fluids       274 
8.9.5 Biochemistry      276 
Chapter 9. Discussion       277 
9.1 Coagulation       277 
9.2 Physiology       279 
9.3 Effect of Blast       282 
9.4 Hypercoagulation      283 
9.5 Comparative Studies      283 
9.6 Model Limitations      285 
9.6.1 Coagulation Differences     285 
9.6.2 Biochemical Differences    286 
9.6.3 Equipment Used     286 
9.6.4 Animal Model      287 
 9.7 Model Improvements      288 
 9.8 Future Studies       288 
 9.9 Summary       289 















This thesis is based on joint research.  Each animal involved in this 
investigation required the concurrent work of at least 8 team members who 
worked on multiple constituent sections including: animal anaesthesia, 
animal monitoring, surgical intervention, blood sampling, management of 
blast, blood gas measurement and coagulation measurement.  The author 
was responsible for sampling and running of all coagulations measurements 






Statement of Copyright 
 
 
The contents include material subject to © Crown copyright (2018), Dstl. 
This material is licensed under the terms of the Open Government Licence 
except where otherwise stated. To view this licence, visit 
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3 
or write to the Information Policy Team, The National Archives, Kew, 
London TW9 4DU, or email: psi@nationalarchives.gsi.gov.uk 
 
The copyright of this thesis rests with the author. No quotation from it should 
be published without the author’s written consent and information derived 












This project is part of a programme of work and research being undertaken 
at Dstl Porton Down where a large team of scientists at the Biomedical 
Sciences department works with dedication and focus to improve the 
medical care of all military casualties; soldiers, sailors and airmen.  I am 
beholden to Dr Emrys Kirkman OBE, a senior scientist and my lead 
supervisor on this project, whose unwavering support has buoyed my work 
from inception to completion; his knowledge, expertise and nagging have 
been invaluable and I will be forever in his debt.  I would also like to thank 
Dr Sarah Watts for her counsel and guidance on veterinary and animal work 
and as a valuable sounding board and second supervisor.  Mr Bob Gwyther 
was a key member of the team and I am very thankful for his exceptional 
effort in providing statistical advice and support during the writing of this 
thesis.  Other special recognition should go to the rest of the team who are 
too many to reference, although special mention goes to Charles Masey 
and Callie Wilson, both of whom have been invaluable on the subjects of 
clotting, coagulation measuring equipment and agriculture.   
 
I am incredibly grateful to Professor Peter Mahoney CBE QHS, who was 
instrumental from the very start of this project and the design of this 
programme of research.  Without his encouragement I would not have 
begun this stimulating journey I am now on. 
 
Finally I must thank my family and friends for their eternal patience and who 
will be glad this thesis is complete.  Their sage advice of “I suggest you just 


































Watts S, Nordmann G, Brohi K, Midwinter M, Woolley T, Gwyther R, 
Wilson C, Poon H, Kirkman E. 
Evaluation of pre-hospital blood products to attenuate acute coagulopathy 
of trauma in a model of severe injury and shock in anaesthetised pigs. 





Nordmann G, Jones A, Park C, Mahoney P. 
The Presence of Acute Traumatic Coagulopathy in Ballistic Casualties in 
the Pre-Hospital Environment. 
European Journal of Trauma and Emergency Surgery (in editorial review). 
 
Woolley T, Thompson P,.., Nordmann G, et al. 
Trauma Hemostasis and Oxygen Research Network position paper on the 
role of hypotensive resuscitation as part of remote damage control 
resuscitation. 
Journal of Trauma and Acute Care Surgery (2018); 84(6) (S1): S3-13.    
 
Nordmann G, Jones A, Park C, Mahoney P. 
Acute Traumatic Coagulopathy is evident on severely injured military 
casualties within 40 minutes of injury. 
Anaesthesia (2016); 71(S2): 68 (Abstract). 
 
Parker P, Nordmann G, Doughty H 
Taking transfusion forward. 
Journal of Royal Army Medical Corps (2015); 161(1): 1 (Editorial). 
 
Tobin J, Nordmann G, Kuncir E. 
Pre-hospital Characteristics of Severely Injured Patients Transported in 
Operation Enduring Freedom / Op Herrick. 
Journal of Special Operations Medicine (2015); 15(3): 72-75. 
 
Curry N, Rourke C, Beer S,…, Nordmann G, et al. 
CRYOSTAT. Early cryoprecipitate for major haemorrhage in trauma: a 
randomised controlled feasibility trial. 
British Journal of Anaesthesia (2015); 115(1): 76-83. 
 
O’Reilly D, Morrison J, Jansen O, Nordmann G, et al. 
Initial UK experience of pre-hospital blood transfusion in combat casualties. 





Nordmann G, Woolley T, Doughty H, et al.  
Deployed Research. 
Journal of Royal Army Medical Corps (2014); 160(2): 92-98. 
 
Lundy J, Oh J, Chung K, Nordmann G et al.  
Frequency and relevance of acute peritraumatic pulmonary thrombus 
diagnosed by computed tomographic imaging in combat casualties. 
Journal of Trauma and Acute Care Surgery (2013); 75 (2S2): S215-20   
 
Keene D, Nordmann G, Woolley T. 
Rotational Thromboelastometry (ROTEM) guided trauma resuscitation. 





The Use of Blood Products in the Pre-hospital Environment. 
International War and Disaster Medicine Conference, Estonia. Nov 17. 
 
Beneficial effects of ‘pre-hospital’ vs immediate ‘in-hospital’ blood products 
during resuscitation in two models of severe military injury.  
Trauma 2015, Gold Coast, Australia. Oct 15. Poster. 
 
Acute Coagulopathy of Trauma is Evident in Severely Injured Military 
Casualties Within 40 Minutes of Injury.  
Trauma 2015, Gold Coast, Australia. Oct 15. 
 
Beneficial Effects of ‘pre-hospital’ vs immediate ‘in-hospital‘ blood products 
during resuscitation in a model of severe military injury. 
International Symposium on Intensive Care and Emergency Medicine, 
Brussels. Mar 15. Poster. 
 
Military Damage Control Resuscitation, What We Do and Why. 
Anesthetic Society of America. Annual Conference, San Diego. Nov 15. 
 
Military Pre-hospital Resuscitation; MERT - Tactical Evacuation from the 
Battlefield. 
Anesthetic Society of America, Annual Conference, San Diego. Nov 15. 
 
Frontline Research and Blood Usage. 
Uniformed Services Society of Anesthesiologists, San Diego. Nov 15. 
 
Damage Control Resuscitation 
Emergency Medicine Section Meeting, Royal Society of Medicine, London. 
Oct 13. 
 
MERT; Bringing Damage Control Resuscitation to the Battlefield 
Confédération Interalliée des Officers Médicaux Réserve, Winter Scientific 









AAGBI  Association of Anaesthetists of GB and Ireland  
α2-AP  α2-Antiplasmin 
ABE  Arterial Base Excess 
ABG  Arterial Blood Gas 
ADP  Adenosine Diphosphate 
ACIT  Activation of Coagulation and Inflammation in Trauma 
ACT  Activated Clotting Time 
ANOVA Analysis of Variance 
APC  Activated Protein C 
APTT  Activated Partial Thromboplastin Time 
ARDS  Acute Respiratory Distress Syndrome 
AT  Antothrombin 
ATC  Acute Traumatic Coagulopathy  
ATLS® Advanced Trauma Life Support 




BCSH  British Committee for Standards in Haematology 
BD  Base Deficit 
BE  Base Excess 
BP  Blood Pressure 




CA 5/10 Clot Amplitude at 5/10 minutes 
CFT  Clot Formation Time 
CGOs  Clinical Guidelines for Operations 
CK  Creatine Kinase 
CMV  Cytomegalovirus 
CO  Cardiac Output 
CO2  Carbon Dioxide 
COX-1 Cyclooxygenase-1  
CPDA  Citrate Phosphate Dextrose Adenine 
CRASH Clinical Randomization of an Antifibrinolytic in Significant  
  Haemorrhage 
CT  Clotting Time 




Da  Daltons 
DAMP  Danger Associated Molecular Pattern 
DCR  Damage Control Resuscitation 
	
	 xvi	
DCS  Damage Control Surgery 
DIC  Disseminated Intravascular Haemorrhage 
DMS  Defence Medical Services 
Dstl  Defence Science and Technology Laboratory 




ECG  Electrocardiogram 
ED  Emergency Department 
ELISA  Enzyme Linked Immunosorbent Assays 
EPCR  Endothelial Protein C Receptor 




FI-XIII  (Clotting) Factors I to XIII 
FIa-XIIIa Activated Factors I to XIII 
FBC  Full Blood Count 
FC   Fibrinogen Concentrate 
FDA  Food and Drug Administration (US) 
FDP  Freeze-Dried Plasma or Fibrinogen Degradation Product 
FDPs  Fibrin Degradation Products 
FiiRST Fibrinogen in the Initial Resuscitation of Severe Trauma  
FlyP  French Lyophilised PLasma 
FFP  Fresh Frozen Plasma 




GP  Glycoprotein  




Hb  Haemoglobin  
Hct  Haemotocrit 
HEMS  Helicopter Emergency Medical Service 
HES  Hydroxyethyl Starch 
HMGB-1 High Mobility Group Box-1 (nuclear protein) 
HR  Heart Rate 
HTS  Hypertonic Saline 




ICP  Intracranial Pressure 
IED  Improvised Explosive Device 
ICU  Intensive Care Unit 
IL  Interleukin 
	
xvii	
INR  International Normalised Ratio 
IQR  Inter Quartile Range 
IRT  Immediate Response Team 




Li/Ly30 Lysis at 30minutes 
LP  Lyophilised Plasma 




MA  Maximum Amplitude 
MAC  Minimum Alveolar Concentration 
MAP  Mean Arterial Pressure 
MATTERS Military Application of Tranexamic Acid in Trauma Emergency 
  Resuscitation 
MCF  Maximum Clot Firmness 
MERT  Medical Emergency Response Team 
MERT-E Enhanced MERT 
ML  Maximum Lysis 
MTF  Medical Treatment Facility 
MT  Massive Transfusion 
MTP  Massive Transfusion Protocol 




NCEPOD National Confidential Enquiry into Patient Outcome and Death 
NHS  National Health Service 
NHSBT NHS Blood and Transplant  
NICE   National Institute for Health and Care Excellence 
NISS  New Injury Severity Score 




O2  Oxygen 
OCS  Open Canalicular System 
OER  Oxygen Extraction Ratio 




PaCO2 Arterial Partial Pressure of CO2 
PaO2   Arterial Partial Pressure of O2 
PAR  Protease Activated Receptor 
PATCH Pre-hospital Antifbrinolytics for Traumatic Coagulopathy and  
  Haemorrhage 
	
	 xviii	
PCC  Prothrombin Complex Concentrate 
PE  Pulmonary Embolus 
PAI-1  Plasmin Activator Inhibitor 1 
POC  Point of Care 
PRBC  Packed Red Blood Cells 
PROMMT Prospective Observational Multicenter Major Trauma   
  Transfusion 
PROPPR  Pragmatic Randomized Optimal Platelet and Plasma Ratios 








RAC  Resuscitation Associated Coagulopathy 
RAF  Royal Air Force 
RAP  Right Atrial Pressure 
RBC  Red Blood Cell 
RCT  Randomised Controlled Trial 
RETIC Reversal of Trauma Induced Coagulopathy 
RISC  Revised Injury Severity Classification 
ROC  Resuscitation Outcome Consortium 
ROTEM® Rotational Thromboelastometry 




SAGM Saline Adenine Glucose Mannitol 
SaO2  Arterial Oxygen Saturation 
SBP  Systolic Blood Pressure 
SEM  Standard Error of Mean 
SIRS  Systemic Inflammatory Response Syndrome 
STAAMP Study of Tranexamic Acid during Air Medical Prehospital  
  Transport 
sVEGFR1 Soluble Vascular Endothelial Growth Factor Receptor 1 




TACO  Transfusion Associated Circulatory Overload 
TAFI  Thrombin Activatable Fibrinolysis Inhibitor 
TARN  Trauma Audit and Research Network 
TBI  Traumatic Brain Injury 
TEG®  Thromboelastograph(y) 
TF  Tissue Factor 
TFPI  Tissue Factor Pathway Inhibitor 
TIC  Trauma Induced Coagulopathy 
TIVA  Total Intra-Venous Anaesthesia 
	
xix	
TM  Thrombomodulin 
TNFα  Tissue Necrosis Factor alpha  
t-PA  Tissue Plasminogen Activator 
TPAI  Tissue Plasminogen Activator Inhibitor 
TRALI  Transfusion-Related Acute Lung Injury 
TRISS Trauma Injury Severity Score 




UK  United Kingdom 




vCJD  Variant Creutzfeldt-Jakob Disease 




WB  Whole Blood  








My stomach lurched into my mouth as we dropped from a great height down 
toward the ground and hopeful cover.  I peered out of the window to see a 
high riverbank above us as we flew towards the incident, hugging the river 
valley and skimming low over the river itself.  Leachy and I spread the 
insulation blanket on the ground ready to receive the casualty; monitoring 
on my right, blood and plasma on my left – already run through the warmer 
– ready to go.  Drug and intubation bags on the seating to my right hand 
side and crucially within reach.  Ventilator and oxygen cylinder on my left.   
 
The other team members worked hard to clear the rear ramp area of bodies 
and equipment.  The previous job had been unpleasant and the mood on 
board was heavy with depression.  They stacked the body bags on the 
starboard side bench to make room for the next set of what we all hoped 
would be live casualties.  I left them to their thoughts, I knew they would 
switch on and be ready for anything when the need arose. 
 
A sharp deceleration and nose up tilt; we were there.  One second we were 
looking back out at the diminishing river valley, green fields and even more 
distant mountains, the next second the ground seemed to tilt beneath us 
and we stared at desert almost touching distance away.  The forward loadie 
opened up the minigun; high pitched rotations, rapidly followed by the low 
timbre of hundreds of rounds towards an unseen enemy.  It stopped as the 
brown out surrounded us; sand kicked up by the landing aircraft’s 
downwash hindered any further vision.  It stops the pilots from knowing 
where the ground is and it floods the rear cabin covering the equipment, 
and us; blinding everyone.  It didn’t stop the enemy though, as we provided 
them with a nice fat target.  I failed to detect the “crack and thump” of 
incoming small arms fire, only seeing the sparks as they hit off what I hoped 
were inessential electrics in the ceiling.  I was yet again, thankful for the 
ballistic protection on the aircraft’s sides. 
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Millsy was off in a shot, in to the murk and cloud of sand to find the 
casualties.  He was back with a team of US Marines carrying two stretchers 
unbelievably quickly; they did not look keen to stay long.  He had done the 
usual excellent job of microsecond triage and they dumped the worst 
casualty with Leachy and I.  A quick thumbs up meant he was happy to 
initially manage the other one by himself.  As soon as the Marines were off 
and clear we immediately lurched skywards.  The minigun opened up again 
and from the corner of my eye an RPG flew past the open rear ramp – how 
close? 
 
The pilots were working hard to avoid small arms fire and RPGs and threw 
the aircraft from one side to the next, as we did what we could to determine 
how our patient was.  At this stage a rough overview was all that was 
possible, at least until they managed to achieve some steady flight.  
Bilateral high lower limb amputee with right arm amputated through the 
humerus.  His left arm was severely damaged with clear open fractures to 
humerus and forearm; I hoped it was salvageable.  There were no obvious 
thoracic or abdominal injuries and the ground medics had tried and failed to 
insert a sternal intra-osseus needle, leaving a distinct subcutaneous 
swelling over the only area I had left as a place for access. 
 
The whites of his eyes stared out of a blackened, filthy face, he couldn’t be 
older than 20.  Unresponsive to voice and pain, he was barely maintaining 
his airway and breathing pattern was intermittent, no more than 3 or 4 a 
minute.  No carotid pulse.  Monitoring failed on blood pressure and oxygen 
saturation but the defibrillator pads picked up a bradycardic trace, with 
occasional ectopics.  He was barely alive; in a low output state due to 
trauma.  Lack of adequate blood to his brain causing reduced 
consciousness, and now his heart was beginning to fail.  He was 
salvageable, but how? 
 
I looked at Leachy who had done his usual superb job of stopping any 
external haemorrhage, first job done.  In his hand was the end of the fluid 
line ready to go.  Replacement of blood volume was crucial and its priority 
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was over and above the airway.  I remembered we had put some Swan 
sheath introducers into the extra kit box; they were the main stay of large 
access in the hospital.  It was his only option.  I amazed myself as to how 
easy it was, putting in at least one a day for the last few weeks probably 
helped, and the vibrations from the aircraft had little impact on finding the 
vessel and the subsequent Seldinger technique.  Not the cleanest central 
access procedure, but life saving, and just in time as he was becoming 
increasingly dysrhythmic.  The team worked hard and unexpected charity 
and help emerged from the cockpit, the RAF padre had been shadowing the 
crew.  He amazed us with; “I’ll hold that blood for you, I used to be an ITU 
nurse!” and we had a new crucial team member.  4 units of blood and 
plasma, intubation, ventilation, (a little) anaesthesia and a 20-minute flight is 
easily written but the memory of that flight, the pile of bodies laid out at the 
back of the cabin, and the fight for his life is etched in my memory.  
 
Having handed over an alive, tachycardic patient with a femoral pulse to the 
trauma team, we pondered exhaustion and sorting out sand covered kit.  
We talked through the resuscitation and discussed where we could have 
improved.  There is no possible way litres of crystalloid would have had the 
same effect.  Blood products were an essential, integral part of what kept 
that boy alive, but mounting pressure was on us to stop taking it forward out 
of the hospital – to reduce wastage and perceived potential risks of giving it 
to patients outside of the hospital environment.  That debate would have to 
wait for another time though as we got the next call out, “IED, Sangin, 2 
casualties. MERT to flight line”. (Nordmann 2010). 
 
Worldwide trauma is a major public health problem accounting for nearly 6 
million deaths annually (WHO 2010).  In England and Wales approximately 
16,000 people per annum die following serious injury (ONS 2018).  During 9 
years of conflict in Iraq and Afghanistan over 2,000 service personnel were 
injured in hostile action, 65% of which were from explosions (Penn-Barwell 
2015).  Uncontrolled post-traumatic bleeding is the leading cause of 
potentially preventable death among injured civilian patients (Cothren 2007) 
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with exsanguinating haemorrhage causing approximately 50% of those 
military casualties who die as a result of ballistic injuries (Champion 2003).   
 
One third of all severely injured civilian trauma patients have abnormal 
clotting (Brohi 2003, Maegele 2007, Frith 2010) and the prevalence of this 
increases to almost 40% in trauma caused by ballistic and blast injuries 
(Woolley 2013).  The early clotting abnormality found in trauma casualties, 
termed the Acute Traumatic Coagulopathy (ATC), has been found to be 
associated with an approximately 50% mortality in addition to larger 
transfusion requirements, septic complications, organ injury and critical care 
stay (Brohi 2003, MacLeod 2003, Maegele 2007).  Management of ATC in 
the UK has improved significantly over the last decade with survival from 
trauma increasing in both UK civilian (Moran 2018) and military patients 
(Penn-Barwell 2015).   
 
The Damage Control Resuscitation (DCR) techniques used within the 
hospital setting to manage these casualties have been well described 
(Holcomb 2007, Jansen 2009).  In Afghanistan they were taken forward 
onto the evacuation aircraft (the Medical Emergency Response Team; 
MERT) with the addition of pre-hospital physicians in 2006 and then blood 
components in 2008.  These changes were driven by expert opinion rather 
than evidence and initial resistance in the clinical community was surprising 
but evident.  Data collection was a challenge in that environment and 
administrative support to studies lacking.  Initial reports struggled to find 
proof of its efficacy and were mostly discursive (Kehoe 2011, Calderbank 
2011) or descriptive (Nordmann 2016).  The exact impact of the pre-hospital 
capability was lacking but there were many aspects to the clinical practice 
that could be attributed to the impact of the MERT – albeit an impact as 
judged by the receiving physicians’ clinical opinion.  
 
In order to isolate and examine the independent effect of pre-hospital blood 
in a military pre-hospital environment, an animal model needed to be used, 
so that the other confounding factors could be standardised.  An existing 
animal model of ballistic trauma in use at the Defence Science and 
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Technology Laboratory (Dstl) Porton Down was adapted to mirror the 
timelines encountered on the patient pathway in Afghanistan and included 
blast and ballistic injury.  
 
The body of work in this thesis explores the background of Acute Traumatic 
Coagulopathy and the use of blood components in the resuscitation of all 
trauma, but particularly military trauma, casualties.  It describes the 
mechanisms and pathophysiology behind wounding in civilian and military 
populations, and the resuscitation regimes used in both domains.  It goes 
onto describe coagulation, the equipment used to evaluate coagulation and 
the coagulopathies observed in trauma patients.  The thesis then describes 
the programme of work undertaken at the Dstl, Porton Down, where an 
animal model of shock, haemorrhage, ballistic injury and blast injury was 
used to determine the effect of different pre-hospital resuscitation regimes.  
For this thesis these resuscitation regimes were pre-hospital saline 
compared to blood and plasma in a ratio of 1:1.  The ultimate aim being to 
determine if a trauma induced coagulopathy is attenuated by the use of pre-
hospital blood component resuscitation.  
 
The work has been approved by the Stakeholders for the Combat Casualty 
Care research programme and endorsed by the Defence Medical Services 
Research Strategy Group. The study was conducted in accordance with the 
Animals (Scientific Procedures) Act 1986 and entailed Ethical Review and 
permission.  The project was forwarded for review to the Home Office 
Inspectorate and a Project Licence was granted, a legal mandatory step for 













2.1  Counterterrorism Campaign 
 
The response of America and its allies to the terrorist attacks of September 
11th, 2001 had far reaching global consequences for security, human rights, 
international law, international co-operation and military conflict.  The 
principal military impact was the American-led, global, multidimensional 
counterterrorism campaign that included within it major wars in Afghanistan 
and Iraq, leading to the longest sustained conflict for the UK and USA, since 
World War 2. 
 
These prolonged conflicts have led a transformation in trauma care in both 
the military (Blackbourne 2012, Butler 2012) and civilian medical 
environments (Howell 2014).  For the UK Armed Forces the focus of the 
military effort was in Helmand Province, Afghanistan and led to casualties 
that were high in number and severity.  There was a significant and 
intensive medical effort to deal with them.  The form of combat changed 
from direct small arms fire to the predominant use of improvised explosive 
devices (IEDs) and in response to this, the medical capability in Helmand 
improved substantially from a small tented medical treatment facility to a 
purpose built trauma hospital (in Camp Bastion) supported by a 24 hour 
pre-hospital evacuation team capable of advanced Damage Control 




2.2  Military Trauma Care 
 
Control of haemorrhage particularly in extremities has been shown to have 
a pivotal role in the management of military casualties, and the ability to 
speedily correct it has had a significant impact on preventable deaths.  Data 
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from Vietnam showed limb wound haemorrhage accounted for more than 
half of all potentially preventable deaths (Bellamy 2005).  More current 
reviews of recent conflicts have estimated that 50% of all potentially 
preventable battlefield deaths are caused by haemorrhage (Champion 
2003).  
 
The UK Defence Medical Services answer to this was the development of 
separate novel haemostatic products during the recent Afghanistan conflict, 
which included new field dressings, active haemostatic agents and self-
applicable tourniquets (Mahoney 2005).  Just as important was the revision 
of the emergency care paradigm to <C>ABC, in recognition that the leading 
cause of combat casualty death is external haemorrhage, where <C> 
stands for catastrophic haemorrhage and its management (Hodgetts 2006).  
The lessons learnt from contingency operations in the 1990s by the USA 
were utilised for this model.  These included a phased methodology of 
trauma care for the military, identified according to tactical threat (Butler 
1996) that commenced with Care Under Fire (ongoing direct threat from 
small arms fire or imminent blast).  Next came Tactical Field Care (threat 
diminished but treatment ongoing in a resource restricted environment) and 
Combat Casualty Evacuation Care (when the casualty is in transit from 
incident to next level of medical care).  In recognition of the importance of 
catastrophic haemorrhage, the <C>ABC algorithm is used in the four stages 
of UK military trauma care.  These four stages represent the increasing 
experience and clinical capability of the successive teams in addition to the 
increasing sophistication of their equipment: Care Under Fire, Tactical Field 
Care, Field Resuscitation (care at the first role of military medical care which 
includes a primary care doctor and medics) and Advanced Resuscitation 
(consultant led teams at a medical treatment facility (MTF)).  
 
Military hospital based trauma care has transformed from Advanced 
Resuscitation into Damage Control Resuscitation (DCR) in recognition of 
the intricate relationship resuscitation and surgery have, in order to save the 
casualty.  Indeed it is now deemed that Damage Control Surgery and 
Resuscitation are not separate entities but concurrent activities, with the 
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resuscitation team’s aim to get the casualty to a normal physiology.  
Damage Control Resuscitation integrates permissive hypotension, 
homeostatic resuscitation and Damage Control Surgery (Jansen 2009) 
within it.  
 
 
2.2.1  Damage Control Resuscitation  
 
Damage control itself is a term borrowed from the Navy where it was used 
to describe the ongoing repair of a damaged ship at sea, in order to reduce 
the size of damage.  Its use was coined for Damage Control Surgery (DCS) 
by military and civilian trauma surgeons and describes the few life saving 
procedures (typically involving an abbreviated laparotomy), that are required 
in order to save the patient’s life (Rotondo 1993).  These are commonly not 
definitive and, like a damaged ship returning to port, the injured patient will 
need definitive surgery and full anatomical reconstruction at a later time 
once their physiology is improved.  Physiology improvement is the 
resuscitation aim and DCS is an integral part of the DCR process. 
 
Damage Control Resuscitation has a number of sub-sets within it and it is 
beyond the scope of this chapter to discuss these all in detail.  Anaesthesia 
provision is a key aspect of any trauma resuscitation, not just in the 
securing of an airway but the method in which anaesthesia is provided for 
surgical intervention and post-operative critical care provision.  The correct 
type and dose of anaesthetic and how this is changed throughout the 
phases and locations of DCR, from Emergency Department (ED) to 
Intensive Care Unit (ICU) through the Operating Room (OR), depend on a 
multitude of factors from type of injury, patient physiology to type of surgical 
procedure required.  It is guided by many factors, some of which are 
discussed further below, but the main aim is facilitating the normalisation of 
physiology and reversing the ongoing pathophysiological processes 
(coagulation and otherwise) caused by the patient’s injury.  The vagaries of 
trauma anaesthesia would easily occupy a 5-day educational course and 
regrettably there are very few peer-reviewed papers that discuss it in detail 
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(Ortega-Gonzalez 2012, Sikorski 2014).  Anaesthesia, imaging, DCS, ICU 
care and many others are all intimately involved and important parts of the 
DCR process but will not be mentioned further. 
 
Initial descriptive papers on DCR; define the initial theories behind it.  
Holcomb (2007) described it as a “proactive early treatment strategy that 
addresses the lethal triad on admission to a combat hospital”.  Hodgetts 
(2007) defined it as a “systematic approach to trauma combining the 
<C>ABC paradigm with a series of clinical techniques from point of 
wounding to definitive treatment in order to minimize blood loss, maximize 
tissue oxygenation, and optimize outcome.” 
 
Fluid resuscitation is one of the features of DCR as is blood pressure 
control and consequently these two aspects are the main goals 
resuscitators concentrate on; Permissive Hypotension and Haemostatic 
Resuscitation.  Many authors include other aspects to DCR, including (and 
not exclusively) rewarming, correction of acidosis and restrictive fluid 
administration (Holcomb 2007, Jansen 2009, Kaafarani 2014).  Rewarming 
is an active and basic part of anaesthesia care, restrictive fluid 
administration is part of hypotensive resuscitation and correction of acidosis 
is one of the main aims of DCR as a whole and will only occur with 
adequate resuscitation (and anaesthetic techniques).  Consequently, these 
won’t be discussed separately.  Many authors and medical practitioners 
discuss Massive Transfusion (MT) as an integral aspect of DCR.  The 
basics of MT are closely related to haemostatic resuscitation and will be 
briefly considered below  
 
 
2.2.2  Hypotensive Resuscitation 
 
Sometimes with the added pronoun of restrictive or permissive, Hypotensive 
Resuscitation is the strategy of restricting fluid administration until 
haemorrhage is controlled, by definitive surgical control or otherwise.  This 
is completed while accepting a limited period of suboptimal end-organ 
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perfusion (Jansen 2009).  The aim is to keep systolic blood pressure below 
normal levels in an attempt to avoid disturbance of any clot formed over the 
injury site, especially within the first hour (Stern 1993).  The key time many 
have used is the first 60 minutes as it is at this time that any undisturbed 
clot will have achieved greater than approximately 80% of its tensile 
strength (Shen 1983).  The target systolic blood pressure is approximately 
80 mmHg as this was deemed to be a pressure that wouldn’t “pop the clot” 
(Sondeen 2003, Krausz 2006).   
 
This method had been adopted by many military medical services both in 
the UK (Greaves 2002, Battlefield Advanced Trauma Life Support, BATLS 
2006) and in the US (Holcomb 2003, Krausz 2006).  It is also recommended 
by NICE who endorsed that in the pre-hospital environment aliquots of fluids 
should be administered to maintain a radial pulse (NICE: Technology 
Appraisal Guidance 74, 2004).  However things have progressed since the 
early 2000’s. 
 
It must be kept in mind that sustained hypotension leads to an oxygen debt 
that can and will cause organ injury.  The level of oxygen debt is commonly 
measured by base deficit.  A worsening base deficit is associated with injury 
severity, coagulopathy and mortality (Frith 2010).  Oxygen debt activates 
inflammatory pathways leading to a rise in IL-6, IL-8, TNF (Martin 1997) and 
HMGB-1 (High Mobility Group Box nuclear protein-1) (Cohen 2009); all 
predictors of systemic inflammatory response (SIRS; Giannoudis 2008), 
renal failure, acute lung injury (Cohen 2009), infection (Claridge 2000), 
multiorgan dysfunction (Kobbe 2008) and death (Martin 1997, Cohen 2009).  
A balance therefore needs to be made between sub-optimal perfusion, 
minimising blood loss and ensuring clot stability. 
 
A number of animal investigations have examined this issue using ovine 
(Sakles 1997), porcine (Stern 1993), and rodent (Burris 1999, Smail 1998, 
Capone 1995) models.  These were evaluated by a systematic review of all 
animal models (Mapstone 2003), which concluded that hypotension reduces 
blood loss and mortality.  Unfortunately the majority of these models employ 
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an experimental method that reduces the validity of their findings.  The 
injury sustained was a vessel injury, which is more sensitive to re-bleeding 
and the anaesthetised animal received a vasodilatory anaesthetic method.  
Despite the limitations of these studies, their results supported that early, 
aggressive crystalloid resuscitation is detrimental.  
 
Clinical human studies have found it challenging to demonstrate clear 
benefits for hypotensive resuscitation.  Two studies investigated delayed 
resuscitation and found that an early resuscitation technique had an 
increased mortality (Bickell 1994, Schreiber 2015).  Bickell (1994) found in 
penetrating torso injuries delaying aggressive fluid resuscitation (a 
hypotensive approach) improved outcomes, while Schreiber found that blunt 
(and not penetrating) injuries may benefit from a controlled, initially 
hypotensive resuscitation regime.  Regrettably the timelines in both were 
short (less than 60 minutes), both used crystalloid resuscitation and the 
latter did not achieve significantly different blood pressures (105 vs 98.7 
mmHg).  Dutton (2002) randomised 110 patients to a hypotensive (70 
mmHg) or normal (>100 mmHg) blood pressure goal for resuscitation and 
found no difference in mortality between groups.  The actual blood 
pressures achieved though were 100 mmHg and 114 mmHg respectively, 
so a pronounced blood pressure difference was not achieved.  Morrison 
(2011) seemed to have the most promising results initially.  They published 
preliminary findings of a randomised control trial of in-hospital trauma 
patient resuscitation for treatment of haemorrhagic shock, randomising to 
mean arterial pressures of 50 or 65 mmHg.  Their initial findings showed the 
hypotensive group had a reduced blood loss and a tendency towards lower 
mortality.  Again, although the intent was there, the mean arterial pressure 
in the two groups was not statistically different and due to futility and 
insufficient clinical equipoise (as they found no difference in patient survival 
and the majority of the studies secondary outcomes) the study was 
terminated (Carrick 2016). 
 
Despite a lack of strong evidence from human studies to support a 
hypotensive resuscitation approach, many national guidelines (Spahn 2013, 
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NICE NG 39 2016) have now adopted it for resuscitation of bleeding 
patients.  This general acceptance of the hypotensive approach is 
presumably due to the positive results from animal studies and the appeal 
of not worsening haemorrhage.  The problem the military face is that its 
medical evacuation chain is not guaranteed and long pre-hospital times with 
a delayed access to surgery is commonplace.  
 
Some have argued that 80 mmHg is too low a target.  A paper from World 
War II (Emerson 1945) studied those battle casualties admitted to a field 
hospital and found that those arriving in severe shock (systolic blood 
pressure <85 mmHg) had a mortality of 35% compared to 11% in the higher 
blood pressure group.  The authors stated that a systolic blood pressure 
(SBP) of 80-90 mmHg was an acceptable target.  Although somewhat old, 
the key aspects of this paper are relevant to the military audience still with 
prolonged timelines and a predominantly young male patient group.   
 
Two further retrospective papers suggest a higher blood pressure is 
required.  The data of 48,000 blunt trauma patients’ records from the UK 
trauma registry was scrutinised (Hasler 2011).  The authors found that the 
odds of dying increased below a SBP of 110 mmHg and doubled below a 
SBP of 100 mmHg.  In the second paper, the US National Trauma Data 
Bank was analysed to look at 871,000 patients (excluding traumatic brain 
injury [TBI]) (Eastridge 2007) and the authors found a correlation between 
admission SBP, base deficit and mortality.  For every 10 mmHg drop in SBP 
below 110 mmHg there was a 4.8% increase in mortality.  They concluded 
that a “SBP ≤ 110 mmHg is a more clinically relevant definition of 
hypotension and shock than 90 mmHg”.  There appeared to be correlation 
in the findings from two different continents with similar well-developed 
trauma systems.   
 
Patient age though was over-looked.  It plays a significant part in these 
civilian studies.  Older patients have cardiovascular co-morbidities that 
make them unable to tolerate lower blood pressures; especially when up to 
two-thirds of some age groups could have hypertension (Stomatos 1994) 
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and the elderly trauma patient is twice as likely to die (Lonner 1995) 
compared to younger patients.   
 
It is likely any study involving older patients will therefore show a higher 
blood pressure would be required to resuscitate them successfully.  A follow 
up study re-examined the American National Trauma Data Bank (Oyetunji 
2011) as the authors suggested the previous papers might be affected by 
analytical bias.  They studied nearly a million records and optimally defined 
hypotension as being the model with the highest area under the receiver 
operating characteristic curve.  The optimal SBP value for patients aged 18 
to 35 years was 85 mmHg, 96 mmHg for patients 36 to 64 years and 117 
mmHg for elderly patients.  They concluded “for patients younger than 65 
years, the classical definition of hypotension (is) less than 90 mmHg”.  This 
latter paper gives pertinent advice to those treating a younger adult patient 
group, such as the military casualty. 
 
Military medical care has to deal with the further problems of extended 
timelines and blast injuries.  Experimental studies, in anaesthetised pigs, 
undertaken by Garner (2010) have investigated hypotensive resuscitation 
(SBP goal of 80 mmHg) and the impact of blast in a model that involved 
liver injury in contrast to vessel injury.  During the first hour, the degree of 
shock, as measured by base excess, increased.  With further time the 
degree of shock became devastating.  This was accentuated if performed 
on a background of combined hypovolaemia (in this case, an experimentally 
controlled blood loss) and blast injury, rapidly leading to increased mortality 
(Garner 2010).  The response to hypotensive resuscitation for the first hour 
was tolerable, so they devised a new resuscitation concept.  This “novel, 
hybrid resuscitation” concept was an initial 60 minutes of hypotensive 
resuscitation followed by normotensive resuscitation in attempt to improve 
tissue perfusion and oxygenation.  This new resuscitation concept worked, 
and was found to improve survival in their porcine military trauma model 
(that incorporated blast injury and blood loss) and also significantly 
extended the evacuation times (Doran 2012).  Novel hybrid resuscitation 
was incorporated into UK military pre-hospital guidelines (CGOs 2017) for 
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the treatment and resuscitation of traumatic haemorrhage in 2012.  
Variations on this theme have been adopted into many national and 
international guidelines, all with an initial hypotensive goal as part of trauma 
resuscitation.  Although most don’t specify exact timings, there is a 
recognition that initial hypotension is warranted for a limited period of time. 
These include European guidelines (Rossaint 2016) recommending a “SBP 
of 80-90 mmHg until major bleeding has been stopped” and NICE 
guidelines (NICE NG39, 2016) on trauma resuscitation in both hospital and 
pre-hospital advising that practitioners should “titrate volume resuscitation to 
maintain a palpable central pulse (carotid or femoral)”. 
 
In summary, the majority of research evidence and clinical experience 
suggests that a lower blood pressure should be targeted early in order to 
reduce bleeding and preserve the initial clot.  Nevertheless, this needs to be 
limited to reduce too great an ischaemic injury to tissues.  Duration and 
level of hypotension is yet to be clearly defined, but it is recognised that this 
is a risk:benefit decision depending on a number of factors including pre-
existing co-morbidities including cardiovascular diseases, patient age and 
traumatic brain injury.  These patients will all be more vulnerable to an 
ischaemic injury.   
 
Hypotensive resuscitation is a relevant and crucial part of DCR in order to 
minimise blood loss before definitive haemorrhage control.  In civilian 
practice and the older population a SBP goal of around 100 mmHg is 
becoming a more accepted value (Woolley 2018), although it has not made 
it into any recognised guidelines.  In military practice and the younger 
population a SBP of 80-90 mmHg is acceptable and in more austere 
locations or prolonged evacuation a return to normotension or at least a 
SBP of 100 mmHg is what I would aim for in practice.  Nevertheless strict 
adherence to blood pressure goals is probably unnecessary, and instead 
the aim should be for adequate flow and a trend (of cardiovascular and 
biochemical indicators) in the right direction.  Strictly adhering to the 60 
minute threshold is probably unwarranted if near patient blood gas testing 
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was possible, meaning in this younger patient group changing the SBP goal 
could be guided by base deficit. 
 
 
2.2.3  Haemostatic Resuscitation 
 
Haemostatic resuscitation is the process of restoring and sustaining normal 
tissue perfusion to the patient presenting in uncontrolled haemorrhagic 
shock, with an emphasis on preservation of effective clotting (Dutton 2012).  
The basis of it has been driven by the military experience of combat 
casualty care in Iraq and Afghanistan in addition to scientific research 
carried out in civilian trauma centres. 
 
The foundation of haemostatic resuscitation lies in the recognition of the 
pathophysiology of haemorrhagic shock and particularly Acute Traumatic 
Coagulopathy (ATC).  Injury causes damage to tissues; disruption of blood 
vessels and organs causes haemorrhage and a decreased cardiac output.  
The sympathetic response to this causes vasoconstriction to non-essential 
tissues (Dutton 2007) which when coupled with bleeding and reduced 
cardiac output causes significant tissue hypoperfusion and oxygen debt.  
Hypoperfused cells release hundreds of mediators (Reilly 1993), toxins, 
inflammatory proteins (Chaudry 2009) and the by-products of anaerobic 
metabolism including lactate and potassium.  Protein C activation as a 
consequence of hypoperfusion is fundamental to the development of ATC 
and its fibrinolysis (Brohi 2008).  It is now well recognised that severely 
injured trauma patients will be coagulopathic independent of any iatrogenic 
cause (Brohi 2003, Hess 2009).  Coagulopathy leads to further 
haemorrhage and ischaemia progression and consumption of essential 
elements of haemostasis (e.g. fibrinogen in the early stages (Rourke 2012)). 
The goal of resuscitation is to restore normal oxygen delivery and reversing 
the pathophysiological causes of ATC; those trauma patients who 
exsanguinate with surgically repairable injuries do so with an overwhelming 
coagulopathy (Cosgriff 1997).  There are two aspects to this, which are 
closely inter-linked; coagulation support and restoring tissue perfusion. 
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2.2.4  Coagulation Support 
 
Early support of coagulation is needed and consequently those fluids that 
do not fulfill this role – crystalloids and colloids – have no role in DCR (see 
Chapter 6 for further detail).  In the hospital environment immediate 
transfusion of PRBC, plasma (FFP), platelets and fibrinogen must occur.  
This needs to be planned for and occur before a complete picture of the 





Figure 2-1.  Military Massive Transfusion Protocol taken from Clinical Guidelines for 




Logistics are key and in order to ensure the right blood components are 
available 24 hours a day the majority of trauma centres have developed 
massive transfusion protocols (MTPs) (Cotton 2008).  These provide a set 
amount of PRBC, FFP and platelets (and sometimes cryoprecipitate) to the 
required location in the hospital, with additional help in the form of porters 
and laboratory staff to enable continued support.  The military MTP is typical 
example (Figure 2-1). 
 
With arterial pressure kept to an acceptable minimum until haemorrhage is 
controlled, an example of how this element of resuscitation should proceed 












2.2.5  Restoration of Tissue Perfusion  
 
The pathophysiological basis of Acute Traumatic Coagulopathy lies at the 
level of the endothelium and hypoperfusion of tissues (see Section 4.10 for 
further details).  Restoration of tissue hypoperfusion is the drive to reverse 
this.  There is however little scientific evidence to support this aspect of 
DCR. It has been briefly described in a few papers (Dawes 2009, Hauser 
2010, Giannoudis 2016) and the evidence of its effectiveness in the 
operating theatres of Afghanistan has been previously published (although 
not described in full detail) (Morrison 2013a).  This latter study was a 
retrospective assessment of 59 patients admitted to the hospital in Camp 
Bastion between 2008 and 2010 suffering severe blast injuries, with a  
combined predicted survival of 50.9%.  Intra-operative changes were noted 
to be; pH 7.19 to 7.45, Base Excess -9.0 to +4.5 mEq/l and Prothrombin 
Time decreased from 18 to 14 seconds.  The method of resuscitation 
(tissue perfusion restoration) employed by the teams in Afghanistan 
improved outcome with survival increasing from 50.9% (predicted) to 90% 
(actual).  
 
The basis of restoring tissue perfusion is the reversal of the 
sympathomimetic response and consequent vaso and veno-constriction.  
This is implemented with anaesthetic agents to reduce sympathetic outflow 
and dilate the constricted vascular beds.  The right agents for this 
(inhalational agents and opioids) are not administered immediately as in all 
likelihood their significant vasodilatory effect in addition to positive pressure 
ventilation would have a disastrous effect on venous return and be 
potentially fatal for a severely injured patient.  My approach, as a trained 
military anaesthetic Consultant, is a ketamine (one of the more 
cardiovascularly stable anaesthetic agents) induction with a small dose of 
benzodiazepine, followed by a Ketamine/Midazolam infusion.  As 
resuscitation proceeds additional anaesthetic agents (inhalational) and 
analgesics (opioids) are titrated carefully.  It is not uncommon to alternate 
anaesthetic titration (fentanyl boluses of 50-100µg or inhalational agent 
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increases of 0.1-0.2 Minimum Alveolar Concentration [MAC]) with blood 
component boluses (of 100-500ml) judging the effects of both by the 
resultant SBP and base excess changes.  The resultant increasing 
perfusion to organs and peripheral tissues should reverse coagulation 
abnormalties, reduce fibrinolysis and inflammatory compound release 
without exacerbating further haemorrhage.  The ultimate aim being to 
achieve a high flow, low-pressure cardiovascular system and vasodilated 
patient with stable blood pressure and normalised pH, base deficit, 




2.3  Military Pre-Hospital Trauma Care 
 
The lack of land evacuation options, increasing injury severity of casualties 
and troops spread over large distances led the UK to develop its forward 
medical evacuation in 2006; 16 Air Assault Brigade was spread across the 
Helmand province with road travel restricted, lengthy and dangerous. The 
Army clinicians at the hospital in Camp Bastion decided to bolster the RAF 
Immediate Response Team (IRT) aircraft with a Consultant Emergency 
Physician or Anaesthetist.  The IRT at that time was used to support ground 
troops with a variety of specialists from explosive technicians to medical 
personnel.  This increase in medical capacity and capability developed 
quickly into the present Medical Emergency Response Team (MERT) model 
of a 4 man team led by a Consultant and including Paramedics and an 
emergency nurse practitioner. 
 
The goal of this manning was to bring forward the capability to initiate DCR 
earlier, bringing it out of the hospital to the patients at the front line.  The 
medical services were then able to by-pass the role 1 general practitioners 
and bring damage control resuscitation to the battlefield.  By 2006 there was 
a dedicated medical helicopter (CH-47 Chinook); a large support helicopter 
able to fly with speed and carry a large numbers of casualties plus the 
equipment to treat them.  By 2008 Packed Red Blood Cells (PRBC) and 
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Fresh Frozen Plasma (FFP) was carried by the aircraft 24 hours a day, 7 
days a week.  
 
The medical techniques and procedures used on the MERT are similar to or 
exactly the same as that found on any civilian pre-hospital air ambulance 
within the UK, with a few exceptions.  Personal danger is ever present and 
not unexpected, meaning the location in which medical interventions took 
place had to be on board the aircraft.  Civilian pre-hospital teams complete 
their interventions at the site of injury and then package the patient for 
transfer to the next level of care.  The risk of small arms and indirect fire 
meant that the MERT carried out all its interventions whilst in transit to the 
next level of care.  This introduces additional challenges to communication 
(noisy environment), fine motor skills (excessive high frequency vibrations) 
and diagnostic skills (it is difficult to feel a radial pulse in the presence of the 
vibrations found on a CH-47 Chinook and an automated non-invasive blood 
pressure monitor will struggle to find an accurate blood pressure particularly 
if it is low).  Motion sickness can incapacitate even the best clinician.   
 
A larger team meant a greater number of casualties could be managed, 
which is useful when the aircraft can take up to 20 or more casualties, 
compared to the usual one carried on civilian aircraft.  Lastly and most 





2.4  Military Pre-Hospital Resuscitation  
 
Treating a trauma patient with active haemorrhage in the pre-hospital 
environment requires a more nuanced approach.  Delivering the least 
cardiac output necessary to sustain vital organ function is required, whilst 
attempting to preserve and support haemostasis.  The threshold of lethal (or 
organ specific) ischaemia is heterogeneous across the population; so early 
resuscitation requires substantial clinical judgement and experience.  
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Management recommendations are used as guidelines rather than definitive 
standards of care.  
 
The current UK military resuscitation guidelines for the pre-hospital 
environment are detailed in Figure 2-3.  Its basis lies in the adaptation of 
current in-hospital DCR regimes and incorporating the crucial aspects of 




Figure 2-3.  Medical Emergency Resuscitation Team Blood Product and Fluid 




environmental constraints those pre-hospital teams are placed under. 
Another fundamental dissimilarity needs to be considered; the teams 
working in that environment are not aiming to resuscitate to incorporate  
DCS as part of their DCR process. Their aim is to keep the patient alive 
long enough to reach a location for Damage Control Surgery.  Cessation of 
haemorrhage aside, they need to incorporate the majority of all aspects of 
Damage Control Resuscitation sufficient enough to reverse or pause the 
progress of Acute Traumatic Coagulopathy.  A vital aspect of this regime is 




2.4.1  Pre-hospital Blood Components 
 
There are national and international guidelines that ensure the quality of 
blood products.  In the UK the “Red Book”: the Guidelines for the Blood 
Transfusion Services, defines guidelines for all materials produced by the 
UK Blood Transfusion Services for both therapeutic and diagnostic use 
(Red Book 2013).  They reflect the legally binding requirements of the Blood 
Safety Regulations (UK Statutory Instrument 2005).  Its overall aim is to 
ensure as far as possible the safety of blood transfusion in the UK, for both 
the donor and the patient. 
 
All blood components for the UK military are provided by the UK Blood 
Transfusion Services and as UK patients are in receipt of them, the 
guidelines in the “Red Book” need to be adhered to.  Wherever the military 
are in the World, clinical governance is at the forefront of patient care and 
patient safety.  
 
Upon delivery of the blood components to the departing port, airhead or 
airport the onus is on military medical personnel to ensure transportation 
and storage guidelines are adhered to.  Although not particularly difficult, 
that task becomes more challenging if personnel deploy to more austere 
locations throughout the globe.  Any surgical team will travel with an ability 
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to both transport and store blood components refrigerated or frozen.  Some 
very small teams will move with a refrigeration capability only and plasma 
and fibrinogen is taken in lyophilised (powdered) form.  
 
Two main challenges face the medical team ensuring that the guidelines on 
storage are adhered to.  Maintaining temperature within the surgical facility 
is the easier challenge, but is very much reliant on an ensured power 
supply.  Each team will take with them two generators to ensure they have 
this at all times.  Both fridges and generators struggle to function adequately 
at temperature extremes, particularly the heat of the desert.  Temperature is 
monitored constantly in accordance with the above regulations.    
 
Ensuring the correct temperature range is adhered to forward of the hospital 
is more challenging.  Working in the back of a military aircraft is a testing 

















Figure 2-4.  CH-47 (Chinook) in Medical Emergency Response Team (Enhanced), pre-




The Golden Hour Box, a sealed container containing a vacuum insulated 
chamber with an inner, removable thermal isolation compartment (Figure 2-
5), is used in this environment and will hold 4 units of PRBC or thawed FFP.  
It can maintain its temperature range (2-6°C) for 48 hours in external 
temperatures of up to 45°C.  Units are rarely kept in these for more than 24 
hours and in normal circumstances they are only given to the pre-hospital 
















Figure 2-5.  Golden Hour Box (Photo credit: Pelicanbiothermal.com)    
 
 
The storage temperature is monitored using a temperature indicator tag 
together with single-use time-temperature indicators (WarmMark® and 
ColdMark®, ShockWatch, Dallas, Tx).  Blood products are only 
administered if the temperature has remained within range.  Components 
are warmed during administration, using a portable battery operated fluid 
warming system (enFLow™, GE Healthcare, Waukesha, WI).  The hospital 
is informed during flight if a transfusion occurs so that the blood container 
may be promptly exchanged for a new one with a full supply of products. 
This process has the clinical benefit of alerting clinical teams to the likely 




The logistic challenges of maintaining a blood supply to austere settings, 
and the impact of shortage, necessitates a much greater degree of 
redundancy than in civilian systems.  Despite the challenges, wastage of 
blood products in the UK system has been managed, with 65% of PRBC 
and 80% of FFP units sent to Afghanistan used, which compares favorably 
with US experience (Rentas 2012). 
 
Blood directives mandate haemovigilance and the traceability of all blood 
components. The documentation of pre-hospital transfusion is as per the 
UK military hospital protocol and consists of a double labelling system. One 
label remains in the patients’ records; the other is returned to the pathology 
laboratory. The exigencies of administering a transfusion in a cramped 
aircraft, sometimes under attack, can make this challenging, especially if 
there are multiple casualties.  Nonetheless, the MERT pre-hospital 
transfusion program achieved 100% traceability.  Furthermore, no serious 
side effects or complications of transfusion attributable to units transfused in 
the pre-hospital setting have been reported. 
 
Provision of blood products in a pre-hospital environment is a significant 
logistical challenge.  The UK military has been successfully deploying blood 
products forward since 2008 when the pre-hospital aircraft was co-located 
with the hospital in Bastion.  Despite the lack of robust scientific evidence to 
justify the challenge of providing pre-hospital blood components, civilian 
pre-hospital providers within the UK have emulated this practice.  The 
London Helicopter Emergency Medical Service (HEMS) was the first, 
starting to take PRBC onto the aircraft in 2012 (Weaver 2013).  They have 
proved it is both feasible and associated with overall reduced blood 
component consumption (Rehn 2017), with other potential benefits (Weaver 
2013).  Other UK pre-hospital capabilities have followed suit (Lyon 2017).  
Studies from other countries have shown that pre-hospital PRBC 
transfusions in trauma are associated with improved outcomes (reduced 
risk of shock and probability of 24-hour mortality; Brown 2017a), reduced 




A plasma only pre-hospital resuscitation investigation (Pre-hospital Air 
Medical Plasma [PAMPer]; Sperry 2018) illustrated the benefits of plasma 
for both survival (lower 30-day mortality) and coagulation (decreased PT 
ratio).   
 
Despite these studies on individual components there is little data on pre-
hospital PRBC and plasma (Holcomb 2015a).  At Camp Bastion the in-
hospital clinicians were in no doubt the effect of having blood products on 
the aircraft.  The overall assessment was that patients were arriving at the 
hospital in a physiologically much better state than would be expected for 
their injuries; significant ballistic injuries including blast and multiple 
proximal amputations.  They were being compared to the patients who were 
admitted by other pre-hospital assets (with no doctor or blood components) 
or to the collective institutional memory of similar patients admitted earlier in 
the conflict.  There was no scientific proof of benefit though and the cost 
financially, temporally and logistically of providing forward blood products 
was not insignificant.   
 
The most notable differences were observed in the most severely injured 
casualties.  It is worth discussing next how these injuries occurred and how 










3.1  Introduction 
 
In order to further improve military trauma care both the UK and America 
carried out many Governance led evaluations on their military casualties.  
These were useful for detailing the type of casualty treated by military 
facilities in Afghanistan and Iraq.  An American review of battlefield deaths 
between 2001 and 2011 reviewed data on 4,956 fatalities (Eastridge 2012).  
The majority (87.3%) of deaths occurred in the pre-hospital environment 
before the casualty reached a surgeon.  They estimated that 24.3% of these 
deaths were preventable and the cause of these deaths was in almost 91% 
of casualties - haemorrhage. 
 
A UK review of all UK casualties, not just fatalities, between 2003 and 2012 
investigated the data for 2,792 UK casualties (Penn-Barwell 2015).  2,227 
were due to hostile action, of which 608 (22%) were fatalities.  1,592 (65%) 
of all casualties from all hostile action were from explosions.  Gun shot 
wounds (GSW) accounted for 684 casualties and represented 31% of all 
hostile action.  The impact of body armour and helmets meant that 
extremities accounted for 45% of all injuries, with head, face, thorax and 
abdomen accounting for approximately 10% each. 
 
Data from previous conflicts show that this ratio of GSW to explosive 
injuries was similar in previous conflicts.  The Falklands had approximately 
30% GSW injuries, compared to almost 60% of injuries secondary to 
explosions in the land campaign (Jackson 1983) with Vietnam having 
similar statistics.  The Wound Data and Munitions Effectiveness Team 
(WDMET) American database on 3 years of the Vietnam War states injuries 
secondary to explosions (fragments, burns, blast) accounted for 71% of all 




An American comprehensive review of combat injuries from past conflicts 
back to and including the conflict in Vietnam (Champion 2003) found 
approximately 50% of those who died, did so as a result of exsanguinating 
haemorrhage, with approximately 80% of these from torso injuries, with 
20% of deaths caused by potentially preventable extremity haemorrhage.  
 
For blast injuries the cardiac and apnoeic effects of blast injury may well be 
a causative reason for death, however at short distances mutilating trauma 
or the total body destruction from the explosion is more likely.  
Fragmentation is the most common wounding mechanism (Bellamy 1995, 
Champion 2003, Penn-Barwell 2015).  The incidence of blast lung is 
significantly higher in the more severely injured casualties of explosions.  It 
has been found in 63% of critically ill ICU blast injured patients (Gutierrez de 
Caballos 2005) and there has been evidence of blast lung in 47% of blast 
immediate fatalities (Frykberg 1989).  In survivors its incidence is variable 
from between 75% (Gutierrez de Caballos 2005) to 38% (Katz 1989), which 
is probably a reflection of the physics of each explosion, and its proximity to 
casualties. 
 
In Afghanistan and Iraq, blast lung incidence between 2003-2009 in UK 
casualties was present in about 113 casualties (Smith 2011).  Blast 
accounted for 1678 casualties out of a total 3109 UK casualties.  Of those 
injuries from explosion 233 had a thoracic injury and 113 had blast lung.  
The mean ISS of those with blast lung was 52.6 – severely injured – which 
fits with previous descriptions.  At the peak of injury incidence in each 
conflict blast lung accounted for 7.3% of injuries in Iraq and 11% in 
Afghanistan – twice previous estimates (Ritenour 2008). 
	
In summary the majority of injuries from hostile action were primarily blast 
and fragmentation trauma resulting from explosive devices, with extremities 
being the most likely region to be wounded.  Fatalities were predominantly 
secondary to haemorrhage and occurred before the patient reached a 




3.2  Civilian Terrorist Injuries 
 
Historically, terrorists have predominantly used explosives to achieve their 
aims on civilian targets.  It is not a new phenomenon for the UK; one of the 
earliest recorded incidents being caused by Irish terrorists who attacked in 
1867 (bombing Clerkenwell prison in order to free Fenian prisoners).  
Throughout the 1970’s on the UK mainland, financial and military 
establishments were targeted with a view to disruption rather than civilian 
loss of life.  This has changed in recent times with the Internet leading to 
easier access to bomb making instructions and materials.   
 
In July 2005 over 650 civilians were injured, with 56 fatalities (8% of 
casualties) in three separate bombings on the same day in July in London 
(Aylwin 2006).  Blast and fragmentation injuries predominated with most of 
the fatalities dying at the scene.  This was one of the first of a new breed of 
terrorist event, large explosions aimed at killing civilians indiscriminately.  
Various terrorist attacks have occurred since 2005, with even more being 
foiled by the security and counter terrorism services.  Explosive related 
attacks such as at the Manchester Arena in 2017 have had the greatest 
impact on indiscriminant loss of life, secondary to blast and fragmentation 
injuries.  That year was both busy for UK terrorist attacks (4 successful, with 
at least 12 thwarted) but also marked a change in their method of attack 
within both the UK and Europe.  This change of method may well be due to 
improved security service vigilance.  The majority of these have been 
caused by blunt trauma from vehicles  (London Bridge and Westminster in 
the UK, Barcelona and Nice in 2017; Paris and Berlin in 2016 in Europe) 
with some penetrating trauma from stabbing (Nice in 2015, Würzberg in 
2016 and Westminster in 2017).   
 
Terrorist events have caused nearly 400 deaths and injured nearly 1800 
civilians in Europe since 2015.  Approximately 60% of casualties have been 
caused by bombings, with just fewer than 40% caused by blunt trauma 
(vehicle versus pedestrian).  Civilian trauma doctors are familiar with blunt 
trauma, but not ballistic trauma causing penetrating, fragmentation and blast 
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injuries.  A comprehensive knowledge on how to deal with these injuries 
ensures their correct management.  In the UK military doctors work in NHS 
hospitals and their knowledge and skills have been invaluable in some of 
these cases both at a local level (MTN 2014) and Nationally (Bowley 2018). 
 
Management of civilian terrorist blast injuries is the same as military 
management of ballistic war injuries.  Blunt trauma management is normal 




3.3  Civilian Trauma Injuries 
 
In the UK blunt trauma predominates.  The Trauma Audit and Research 
Network (TARN) allows investigation into the epidemiology of UK trauma.  
Subsequent to the National Confidential Enquiry into Patient Outcome and 
Death report of 2007 (NCEPOD 2007) the NHS formed Regional Trauma 
Networks and Major Trauma Centres.  With the formation of these a greater 
number of hospitals logged data for TARN.  A recent study of this data 
(Moran 2018) shows over the last decade the causes of UK trauma has 
been predominantly blunt with less than 5% from penetrating injuries.  Road 
Traffic Collisions (RTC) account for nearly 30% of injuries, with falls 
accounting for almost 60% of UK trauma.  Throughout the UK, management 
of this trauma is improving despite an increased frequency of older patients 
with a greater number of co-morbidities; the odds of survival from severe 
injury has increased by 19% (Moran 2018).  When taken into the context of 
probably forty to fifty thousand trauma cases in the UK per annum, this 
improvement translates to thousands of lives saved in the UK in the next 5 
years (Lockey 2018).  
 
What is the physical impact of these differing mechanisms of injury?  Does 





3.4  Physical Impact of Penetrating Injury  
 
Low velocity penetrating – stab – injuries involving knives have become a 
high profile incident in the UK (Campbell 2018).  Knives are not omnipresent 
in causing stab injuries which can be due to anything from scissors, to 
barbecue forks to ice picks.  The results are similar; depth of injury can be 
significantly greater than skin injury length with the impact force 
concentrated at the tip.  The effect is determined by angle and depth of 
penetration (weapon trajectory both on insertion and removal), the type of 
tissue involved, location of injury and how compressible the area wounded 
is (e.g. the abdomen can indent significantly so that the area penetrated can 
be at a greater depth than the weapon; Butt 2009). 
 
Injuries can compromise the respiratory system (pneumothorax), cause 
airway complications (disrupt trachea patency) and produce visceral injuries 
like intestinal perforation.  Depending on the location though it is vascular 
injuries (aortic, carotid) and injuries to highly vascular organs (spleen) that 
are the most concerning, producing a casualty with minimal external signs 
of violence but suffering substantial exsanguinating haemorrhage, although 




3.5  Physical Impact of Ballistic Injuries 
 
The projectiles in ballistic injuries are most commonly bullets from firearms 
or fragments of explosive devices, however they can include anything from 
the surrounding environment of an explosion.  The damage to the tissues 
caused by the projectile depends on a number of factors (Table 3-1).   
 
The kinetic energy of the projectile is key (Ek = ½ m v2 ; where m is the 
projectile mass and v its velocity) and the damage is determined by how 
much of this is deposited after striking the casualty.  Shape and size will 
determine how it travels through the tissue.  A missile crushes the tissue it 
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strikes creating a permanent wound channel (permanent cavity; Figure 3-1), 
the size of which is determined by the yaw of the projectile.  A bullet fired 
from a weapon with spiral grooves (rifling) will be stabilised by the spin 
imparted on it leading to nose first flight and presenting a smaller surface 
area for the creation of a permanent cavity.  In contrast: a bullet arriving at 
90° (side on); a soft- or hollow-point bullet that deforms on impact creating a 
significantly greater surface area; or an irregularly shaped fragment will 




Table 3-1.  Factors influencing damage to tissues in ballistic injuries (Russell 2014) 
 
 
Once the projectile hits tissue any spin will be insufficient to maintain its 
nose forward orientation through a denser medium (Hopkinson 1967) and 
the heavier base will move forward.  This rolling motion (yaw) crushes the 
maximal amount of tissue, slowing the projectile down rapidly as its energy 
is used to move tissue radially away and the force expended in this roll 
(yaw) creates the temporary cavity (Figure 3-1).  Yaw occurs to a much 
lesser extent in soft/hollow-point projectiles as on contact with the tissue 
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they “mushroom”, rapidly making the heaviest part of the projectile at the 
forward edge.  It is also unlikely to occur in irregular fragmentation 





Figure 3-1.  Wound profile of NATO 7.62 mm round (Fackler 1996). 
 
 
The wound produced depends on the density and elasticity of wounded 
tissue, thickness of body part and the points at which the projectile yaws or 
when fragmentation occurs (Figure 3-2).  A heavier, slower bullet crushes 
more tissue with little temporary cavity compared to a faster, lighter 
projectile with less crush and greater cavitation.  The heavier, slower 
projectile will cause more severe wounding in elastic tissue, than the lighter 
projectile, which causes cavitation (which is well tolerated by elastic tissue, 
such as lung or muscle).  In non elastic tissue (such as liver or brain) the 
temporary cavity will produce a more severe wound (Fackler 1996, 
Hollerman 1990, Russell 2014).  Although the influencing factors are many 
as to the degree of injury, the results are consistent – significant tissue 
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Figure 3-2.  Gunshot wound to the thorax from high velocity rifle bullet, illustrating fractures, 
missile fragmentation and soft tissue disruption. (www.medscape.com Forensic Pathology 




3.6  Physical Impact of Explosions 
 
3.6.1  The Physics of Explosions 
 
An explosion is a violent expansion in which energy is transmitted outwards 
as a shock wave.  High order explosive detonations result in the rapid 
transformation of the explosive material into a highly pressurised gas, which 
releases energy at high speeds in a very short space of time (Wolf 2009). 
This energy “shock wave” travels faster than the speed of sound and it 
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compresses a rim of air around the ball of explosive products moving out. 
This energy “shock wave” travels faster than the speed of sound away from 
the explosion (Figure 3-3). 
 
The magnitude of the peak over pressure rapidly decays with increasing 
distance from the centre of the explosion.  The explosion also pushes and 
accelerates the air producing a blast wind (dynamic over pressure), which 
carries with it energised fragments from the explosive container, the 
explosive itself and near by objects.  The pressure differences that occur as 
part of the blast wave are well described by Friedlander (1946; Figure 3-4).  
 
The outwards movement of the blast wind eventually dissipates leaving a 
volume of low-pressure gas nearest the point of explosion initiation.  There 
is then a reversal of air movement to correct this under pressure, leading to 
a pressure oscillation until the norm is restored (Wolf 2009). 
 
The importance of the peak over pressure and blast wind depends on the 
location of explosion.  In an incompressible medium (water) the blast wave 
is transmitted much further compared to air where its compressibility allows 
energy to accelerate and heat the air.  Water will reduce the movement of 
the dynamic over pressure and fragments reducing their radius of effect 
compared to air.   
 
Interaction of the shock wave with solid surfaces will result in reflection, so 
that a shock wave can reverberate within a structure.  In addition the shock 
wave can be amplified by up to eight times at a reflective surface, so that 
the reflected wave can interact with the incident wave resulting in peak over 
pressure summation (Wolf 2009).  More severe injuries can therefore occur 
in confined spaces due to these reflections and summations. 
 
There are four classical categories of blast injury (Mellor 1988, Table 3-2) 






Figure 3-3. Photo of explosion and blast wave (arrowed)(from Defence Research and 
Development Canada, www.canada.ca/en/defence-research-development). 
   
 
 
Figure 3-4.  Illustration of the blast air pressure changes in an idealised shock wave – a 
Friedlander curve illustrating the peak overpressure and subsequent negative pressure 
after an explosion (Mediavilla Varas 2011) 
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3.6.2  Primary Blast Injury 
 
Primary blast injuries are caused by the interaction of the shock wave with 
the body.  The shock wave couples into the body and travels through the 
tissue water, principally depositing energy as it moves from areas of high 
acoustic impedance to low acoustic impedance e.g. gas filled spaces (Guy 
1998). 
 
The organs affected are those that are gas filled such as the lungs (causing 
contusions, haemothorax, pneumothorax and pseudocysts), the gastro-
intestinal tract (haemorrhage and perforation) and the middle ear (tympanic 
membrane rupture and middle ear damage).  Eye globe ruptures (DePalma 
2005) and traumatic brain injury (with no physical signs of head injury; Ling 
2009) have also been described. 
 
 
Table 3-2.  Blast injury classification. (Mellor 1988) 
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3.6.3  Primary Blast Injury - Blast Lung 
 
The shock wave impacts on the body surface resulting in rapid acceleration 
and movement on the body’s surface with resultant transmission of shear 
and stress waves through the tissue (Horrocks 2001).  This tissue stress 
leads to mechanical failure and resultant injury in primarily gas containing 
structures, particularly the lungs.  The direct effect of the blast wave at the 
largest air/tissue interface; the lungs, produces the primary blast injury of 
“blast lung”.   
 
Blast lung is a significant cause of mortality both at the scene and in initial 
survivors (Stein 1999). The shock wave causes rupture of alveolar 
capillaries with resultant macroscopic haemorrhage and fluid extravasation 
into lung tissue (Brown 1993).  There is an initial respiratory compromise as 
a result of this intra-pulmonary haemorrhage and oedema (Grobunov 2006).  
Free radical mediated oxidative stress and the subsequent inflammatory 
response has also been recognised to have a role in blast lung 
pathogenesis (Gorbunov 2005).   
 
Microscopically the histological changes observed are initially leucocyte 
accumulation and haemorrhage (and little evidence of direct endothelial 
damage) within 12 hours.  Subsequent development of inflammation leading 
to epithelial and endothelial cell damage is observed by 72 hours after 
injury. These changes lead to impairment in lung mechanics and the 
physiological process of gas exchange, and it results in a severe pulmonary 
injury which is defined by haemorrhages, contusions and oedema resulting 
in both vascular and alveolar injury (Knapp 1990, Stein 1999). 
 
Macroscopically haemothoraces and pneumothoraces are common.  
Fistulas (both bronchopleural and alveolar vasculo-pulmonary) can present 
with evidence of subsequent air embolism.  Patients present with a range of 
respiratory symptoms including non-specific breathing difficulties, cough, 
haemoptysis and chest pain.  The respiratory signs evident are tachypnea, 
hypopnea, cough, haemoptysis and ultimately hypoxia (Kirkman 2010b). 
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3.6.4  Primary Blast Injury - Cardio-respiratory Response to Blast 
 
The cardiorespiratory response to blast is mediated by the autonomic 
nervous system.  It results in bradycardia and hypotension – with resulting 
diminished cardiac output – apnoea or rapid shallow breathing (Ohnishi 
1997, Guy 1998, Kirkman 2011a).  The delay in these responses (2-4 
seconds) after blast suggests that these responses are secondary to a 
reflex (Irwin 1999), rather than a direct effect of blast on the tissues.  The 
reflex is predominantly vagally mediated (Ohnishi 1998, Irwin 1999), 
although hypotension has additional contributory factors.  Vagotomy will 
abolish the bradycardia and apnoea, but only partly abolish the hypotension 
(Ohnishi 2001).  The reduced peripheral vascular resistance and therefore 
hypotension and diminished cardiac output can last many hours (Harban 




3.6.5  Secondary Blast Injuries 
 
Secondary injury is caused by the effect of projectiles causing penetrating 
and fragmentation ballistic injuries (Mellor 1998).  Ballistic injuries from 
primary fragments (that are part of the weapon) and secondary fragments 
(resulting from the explosion) are the leading cause of death and injury in 
both military scenarios and civilian terrorist attacks (except in cases of major 
building collapse; DePalma 2005).  The physics and consequent injury from 
these are similar to projectiles as described in section 3.5 except they are 
potentially greater in number, their velocity diminishes faster and they are 
irregular in shape (Fackler 1996).   
 
 
3.6.6  Tertiary Blast Injuries  
 
Tertiary blast injuries are due to the effects of persons being thrown by the 
blast wind.  Tertiary blast injuries are primarily seen as blunt and sometimes 
	
	 40	
penetrating trauma, leading to fractures, traumatic amputations and not 
uncommonly traumatic brain injuries. Large airborne fragments lead to 
extensive blunt trauma (and crush injuries).  Flying smaller fragments cause 
penetrating and ballistic injuries (Mellor 1998, DePalma 2005). 
 
 
3.6.7  Quaternary Blast Injuries 
 
Quaternary blast injuries refer to explosion-related injuries, illnesses, and 
diseases not due to primary, secondary, or tertiary injuries and can include 
burns, asphyxia and exposure to toxic inhalants (DePalma 2005).  They 
include injuries due to structural collapse, in which few people survive 
(Arnold 2004). A quinary pattern of a hyper-inflammatory state manifesting 
as hyperpyrexia, sweating, low central venous pressure and positive fluid 
balance has more recently been described (Kluger 2007), its mechanism 





3.7  Physical Impact of Blunt Injury 
 
In the UK blunt trauma from vehicles or falls are the commonest form of 
injury (Moran 2018).  The sequelae to any blunt injury will depend on the 
amount of energy transferred and the tissues or organs involved.  The 
pathophysiological insult is essentially varying amount of tissue damage, 
with the individual anatomical areas involved producing differing additional 
effects.   
 
Blunt abdominal trauma predominantly causes injury to solid organs.  If both 
spleen and liver are involved these casualties are more likely to have lower 
systolic blood pressure, higher acidosis and lactate and a higher Injury 
Severity Score (ISS) and transfusion requirements.  This is mirrored by a 




Chest blunt trauma severity and the existence of associated injuries is 
related to the presence of rib fractures.  Haemo/pneumothorax incidence is 
less than 7% in patients with no rib fractures compared to 81% in those with 
more than 2 rib fractures.  Mortality is understandably greater in this latter 
group particularly in older patients or in those with associated additional 
injuries (Liman 2002).  
 
Blunt Traumatic Brain Injuries have consistently accounted for 30-35% of all 
UK trauma injuries in the last decade (Moran 2018).  They are not closely 
associated with significant haemorrhage or massive tissue injury, however 
their mortality is ten-fold higher than patients without head injuries (Patel 
2005) and for survivors and their families the consequential 
neuropsychological and social costs are substantial.   
 
Blunt injury is the main civilian injury seen in UK hospitals and the revision 
of trauma care within the UK has improved post-blunt injury survival (Moran 
2018).  Individual injuries are associated with specific anatomical sequelae 




3.8  Cardiovascular Response to Haemorrhage 
 
3.8.1  Simple Haemorrhage 
 
Haemorrhage without tissue damage in trauma is uncommon; however 
examining it allows discussion on how other factors found in a trauma 
patient (pain, tissue damage, pharmacological interactions) affect the simple 
physiological response to it. 
 
Acute blood loss reduces venous return, decreasing cardiac stroke volume, 
which in turn leads to a drop in systemic arterial pulse pressure.  The 
cardiovascular system and other homeostatic mechanisms that play a role 
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in the maintenance of substrate supply to the tissues react to blood loss and 
the drop in cardiac output.  In an attempt to preserve blood flow to certain 
vital organs such as the brain they reduce flow to other organs such as the 
kidney.  The arterial baroreceptors play a key role (Secher 1985) in this 
function; they are sensitive to both absolute blood pressure, but also degree 
of change within a pulse (Angell James 1971). 
 
The initial drop in pulse pressure is sensed by the carotid sinus causing an 
increase in sympathetic outflow to the heart and vasculature and a 
reduction in parasympathetic vagal stimulation.  There is a rise in 
chronotropy and an increased peripheral arterial vasoconstriction in order to 
maintain blood pressure in addition to veno-constriction leading to improved 
venous return to the heart (Secher 1985, Little 1989).  
 
Sympathetic stimulation of the adrenal glands stimulates the release of 
catecholamines into the blood, reinforcing the effect of sympathetic 
stimulation on the heart and vasculature.  This increased sympathetic 
outflow has little influence on both cerebral and coronary circulations, but 
they both benefit from the vasoconstriction that occurs in other organs (e.g. 
gastro-intestinal, skeletal muscle and renal).  Blood is moved away from 
peripheral vessels decreasing blood flow to certain inessential organs such 
as skeletal muscle.  The kidneys can receive 25% of the cardiac output, 
which is far in excess of their oxygen requirements.  Renal vasoconstriction 
moves blood away from the kidneys and their diminished blood flow also 
causes oliguria leading to retention of salt and water, aiding blood volume 
maintenance.  Reduced organ blood flow results in poor oxygen delivery 
and a subsequent acidosis that is sensed by the chemoreceptors.  The 
chemoreceptor reflex strengthens the baroreceptor reflex and activates 
further the sympathetic/adrenergic system.   
 
The increased venous return from veno-constriction results in an 
autotransfusion that limits cardiac output reduction.  The arterial 
baroreceptors are able to transduce information on pulse pressure resulting 
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in continued compensation despite no drop in systolic or mean arterial blood 
pressure.  It is postulated that haemorrhage actually leads to an increased 
sensitivity of the arterial baroreceptor reflex such that a given change in 
blood pressure evokes a greater alteration in heart rate (Little 1984), which 
would explain the increased efficacy of this mechanism in haemorrhage.  A 
fairly consistent blood pressure can initially be kept by these mechanisms in 
a physically fit human being, in the face of on-going haemorrhage. 
 
Changes in Starling forces across the capillaries result in net reabsorption 
of interstitial fluid into the blood to increase plasma volume at about 1 litre 
per hour (Carroll 2007, Klabunde 2012).  A reduced capillary hydrostatic 
pressure leads to net reabsorption in the capillary of fluid including 
electrolytes and some protein, but no cells.  It leads to an increased plasma 
volume and haemodilution of blood resulting in a drop in red cell 
haematocrit. 
 
The initial acute cardiovascular response to haemorrhage is therefore 
tachycardia, arterial vasoconstriction and veno-constriction in an attempt to 
maintain blood pressure and blood flow to vital organs.  
 
 
3.8.2  Delayed Cardiovascular Response to Haemorrhage 
 
Delayed responses to blood loss help aim to restore plasma volume, 
proteins and red cells.  Volume restoration is secondary to a number of 
humoral actions; renal renin release leads to increased angiotensin II and 
aldosterone.  Increased ADH (Vasopressin) release occurs due to input 
from volume receptors.  These result in increased thirst mechanisms and 
increased sodium and water reabsorption from the kidneys.  This renal 
mechanism is important in the long-term recovery from blood loss. 
 
Hepatic protein synthesis restores plasma protein levels to normal levels in 
a few days.  Bone marrow erythropoiesis is stimulated leading to increased 
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erythropoietin levels.  Reticulocyte levels will peak at 10 days with full red 
cell restoration by 4 to 8 weeks after blood loss.   
 
3.8.3  Experimental Studies 
 
In experimental studies in response to a “pure” haemorrhage with no tissue 
injury or nociception there is a distinct second staged response to 
haemorrhage.  After significant blood loss in excess of 20% of blood volume 
a depressor reflex occurs exhibiting as a bradycardia and vasodilatation 
leading to a fall in blood pressure (Barcroft 1944, Secher 1985; Figure 3-5).  
This is a vagally mediated depressor response arising from the heart 
(Evans 1989) and is mediated possibly via cardiac C fibres (Öberg 1972).  
Studies on animals deficient of C fibres (Öberg 1972) and in animals with 
vagotomies (Little 1989) have shown a markedly attenuated bardycardic 
response.  The exact mechanism is not clear as it is preserved after cardiac 
transplantation (total denervation of the heart) suggesting other signaling 
pathways are involved.  It has been postulated this is a basic reflex in order 
to reduce cardiac workload at a time when coronary blood flow is 
compromised (Little 1997). 
 
The initial response to simple haemorrhage is therefore biphasic (Figure 3-
5); an initial tachycardia and vasoconstriction maintaining mean arterial 
blood pressure in the face of reduced cardiac output associated with 
moderate hypovolaemia.  As haemorrhage continues beyond 20% of blood 
volume a vagally mediated depressor reflex results in decompensatory 
bradycardia and vasodilation, which increases hypotension. 
 
A further third phase has been shown to emerge before irreversible shock 
occurs.  When over 40% of volume has been lost a pre-terminal phase of 
tachycardia and hypotension occurs (Jacobsen 1990, 1992) and appears to 


































Figure 3-5.  Simple haemorrhage in a male volunteer showing biphasic response.  Blood 
removed by venesection until volunteer fainted.  Total Peripheral Resistance (TPR), Heart 
Rate (HR), Systolic Blood Pressure (BP), Right Atrial Pressure (termed Auricular) RAP, 
Cardiac Output (CO).  (Barcroft 1944)  
  
Simple or “pure” haemorrhage is a rare event and it is more commonly 
associated with pain or musculo-skeletal injury.  The cardiovascular 
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changes that occur in simple haemorrhage are significantly diminished by 




3.9  Cardiovascular Response to Haemorrhage and Injury 
 
Isolated musculoskeletal injury itself diminishes the vagal outflow producing 
an increase in heart rate and elevating arterial blood pressure via increased 
sympathetic outflow (Redfern 1984).  The effect of experimental animal 
injury on the cardiovascular response to hemorrhage has been studied and 
shown to attenuate or completely prevent the vagally mediated bradycardia 
reflex in the biphasic response to haemorrhage (Little 1989).  This protects 
the animal against the hypotensive effects of severe haemorrhage meaning 
a larger loss of blood was required to produce a fall in blood pressure in the 
injured animal.  
 
This attenuation of the bradycardic reflex is most likely to be due to central 
inhibition of the medullary central depressor region by afferent nociceptor C 
fibres from the injured area (Quest 1972). 
 
It appears the preservation of a better blood pressure though is at the cost 
of peripheral vasoconstriction leading to organ ischaemia and damage 
exacerbating the resulting injury.  Unlike simple haemorrhage where blood 
flow is redistributed away from skeletal muscle the opposite occurs with 
haemorrhage and injury.  In the latter blood is diverted from the gut towards 
skeletal muscle (Mackway-Jones 1999).  An understandable reflex for 
survival in fight or flight where skeletal muscles will be used but in the 
experimental animal model or indeed the patient receiving medical 
treatment and no longer “in the fight” the net result is diminished survival.  
Oxygen delivery is wasted on inactive muscle at the expense of the 
metabolically active gut.  Ischaemic damage to the intestines may result in 
both an enhanced endotoxin translocation (Xu 2004) and a resultant 




Therefore although injury reduces the initial bradycardic response to 
haemorrhage and enables a greater tolerance of blood loss it results in 
reduced survival in an animal model (Wang 1949).  When haemorrhage is 
superimposed on real rather than simulated tissue injury, the tolerance to 




3.10  Cardiovascular Response to Haemorrhage and Blast 
 
The cardio-respiratory effects of primary blast injury producing bradycardia, 
hypotension and apnoea have already been described (Guy 1989, section 
3.6.4).  Vagotomy completely abolishes the bradycardia and apnoea and 
partially abolishes the hypotension (Ohnishi 2001).  The majority of blast 
casualties will have ballistic injuries secondary to fragmentation, with 
resultant haemorrhage (Cooper 1983).  Simultaneous musculo-skeletal 
(blunt) injury attenuates the depressor response to haemorhage (section 
3.9), but this is not so in the case of primary blast injury.  Blast injury will 
augment the bradycardic, hypotensive response to haemorrhage with the 
bradycardic element occurring after significantly less blood loss.  It appears 
blast augments the depressor response to haemorrhage seen in pure 
haemorhage, abrogating the baroreceptor reflex; inhibiting the initial 
compensatory response (tachycardia and vasoconstriction) and 
accentuates the secondary phase of bradycardia and hypotenson (Sawdon 
2002).   
 
This response is further modulated by morphine, which is known to reduce 
the depressor response to blood loss (Evans 1989, Ohnishi 1997).  
Intravenous morphine prevented the bradycardia associated with severe 
haemorrhage and delayed the onset of hypotension (Sawdon 2002).  Thus, 
contrary to injury and haemorhage where the cardiovascular depressor 
effects of blood loss are attenuated by concurrent injury, in primary blast 
injury these depressor effects are augmented.  The incidence of isolated 
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haemorrhage and primary blast injuries are very low though, with the 




3.11  Helmand Casualties 
 
How does the physical impact of these injuries and the responses to them 
translate into the actual casualties observed in Helmand?  Two articles give 
a good insight into these.  One prospective study investigated the 
coagulation status of casualties injured by Improvised Explosive Devices 
retrieved from the front line by the MERT (Nordmann 2016).  Their 
demographic data is detailed in Table 3-3.  Ten severely injured patients (at 
least one limb amputation, NISS 47.8±12.63), with systolic blood pressures 
of 55.0±10.8mmHg had their coagulation measured by rotational 
thromboelastometry (ROTEM®).  They were found to be severely 
coagulopathic with evidence of hyperfibrinolysis and significantly reduced 
fibrinogen - the common features of Acute Traumatic Coagulopathy.  This 
coagulopathy was evident within 40 minutes of injury. 
 
A retrospective intra-operative study based in the UK hospital at Camp 
Bastion studied intra-operative resuscitation methods on 51 casualties 
(Morrison 2013a).  It gives an idea of the status of patients on admission to 
the hospital (Table 3-3).  Both studies describe a severely injured patient 
group that has suffered blast and fragmentation injuries.  They are 
hypotensive, acidotic and coagulopathic.  
 
For these patients to survive in the pre-hospital environment they need to 
form a clot to avoid bleeding to death, yet we see evidence in them of a 
coagulopathy (reduced ability to clot).  What is the cause of this 
coagulopathy?  Has the large amount of clot needed to survive consumed 




















Table 3-3.  Military ballistic casualty demographics. Patient demographics from two studies 
describing patient physiology in the pre-hospital space (Nordmann 2016) and on admission 
to hospital (Morrison 2013a) having been transferred by the Medical Emergency Response 
Team (MERT) and admitted to the military trauma hospital in Camp Bastion, Afghanistan. 
(SEM, Standard Error of the Mean; IQR, Inter Quartile Range; NISS, New Injury Severity 
Score; ISS, Injury Severity Score; BE, Base Excess; PT, Prothrombin Time).  
 
 
blast, haemorrhage and ballistic fragmentation) have an influence?  Can we 
do anything to improve or reverse this coagulopathy? 
 
In summary, the general effect of injury is varying degrees of tissue damage 
and haemorrhage.  Blast injuries can cause injuries peculiar to it, but most 
blast casualties also suffer injuries in common with the rest of the injured 
population: blood loss and major tissue damage.  The physiological 
consequence to these injuries is well documented with casualties from 
Helmand illustrating that they are hypotensive, acidotic and coagulopathic.  
Haemorrhage is known to be the leading cause of death and for these 
patients to survive they need to form a clot to avoid bleeding to death.  
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There is evidence here that the coagulation system becomes altered over 
time, not only secondary to consumption of clotting factors, but also as a 
result of the physiological derangement caused by these injuries.  In the 
next chapter the coagulation system and how it can be impacted by trauma 













4.1  Introduction 
 
Haemostasis is the process of preventing blood loss.  Upon blood vessel 
damage this action is mediated through blood vessel constriction and the 
balance of interaction between platelets, the coagulation system (clot 
formation) (Figure 4-1) and fibrinolysis (breakdown of clots).  The end result 
is an impermeable plug, or clot, of platelets and fibrin formed at the site of 
injury.  The activation of the platelets and the coagulation system is 
restricted to the site of injury only, to ensure the plug or thrombus does not 
spread into the vascular lumen.  This final regulatory process of 





Figure 4-1. Homeostasis overview. (From Hoffbrand 2011 Essential Haematology 6th Ed.© 




A fine equilibrium exists between blood fluidity and thrombus formation and 
this is managed by a tight regulation of platelet activation, coagulation 





4.2  Vasoconstriction 
 
When blood vessels are damaged, circular smooth muscle in the vessel 
wall contracts.  The vascular contraction or spasm reduces the blood flow to 





4.3  Platelets 
 
Platelets are discoid structures 2-4µm in size that circulate at the margins of 
blood vessels (Loscalzo 2003).  The platelet ultrastructure is shown in 
Figure 4-2.  The plasma cell invaginates into the cell producing canaliculi, 
which increase the cell surface area in order to better absorb coagulation 
proteins.  The platelet surface is packed with functional glycoprotein 
receptors that facilitate platelet activation and interactions with the 
subendothelial matrix, other platelets and other blood cells (Hoffbrand 
2011). 
 
Within their complex structure lies a number of granules within the cytosol 
(Jurk 2005) that upon activation can fuse with the platelet membrane and 
release their contents into the surrounding media (Harrison 2005).  α-
granules are the most prevalent and contain adhesive proteins 




Figure 4-2. Platelet ultrastructure (From Hoffbrand 2011 Essential Haematology 6th Ed.© 
2011 Wiley-Blackwell Publishing) 
 
 
FXIII) and regulators of coagulation (protein C, plasmin activator inhibitor 1 
[PAI-1], tissue factor pathway inhibitor [TFPI]).  Electron dense granules 
contain secondary agonists of platelets which will signal for further platelet 
activation once released in addition to Calcium; a vital co-enzyme in 
coagulation and platelet activation (Jurk 2005).   
 
The open canalicular system (OCS) is a network of cell membrane lined 
channels that pass through the platelet and provide an initial area in which 
exocytosis can occur and a cell membrane “store” for when platelets divide 
or expand.  A dense tubular system forms a cytoskeleton that is involved in 
allowing shape change.   
 
 
4.3.1  Platelet Adhesion 
 
Once the vessel wall is damaged platelets adhere to the exposed collagen 
in the subendothelial matrix mediated by synergistic reactions occurring 
between several receptors in the platelet surface (Figure 4-3; Furie 2008).  
Initially Glycoprotein Ib (GPIb) interacts with vWF binding the platelet to the 
area of damage.  Activation of these various receptors leads to intracellular 
	
	 54	
signals that cause a conformational change in the platelet GPIIb/IIIa 
complex.  This exposed binding site can then bind to vWF fixing the platelet 
in location or it can bind to fibrinogen enabling crosslinking.  
 
 
4.3.2  Platelet Activation 
 
Once bound to the subendothelial matrix the platelet becomes activated 
(Furie 2008) which initiates a change in platelet morphology: they sphericise 
and extrude pseudopodia, which enhance interactions between platelets 
and vessel walls.  The cytoskeleton changes cause the classical “fried egg” 
appearance: long and flat with centralised granules and organelles.  The 
next stage is for further platelet recruitment, which needs the transmission 
of the activated state of adhered platelets to newly incoming platelets.  This 
occurs through autocrine and paracrine signaling released from intracellular 











4.3.3   Platelet Aggregation 
   
Once the initial layer of platelets has covered the subendothelial matrix, 
adhesion continues in the form of aggregation with two platelets binding to 
the same fibrinogen molecule (Figure 4-3).  These aggregated platelets 
then form a plug, which (in addition to vasoconstriction) blocks the blood 
loss from the vessel.  Microvesicle extrusion provides a large surface area 
for large amounts of thrombin to be generated, which in turn leads to clot 
stabilization by fibrin cross-linking.  The final aspect is platelet contraction 




4.4  Coagulation Cascade 
 
4.4.1  Tissue Factor  
 
Vessel injury exposes tissue factor (TF) - a class II cytokine held in vascular 
smooth muscle cells and pericytes - to the plasma and it binds to 
coagulation factor 7 (FVII, where F and Roman numerals are the 
recognized nomenclature for coagulation factors).  These form a complex 
on cellular surfaces that triggers the coagulation cascade. 
 
 
4.4.2   Classic Clotting Cascade 
 
The “classic clotting cascade” was traditionally described as consisting of an 
“extrinsic pathway” which was initiated by TF interacting with FVII and an 
“intrinsic pathway” initiated by Thrombin and involving FVIII and FIX (Figure 




Figure 4-4. The classic view of the clotting cascade, the intrinsic pathway is initiated by the 
exposure of blood to a negatively charged surface (e.g., thrombin or glass) and the 




Both of these pathways resulted in activation of their relevant coagulation 
factors, eventually coming together to form a “common pathway”.  This 
pathway resulted after the activation of coagulation factor 10 (FX), which 
bound to factor 5 (FV) to form the FXa/FVa complex (where the a describes 
an activated coagulation factor) known as pro-thrombinase (Dahlback 




4.5  Cell Based Coagulation 
 
The modern concept of coagulation, that has replaced the concept of 
extrinsic and intrinsic pathways, is the cell-based theory, so called because 
cell surfaces are the keystone of its progression.  Cell-based coagulation 
consists of highly regulated reactions that take place on cell surfaces 
(Hoffman 2001, Monroe 2002) in three phases: initiation, amplification and 
propagation (Figure 4-5).  These phases start with the exposure of TF-
bearing cells (such as myocytes or adventitial fibroblasts) from the cell wall, 
resulting in the production of pro-thrombinase complex (FXa/FVa complex).  
This initial pro-coagulant signal is amplified involving the activation of 
platelets and finally leads to the propagation of the thrombin generation 
(Monroe 2006, Mann 2003a, Roberts 2006), known as the “thrombin burst” 






Figure 4-5. Cell based coagulation (From General mechanisms of coagulation in 







4.5.1  Thrombin 
 
Thrombin is central to the whole process of haemostasis and the regulation 
of homeostasis.  It is has both pro- and anti-coagulant properties.  Produced 
early in the clotting process: it activates platelets initially and then the 
“thrombin burst” causes fibrinogen conversion to insoluble fibrinogen.  It 
stabilises the clot by activating FXIII to form the fibrin stabilising factor 
(FXIIIa) and inhibits fibrinolysis through its action in thrombin activated 
fibrinolysis inhibitor (TAFI).  Thrombin is also anti-coagulant as it activates 
protein C once it is bound to Thrombomodulin.  Thrombin is involved in all 3 
phases of cell based coagulation: initiation, amplification and propagation. 
 
 
4.5.2  Initiation 
 
Initiation is localized to TF-bearing cells exposed after vessel endothelial 
injury.  The proteolytic TF/FVIIa complex activates coagulation factors FIX 
and FX.  On TF-expressed cells, FXa binds with FVa to form the pro-
thrombinase complex.  This complex cleaves prothrombin (FII) to generate 
a minor quantity of thrombin (FIIa) (Figure 4-6), the enzyme responsible for 
fibrin formation.  The amount of thrombin generated is not enough to 
produce a significant amount of fibrin, and a subsequent clot, but that is not 
its function in this part of the clotting pathway; its function here is for the 
initiation of the next stage – amplification. 
 
 
4.5.3   Amplification  
 
In the amplification stage, platelets adhere to the injury site and are 
activated by the low concentration of thrombin (FIIa) initiating the release of 
more FV and a positive feed back loop is formed; thrombin activates 
circulating FV, releases FVIII from von Willebrand factor (vWF) and 
activates it.  vWF also has a key role to play in platelet adhesion.  The FVa 







Figure 4-6.  Clot Initiation. TF: Tissue Factor, FII: Prothrombin, FII: Thrombin, FV: 
Proaccelerin, FVII: Proaccelerin, FVa/FXa: Prothrombinase complex, FIX: Christmas factor, 




platelet surfaces and act as co-factors for a massive generation of thrombin 
produced in the propagation phase (Figure 4-7). 
 
 
4.5.4  Propagation   
 
The propagation phase results from the two complexes – FVIIIa/FIXa 
“intrinsic tenase” and FVa/FXa “prothrombinase”– assembling on the 
activated platelet surface and accelerating the production of FXa and in turn 
thrombin (FIIa). The brisk linking of FXa and FVa results in a “thrombin 
burst” which in turn converts fibrinogen (FI) to fibrin.  
 
The soluble fibrin monomers polymerise to form fibrin protofibrils. These are 
stabilized by FXIIIa (also activated by thrombin) to form a solid fibrin mesh 
network that stabilizes the assembled platelets to form a platelet/fibrin 






Figure 4-7.  Clot Amplification and Propagation. FI: Fibrinogen, FVIII: Antihaemophilic 
factor, XIII: Fibrin stabilizing factor. 
 
 
Coagulation is essentially comprised of a number of enzymatic processes, 
the activation of each factor or complex results in a magnification in the next 
resultant reaction so that thrombin production is the result of significant 
amplification; one FXa molecule generates approximately 1000 molecules 




4.6  Anti-coagulation 
 
The activation of coagulation, its “thrombin burst” and the formation of fibrin 
need to be regulated or there is the potential for pathological thrombus 
formation.  To control this process and ensure it is confined to the precise 
location of injury, there are a number of regulatory mechanisms including 
enzyme inhibition and alteration of cofactor activity.  The main inhibitory 
systems are anti-thrombin, protein C and protein S (and to some extent 
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TFPI) as the most important regulators of coagulation initiation (prevention 
of inappropriate clots forming).  In addition there is the fibrinolytic system 
(breakdown of clots) led by plasmin.  
 
 
4.6.1  Tissue Factor Pathway Inhibitor 
 
Tissue factor pathway inhibitor is a circulating plasma protease inhibitor that 
is synthesized by the microvascular endothelium.  Approximately 20% of 
TFPI circulating in plasma is associated with lipoproteins; the majority 
remaining associated with the endothelial surface bound to the glycocalyx 
(Lupu 1995).  TFPI has a very low plasma concentration and inhibits FXa. 
The TFPI/factor Xa complex becomes an effective inhibitor of tissue 
factor/factor VIIa (TF/FVIIa complex).   
 
 
4.6.2  Antithrombin 
 
Antithrombin (AT) is a protease inhibitor and inhibits the majority of the 
enzymes generated during the activation of coagulation.  As it inhibits 
preferentially free enzymes, rather than those that are part of the intrinsic 
tenase or prothrombinase complexes, it is probably fundamental to reducing 
and localizing coagulation to the sites of vascular injury plus protecting the 
circulation from liberated enzymes (Dahlback 2000, Monroe 2006).  AT by 
itself is inefficient but the heparin-like molecules on vascular endothelium 
stimulate its activity. 
 
 
4.6.3  Protein C and S 
 
Thrombomodulin (TM) is a molecule present on vascular endothelium, 
which binds thrombin.  This thrombin/TM complex converts protein C to its 
activated form (Esmon 2003); activated protein C (APC).  Activation to APC 
via thrombin is a slow process but is accelerated 100 fold when thrombin 
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binds to TM and another 20 fold when this complex binds to endothelial 
protein C receptor (EPCR) - a receptor which offers protein C to the 
thrombin/TM complex.  This suggests that this the mechanism for 
endothelial control of thrombosis (Esmon 2003). 
 
Activated protein C regulates or suppresses coagulation by reducing the 
activity of co-factors, in particular FVIIIa and FVa (Dahlback 2000) 
 
Protein S, like protein C, is another Vitamin K dependent co-factor that 
supports the anticoagulant activity of APC.  APC and protein S form a 
membrane bound complex that can split FVIIIa and FVa even when these 
are part of fully formed pro-coagulant complexes.  FVIIIa is normally bound 
to von Willebrand factor, which prevents it from reacting with the 
phospholipid membranes.  APC can split off FV even if bound to 
phospholipids and so the anticoagulant FV produced works in collaboration 
with protein S as a cofactor with APC in the degradation of FVIIIa.  
 
The importance of the protein C system is illustrated by the symptoms 
associated with protein C or S deficiency in humans (Jalbert 1998), which 
produces a severe thrombo-embolic disease. 
 
The thrombin/TM complex, although anti-coagulant in action here with its 
establishment of protein C into inhibiting clotting factor activity, also has pro-
coagulant anti-fibrinolytic activity.  Thrombin/TM activates thrombin 
activatable fibrinolysis inhibitor (TAFI), which by its action on fibrin inhibits 
fibrinolysis (Bouma 2003). 
 
Thrombin therefore has a key part in both coagulation and anticoagulation; 
at a site of vascular injury it is pro-coagulant in contrast to the intact 
vascular system where it has anticoagulant activity when it binds to TM and 






4.7  Fibrinolysis 
 
The process of clot breakdown is termed fibrinolysis, which exists to limit or 
prevent excessive thrombus production (Figure 4-8).  The process is driven 
by plasmin, the main action of which is to cleave fibrin resulting in a number 
of soluble fibrin degradation products (FDPs). These in turn compete with 
thrombin and consequently reduce further clot formation.    
 
Tissue-plasminogen activator (t-PA) and urokinase convert plasminogen to 
active plasmin that in turn breaks down fibrin.  t-PA is a proteolytic enzyme 
produced by intact endothelial cells and is a crucial part of restricting 
coagulation to the site of vessel damage.  The half-life of t-PA is short and it 
is a poor activator of plasminogen, yet in the presence of fibrin (which acts a 
co-enzyme) its action is increased 100 fold (Rijken 2009), is prolonged and 
concentrates the production of plasmin to the clot site. 
 
Reduced activity of t-PA can lead to thrombosis or embolic events, whereas 




4.7.1  Fibrinolysis Inhibition 
 
Plasmin is the main enzyme in fibrinolysis and its activity can be reduced by 
the presence of α2-Antiplasmin (a2-AP) and thrombin activatable fibrinolysis 
inhibitor (TAFI).  The former inhibits plasmin whereas the latter inhibits 
plasmin function (figure 4-8).  Fibrin terminal lysines are exposed upon 
limited proteolysis of fibrin by plasmin and act as ligands for the lysine-
binding sites of plasminogen and tissue-type plasminogen activator (t-PA) 
that then produce further plasmin.  Elimination of these lysines by TAFI 
abolishes the fibrin cofactor function of t-PA-mediated plasminogen 
activation, resulting in a decreased rate of plasmin generation and thus 


















Figure 4-8. Fibrin degradation. Plasminogen is activated by tissue type plasminogen 
activator (t-PA) or urokinase.  These enzymes are regulated by plasminogen activator 
inhibitor-1 (PAI-1). Plasmin degrades fibrin into soluble fibrin degradation products (FDP) 
and is regulated by α2-Antiplasmin (α2-AP). Thrombin converts fibrinogen into fibrin and 
also activates thrombin activatable fibrinolysis inhibitor (TAFI) which inhibits fibrinolysis by 
modifying the fibrin substrate. (Adapted from Bouma 2003). 
 
 
The conversion of plasminogen to plasmin is controlled by t-PA.  t-PA is 
inhibited by plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2).  
PAI-1 is the most significant and its release is stimulated by various 
inflammatory and coagulation mediators including thrombin (Cesarman-
Maus 2005).   
 
On the contrary excessive APC enhances fibrinolysis by degradation of PAI-
1, further evidence of the multiple contrary actions of thrombin, which 
influences APC generation.  This latter aspect of inhibition of fibrinolysis 
inhibition, or in other words fibrinolysis stimulation as mediated by APC is a 
critical aspect of the coagulation abnormalities observed in the trauma 




4.8  Coagulopathy 
 
Coagulopathy is used to describe a pathological fault in homeostasis, which 
leads to either hypercoagulopathy (an increase in thrombosis in either 
quality or quantity) or hypocoagulopathy (a decrease in thrombus formation 
through inadequate coagulation or excessive degradation).  The focus of 
this thesis is Acute Traumatic Coagulopathy, which is a hypocoagulopathic 
state, and as such for the remainder of this text the term “coagulopathy” will 
be used to describe hypocoagulopathy.  
 
Coagulopathies are either acquired or inherited.  Inherited coagulopathies 
are usually secondary to a deficiency of one aspect of the clotting system 
resulting in poor clot formation, such as Haemophilia where there is a 
deficiency in certain clotting factors (paucity of FVIII in Haemophilia A, FIX 
in B, FXI in C) and in Von Willebrands Disease (missing or defective vWF). 
Acquired coagulopathies are either iatrogenic or pathological.  Iatrogenic 
are caused by anticoagulant treatment, given for a variety of reasons, but 
predominantly prophylaxis in conditions where the risk of abnormal 
thrombus formation is increased.  Examples of this are patients with Atrial 
Fibrillation or those with prosthetic heart valves treated by Warfarin; patients 
with Acute Coronary Syndrome treated by heparin; or in post-operative 
prophylaxis against venous thrombo-embolism given Low Molecular Weight 
Heparins.  Examples of pathological acquired coagulopathies are Vitamin K 
deficiency in liver disease, Disseminated Intravascular Coagulopathy in 
Obstetric patients or the Trauma Induced Coagulopathies in trauma patients 
(Kumar 2016). 
 
The causes of Trauma Induced Coagulopathy are multifactorial (Davenport 
2011a; Figure 4-9) and were originally described as being the lethal triad of 
dilution, acidosis and hypothermia.   
 
In the last decade the role of hormones, cytokines and the immunological 
system have all been better understood to have a role in Trauma Induced 
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Coagulopathy (TIC) and in particular a separate pathological division of that 










4.9  Trauma Induced Coagulopathy 
 
Trauma Induced Coagulopathy (TIC) is the term used to describe 
coagulation abnormalities, particularly hypo-coagulation, associated with 
and found in a trauma casualty.  
 
Coagulation abnormalities in trauma casualties were identified over half a 
century ago.  In the Vietnam War (Second Indochina War) a direct 
association was identified between the presence of shock and clotting 
abnormalities in casualties (Simmons 1969).  A couple of decades later a 
causal relationship was found between a drop in blood pressure (BP) to less 
than 100mmHg and activation of the clotting system (Risberg 1986) and 
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that those casualties receiving resuscitation with dilution by crystalloid 
infusion developed a coagulopathy (Hewson 1985).  Until recently 
crystalloids were the principle initial therapy used in trauma patients as 
advised for decades by the American College of Surgeons Committee on 
Trauma and taught on the Advanced Trauma Life Support (ATLS) course 
(Kortbeek 2008).  The advice for its use was continued on this side of the 
Atlantic by the reasonably recent recommendation in the European 
Guidelines on the management of bleeding (Rossaint 2016).  In this 
guideline it was only once anaemia developed that the patient was treated 
with packed red blood cells (PRBC) and other component therapy was not 
used until much later (Curry 2012) in the resuscitation pathway. This 
resulted in the dilution of clotting factors establishing a dilutional 
coagulopathy. 
 
In the first few minutes after injury increased clotting (excessive clot 
formation) will occur (Riha 2013, Duan 2014).  This is an appropriate and 
reasonable response if it is localised only to injury site, however subsequent 
significant or excessive clot formation in an attempt to cessate bleeding can 
lead to a reduction in available clotting factors; a consumptive 
coagulopathy.  Continued bleeding exacerbates this response.  
 
The inadequate resuscitation methods, recommended by ATLS and other 
bodies, based around the use of crystalloids commonly led to the production 
of an acidosis.  The excessive cold crystalloid infusion, in addition to over 
exposure of the patient in order to fully examine their injuries led to patients 
becoming cold.  The culmination of all these factors contributed to a 
worsened coagulopathy.  This iatrogenic “resuscitation associated 
coagulopathy” or lethal triad (described later) is generally found later in the 
patient’s pathway. 
 
A separate pathological coagulation abnormality has been identified not 
related to the lethal triad.  This separate pathological process has been 
found early in the trauma process and temporally seems to be important 
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initially, with the lethal triad resuscitation based coagulopathy predominating 









Brohi (2003) and his team at the Royal London Hospital - arguably one of 
the busiest UK trauma centres - studied just over 1000 patients suffering 
from traumatic injuries.  They had a typical UK trauma pattern of 75% 
suffering blunt trauma and a median injury severity score (ISS) of 20.  
These patients were predominantly male, had been rapidly brought to the 
hospital (median 73 minutes) and had received less than a litre of fluid.  
There was no significant relationship between type and quantity of fluid 
received and coagulopathy.  They had therefore not achieved the 
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parameters of the “lethal triad” of trauma, yet 24.4% of the patients were 
coagulopathic on arrival.  
 
Coagulopathy was determined by aPTT or PT of greater than 1.5 times 
normal and was not affected by age or mechanism of injury (blunt versus 
penetrating).  However the incidence of coagulopathy increased with a rise 
in ISS; the median incidence of coagulopathy was 24.4% but this rose to 
33.1% for those who had an ISS >15 and 61.7% for those with an ISS  >45.   
Key to this paper was the effect on mortality, as coagulopathic patients had 
a mortality of 46% compared to 10.9% in non-coagulopathic patients.  This 
paper showed evidence of an early coagulopathy that was evident in trauma 
casualties, related to injury severity and had a direct relationship with 
mortality.  This was a coagulopathy that was not caused by dilution or 
hypothermia but was a separate additional pathological element to TIC and 




4.10  Acute Traumatic Coagulopathy 
 
In the last decade a number of trauma centers both in UK and USA have 
found that some trauma casualties on admission to the hospital are 
coagulopathic despite little or no haemodilution, no excessive acidosis and 
minimal reduction in temperature (Brohi 2003, MacLeod 2003, Maegele 
2007).  These patients are more likely to need a “massive” blood 
transfusion, develop multi-organ failure and have a four fold chance of 
dying.  
 
In the USA MacLeod’s team (2003) analysed the data on nearly 8000 
trauma casualties from their hospital in Florida over a 5-year period.  The 
population was similar (predominantly male, suffering blunt injury arriving at 
about 70 minutes post injury).  28% of the patients were coagulopathic and 
had an increased mortality of 19.3% compared to 6.3% in non-
coagulopathic patients.  Maegele’s (2007) larger, but retrospective, study of 
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over 17000 patients from the German trauma registry had a higher 
incidence of blunt trauma (96%) and found 34.2% were coagulopathic.  
 
These arguably seminal papers were of a civilian population suffering 
predominantly blunt trauma.  The military casualty is different particularly in 
mechanism of injury with ballistic injuries and high injury severity scores 
predominating.  The proportion of military patients who have ATC remains 
unclear, although several papers have suggested rates around 40 - 50% 
(Plotkin 2008, Niles 2009, Doran 2010), which is considerably higher than 
the civilian population.  As the presence of ATC on admission is related to 
mortality (Brohi 2003, Macleod 2003, Maegele 2007), detecting its presence 
and finding ways to reduce it or indeed ameliorate the treatment of it are at 
the forefront of every military physicians and researchers mind.  
 
 
4.10.1  Pathophysiology of ATC 
 
Continued work into this coagulopathy is improving our knowledge into its 
pathophysiology.  The underlying processes appear to be an unwarranted 
activation of haemostasis that leads to excessive coagulation and 
fibrinolysis (Brohi 2007a, Doran 2012).  Collagen and Tissue Factor (TF) 
exposure with tissue damage leads to thrombin generation that is related to 
the amount of TF exposed (Dunbar 2009).  Excessive TF exposure causes 
a disproportionate activation of haemostasis.  
 
A number of observational studies have illustrated some of the changes that 
occur in ATC.  These have led to a generalized theory of the ongoing 
processes, the pathophysiology of ATC and in particular the role of 
activated protein C (Brohi 2007a, Cohen 2012).  
 
The initiator of this coagulopathy is excessive thrombin.  High thrombin 
generation has been illustrated by a number of studies (Dunbar 2009, 
Chandler 2010, Woolley 2013).  These and others (Brohi 2007a, Shaz 
2011, Floccard 2012, Rourke 2012) have illustrated low quantity of clotting 
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factors, reduced protein C levels, low platelet counts, low fibrinogen and low 
antithrombin – an indication of consumption of vital coagulation reagents.  
Fibrinogen is one of the first coagulation proteins to fall to critically low 
levels (Rourke 2012, Curry 2012) and FV is consistently the lowest clotting 
factor (Bickell 1994, Yuan 2007, Rizoli 2011).   
 
This reduction in fibrinogen is as a result of a number of elements, but of 
note is the role of thrombin.  Thrombin is pro-coagulant in leading to fibrin 
polymerization and deposition but it also triggers the endothelium to release 
tissue plasminogen activator (tPA), which in turn leads to plasmin 
production and therefore fibrin breakdown.  This release of tPA is 
augmented by the presence of hypoperfusion (Brohi 2008, Hayakawa 2011) 
and many see hypoperfusion as the key initiating mechanism for ATC.  
 
The endothelium is a vital aspect of the control and initiation of clotting.  The 
surface of the endothelium is lined by a group of proteins linked with 
glycosaminoglycan chains termed the glycocalyx (Reitsma 2007).  The 
glycocalyx or rather its destruction is an important intercessor for ATC 
development and hypoperfusion is a crucial initiator of glycocalyx 
destruction.   
 
 
4.10.2  Endothelial Glycocalyx 
 
The glycocalyx (Figure 4-11) lines the vascular endothelium and one of the 
glycocalyx proteins is Syndecan-1, a proteoglycan.  Its presence in the 
serum correlates well with glcocalyx destruction (Rehm 2007).  A number of 
factors associated with trauma disrupt the glycocalyx in addition to 
hypoperfusion, including direct tissue trauma, catecholamine levels and 
inflammation (Maegele 2014, Johansson 2011).  
 
A number of potential mechanisms for the role of the glycocalyx have been 

























Figure 4-11. Electron microscope views of the glcocalyx. A Intact glycocalyx. B Disrupted 
glycocalyx. (From Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, et al. 
Hydrocortisone Preserves the Vascular Barrier by Protecting the Endothelial Glycocalyx 
Anesthesiology 2007; 107:776–84.) 
 
 
into the circulation upon glycocalyx damage with its heparin-like properties 
having an anticoagulant effect (Johansson 2010, Liu 2007).   
 
The main concentration of work in this field has been on the link between 
glycocalyx disruption and the activated protein C (APC) pathway.   
Johansson (2011) showed that significant endothelial glycocalyx destruction 
led to increased Thrombomodulin, reduced protein C concentrations, 
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hyperfibrinolysis and prolonged coagulation times (as measured by 
conventional laboratory tests - activated partial thromboplastin time [aPTT]). 
 
These results all infer a significant correlation between glycocalyx 
destruction and Acute Traumatic Coagulopathy development mediated by 
APC.   However when that group looked at the correlation between 
glycocalyx destruction and directly measured APC levels their findings were 
conflicting (Ostrowski 2012a) and more in keeping to with the auto-
heparinisation mechanism.  They found more severely injured patients had 
a higher level of glycocalyx destruction and a lower level of protein C, but 
APC levels were no different between the severity groups, while 
heparinisation (measured by TEG) was greater in the higher injury severity 
group.  It may well be that APC is rapidly broken down within the systemic 
circulation and doesn’t correctly reflect local endothelial and injury site 
concentrations – but this is merely conjecture.  The evidence is suggestive 
that glycocalyx breakdown has probably both auto-heparinisation and APC 
activity in its role in Acute Traumatic Coagulopathy. 
 
Fundamentally the glycocalyx has a key role in the pathophysiology of ATC 
with a number of theories merging into how important the endothelium’s role 
has in this: be it termed the “endotheliopathy of trauma” (Pati 2016, 
Naumann 2017, 2018) or “shock-induced endotheliopathy” (Johansson 
2017).  Trauma is not the only cause of endothelial pathology however, with 
a number of factors being shown to produce evidence of glycocalyx 
disruption including hypoxia (Annecke 2011), sepsis (Nieuwdorp 2009) and 
sympatho-adrenal activation (in trauma)(Ostrowski 2017).  Elements of all 
these are seen in hypo-perfused trauma patients and so this is not entirely 
unexpected.  The presence of Syndecan-1 (evidence of glycocalyx 
destruction) correlates with a number of fundamental consequences to 
trauma including increased vascular permeability (Rahber 2015) and 
inflammatory changes (Ushiyama 2016, Schmidt 2011).   
 
In summary the glycocalyx is influential in the pathophysiology of ATC, with 
studies providing evidence of a number of uniting factors: tissue destruction, 
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endothelial damage, coagulopathy, inflammation and higher mortality.  A 
key finding is the close relationship between hypoperfusion, glycocalyx 
destruction and activation of protein C. 
 
 
4.10.3  Hypoperfusion and the Role of APC 
   
Significant blood loss leads to increased sympathetic drive and natural 
inotrope secretion in order to preserve perfusion pressure to vital organs, 
resulting in vasoconstriction peripherally and in certain organs.  This 
vasoconstriction to deviate blood flow towards vital organs leads to a 
reduced blood flow, or hypoperfusion, elsewhere.  Tissue hypoperfusion 
means inadequate oxygen supply to cells and in the case of ATC it is a 
hypoxic microcirculation – also termed microcirculatory shock – that is the 
driver for this coagulopathy (Brohi 2008, Johansson 2011, Gruen 2012).   
 
Protein C has been shown to be a crucial aspect of ATC.  Tissue 
hypoperfusion produces pathological amplification of protein C activation 
(Brohi 2007b).  The activated protein C (APC) then has a dual action of both 
negative feedback on thrombin production and removal of the inhibition of 
tPA, thus causing a consequent increase in fibrinolysis (Figure 4-12). 
 
Brohi’s team investigated this mechanism at the Royal London trauma 
centre on 208 major trauma patients (Brohi 2007a).  Mean Injury Severity 
Score (ISS) was 17 and initial blood samples were taken at a median time 
of 32 minutes from injury.  Pre-hospital treatment for resuscitation was as 
per local guidelines and hence none received vasopressors nor colloid, and 
crystalloid use was minimal (mean volume 150millilitres).  The data was 
investigated for presence of hypoperfusion (as judged by a base deficit - BD 
- of 6mEq/l or more) and coagulopathy (using conventional laboratory 
results of either Prothrombin Time [PT] or activated Partial Thromboplastin 
Time [aPTT] ratios to normal being increased to 1.5) and compared to injury 
severity.  They found that coagulopathy only occurred if BD >6mEq/l.  At 
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this level of hypoperfusion; thrombomodulin levels increased, protein C 
levels decreased and plasminogen activator inhibitor one (PAI-1) reduced.   
 
The drop in protein C was assumed by the authors to be secondary to an 
increase in APC formation, although APC was not measured directly.  They 
hypothesized that the hypoperfusion as indicated by increased BD led to 
increased thrombin-TM complex production, conversion of protein C to APC 
and subsequent anticoagulation via FVa and FVIIIa inhibition.  In addition 
the reduced PAI-1 (which inhibits t-PA) leads to a rise in t-PA activity 




Figure 4-12. Acute Traumatic Coagulopathy caused by activated Protein C. (From bBrohi K, 
Cohen J, Davenport R. Acute coagulopathy of trauma: mechanism, identification and effect. 
Curr Opin Crit Care 2007; 13: 680-5.) 
 
 
Elements of this theory on ATC pathophysiology is supported by previous 
and subsequent studies.  Animal translational studies (Faller 1999, Doran 
2012) and human studies (Brohi 2003, Niles 2008, Frith 2010, 2012, Cohen 
2013) have all demonstrated the crucial relationships in this theory.  As 
hypoperfusion or shock worsens, indicated in most studies by worsening of 
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BD, then coagulation deteriorates.  Increased injury severity (ISS) and 
hypoperfusion synonymously increase the level of coagulopathy.   
 
The presence of a raised APC (and hence ATC) is important for patient 
outlook.  A raised APC in certain patients (with severe injuries and elevated 
base deficits) is associated with organ injury, raised transfusion 
requirements, and importantly increased mortality (Brohi 2007a, Cohen 
2012).  Interestingly if APC is inhibited (in mice), early traumatic 
coagulopathy is prevented (Chesebro 2009). 
 
The production of APC driven by hypoperfusion appears to be a key part of 
the complex process that leads to ATC, as it both reduces thrombin 




4.10.4  Fibrinolysis 
 
The removal of the inhibition of tissue Plasminogen Activator (tPA) by APC 
leads to increased Plasmin and thus increased fibrinolysis. The presence of 
severe hyperfibrinolysis (defined as 95% lysis within 30 minutes on 
ROTEM®) in trauma patients is associated with mortality rates in excess of 
70% (Ives 2012, Cotton 2012, Schöchl 2009).  The Clinical Randomization 
of an Antifibrinolytic in Significant Hemorrhage (CRASH-2) trial (CRASH-2 
Trial Collaborators 2010) showed a statistical improvement in survival with 
the use of an antifibrinolytic (Tranexamic Acid) in trauma.   
 
Pharmacological cessation of all fibrinolysis is not the panacea for ACT 
though, as patients treated with Tranexamic Acid more than 3 hours after 
injury have an increased mortality (Napolitano 2013), a disturbing fact when 
all UK trauma centres advocate empiric use of Tranexamic Acid in trauma 




The pathophysiological cause of the hyperfibrinolysis is not clear-cut.  The 
theory on ACT foundation as described above (Brohi 2007a) is supported 
by other investigators (Ganter 2010, Lier 2011); its presence mediated by 
an amplified APC pathway instigated by an increased TM release from the 
hypoxic vascular endothelium.  An alternative mechanism is argued by 
Gando (2011) who believed that it is secondary to Disseminated 
Intravascular Coagulopathy (DIC) or rather a sub-group of it - DIC with 
fibrinolytic phenotype - rather than a separate trauma specific pathological 
process (Gando 2013).   
 
Risberg (1978) described two types of fibrinolysis in early trauma; primary 
and secondary. Primary systemic fibrinolysis is “shock-induced” from 
hypoxic endothelium leading to increased t-PA.  Secondary fibrinolysis 
occurs in the microcirculation as a secondary reaction to the deposition of 
fibrin thrombi due to DIC.  It is their belief that this secondary DIC 
fibrinolysis reaction occurs in trauma and is illustrated by high t-PA levels 
and low protein C levels (Hayakawa 2011).  The problem with this 
alternative DIC hypothesis is that normal levels of PAI (t-PA inhibitor) are 
seen in DIC (Gando 2011) compared to reduced levels in the ATC driven 
hypothesis.  
 
Despite the disagreement on exact process or nomenclature of the 
fibrinolysis in trauma, its presence is un-argued (Gando 2011, Brohi 2003, 
Bluth 2011, Levrat 2008, Schöchl 2009) and most importantly its presence 
significantly increases mortality (Ives 2012, Cotton 2012, Schöchl 2009). 
 
Some investigators have identified three separate “phenotypes” of 
fibrinolysis in trauma, each having a different effect on mortality (Moore 
2014); a normal physiological fibrinolysis which has the lowest mortality 
(3%), hyperfibrinolysis as identified and described by many with a higher 
mortality of 44% from typically exsanguination in the first 24 hours, and 
lastly fibrinolysis “shutdown” described as the inhibition of fibrinolysis.  This 
latter phenomenon has been previously described in elective surgery and 
was associated with deep venous thrombosis and multiple organ failure 
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(Chakrabati 1969, Griffiths 1979, Yukizawa 2012, Hayakawa 2012).  Moore 
(2014) showed that fibrinolysis “shutdown” occurred most frequently (64% 
of patients) and was also associated with a raised mortality (17%).  Mortality 
in this latter group was lower than the high mortality hyperfibrinolysis and 
occurred later, more characteristically being from multi-organ failure.  
 
Although the presence of hyperfibrinolysis is concerning due to its high 
mortality, it is potentially diagnosable early through near-patient 
thromboelastometry and readily treatable with Tranexamic Acid.  This latter 
medication has been readily used in UK practice buoyed by the results of 
CRASH-2 – 9% reduction in mortality in bleeding patients.  The UK Defence 
Medical Services condone its use, again supported by relevant, although 
retrospective, data in the military population (Morrison 2012).  The concern 
of a few is the possible harm if Tranexamic Acid is given after 3 hours 
(CRASH-2 collaborators 2011).   
 
The hypothesis is that hypercoagulopathy occurs after trauma secondary to 
the activated endothelium responding to the pathological processes of 
trauma by producing increasing amounts of PAI-1 (inhibited by APC 
normally in trauma).  This now elevated PAI-1 inhibits the t-PA action on 
plasminogen, resulting in a decrease in fibrinolysis (Selby 2009, Curry 
2012).  If this is the cause of fibrinolysis shutdown shown in Moore’s study 
(2014), the concern for the clinician is its incidence (64% in his population) 
and the potential harm that Tranexamic Acid may cause them in a 
population with an already increased mortality. 
 
Critics of CRASH-2 illustrate the differences between 1st World trauma 
treatment, the lack of blood received and level of trauma severity in that 
population compared to what is seen in the US, UK and Australia (Mitra 
2014).  A randomised controlled trial of Tranexamic Acid use in this 
population will hopefully guide clinicians better.  
 
Moore’s fibrinolytic shutdown group’s mortality of multi-organ failure 
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illustrates the close relationship between the coagulation system and the 
immune system.  The MATTERs (Morrison 2012) paper on military trauma 
patients receiving a varied amount of Tranexamic Acid and found a 
difference in mortality after 48 hours compared to CRASH-2 at 24 hours.  
Many confounding factors may explain this, but one postulation was the 
effect of Tranexamic Acid on not just fibrinolysis but also the immune 
system, which is significantly affected in trauma patients and not 
uncommonly leads to a systemic inflammatory response. 
 
Lysis of fibrin will have an effect on clot stability and strength but some 
authors have found that fibrinogen has only 31% contribution to clot 
strength in trauma.  The majority of the clot strength being secondary to 
platelets (69%; Komblith 2014).  
 
 
4.10.5  Platelet Dysfunction 
 
Platelets and their surfaces play a key role in the amplification and 
propagation stages of the cell-based model of coagulation (Hoffman 2001).  
It is not uncommon to find that patients with proven ATC actually have 
normal platelet levels.  In fact low counts have been found to occur in less 
than 10% of severely injured (ISS>45) patients (Hess 2009).  Although 
trauma patients with a higher platelet level on admission have a higher 
survival, it has still been recognized that patients with normal platelet counts 
on admission also had high mortality rates (Brown 2011, Stansbury 2013).   
 
Despite these patients having quantitatively normal platelets the higher 24-
hour mortality is associated with abnormal platelet function (Kutcher 2012).  
This abnormal platelet function in ATC is prevalent, varying from 45% 
having “platelet hypofunction” (Kutcher 2012) to 86% showing ADP 
inhibition of platelet function (Wohlauer 2012), with a postulated cause 
being the extensive disrupted endothelial ADP release producing initial 
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platelet hyperactivity leading to “exhausted platelet syndrome”.  These 
platelets, although normal in number, are consequently unresponsive 
despite stimulation.   
 
Using viscoelastic testing (ROTEM®) British military ballistic casualties had 
an incidence of hypocoagulopathy in 40% (Doran 2010), showing evidence 
of diminished clot strength secondary to platelet function rather than through 
deficiency of fibrinogen.  These findings not only reflect the important role 
that platelets play in ATC, but also highlight the fact that normal admission 
platelet counts do not correlate with adequate function. 
 
Platelet activation is dependent on initiation of the clotting process 
determined by activity at the endothelium, bringing us full circle to the vital 
role of the lining of the endothelium – the glycocalyx – and its key position 
for platelet and protein C activation. 
 
This separate pathophysiological cause for coagulopathy (ATC) is what is 
immediately seen after trauma.  Once medical care and resuscitation 
commences then the picture becomes more opaque as iatrogenic factors 
that influence coagulation play a larger part.  This resuscitation associated 
coagulopathy is therefore found later in the patient’s pathway taking a more 
predominant role and ATC having a lesser impact as time progresses 
(Figure 4-10).  Part of this iatrogenic coagulopathy has historically been 
described as the lethal triad and can be potentially avoided. 
 
The key elements of the lethal triad – dilution/consumption, hypothermia 
and acidosis - were commonly called the lethal triad or bloody vicious cycle 
(Kashuk 1982, Curry 2012).  A term originally used to describe patient 
pathology subsequent to haemorrhage from abdominal vascular trauma but 
then readily used consequently in all trauma.  The presence of the 
described triad has been shown to result in worsening haemorrhage and an 





4.11  Resuscitation Associated Coagulopathy 
 
4.11.1  Consumption 
 
Initiation, activation and propagation of haemostasis, particularly if 
excessive or in a high injury severity patient, will cause a subsequent 
consumption of clotting factors, fibrinogen and platelets - the initial basic 
intrinsic constituents of coagulation.  The presence of early pulmonary 
thrombus in military ballistic trauma patients (Lundy 2012) demonstrates 
(abnormal) excessive clot formation distant to the injury site can occur in 
severely injured patients.  This abnormality is for both quantity of reaction, 
but also location.  Excessive clot formation will result in coagulation 
substrate depletion.  Thrombin generation, distant to the wound site, 
secondary to systemic activation of the coagulation system has also been 
found in civilian trauma patients (Dunbar 2009).  The peak thrombin 
generation in their patients was at times 300% more than normal patients.  
This excessive consumption distant to the wound site leads to not only 
widespread coagulation activation, but also ensuing activation of the 
fibrinolytic pathways in response to it with subsequent development of a 
reaction not too dissimilar to disseminated intravascular coagulation (DIC) 
resulting in excessive clotting factor consumption.   
 
Some authors (Gando 2011) believe that there are high amounts of Tissue 
Factor (TF) from direct presentation on exposed sub-endothelial TF-bearing 
cells at the site of injury, and also other systemic intravascular TF-bearing 
cells such as monocytes and cytokines induced as a result of tissue 
damage. These authors believed that DIC occurs as a result of a substantial 
surfeit of thrombin production caused by these high amounts of TF found in 
the blood immediately after trauma.  This predictably leads to extensive 
coagulation activation and consumption of clotting factors. 
 
Haemostasis does not have a simple on/off switch.  Certainly there is one 
for activation, but the quantity and quality of the resultant reaction is not so 
clear-cut and a spectrum exists which can be influenced.  The presence of 
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injury, injury severity and type of injury has an influence.  High severity, 
blast injuries (Lundy 2012) cause abnormal clotting pathology in the 
pulmonary vascular tree and lower limbs – a systemic coagulation 
response, compared to the less severe, civilian blunt trauma where 
coagulation is more localized to injury site.  There seems to be evidence 
that these severely injured casualties who have suffered total body injury 
from the blast wave have a systemic coagulation activation and subsequent 
consumption of clotting reactants.  
 
Resuscitation methods vary throughout the World. For decades the initial 
use of an easily transportable fluid has predominated and crystalloids have 
filled this role.  Inappropriate, excessive use of a fluid that contains no 
clotting products will understandably cause a dilution of clotting reactants 
and other essential blood components.  
 
 
4.11.2  Haemodilution 
 
Diluting the blood and therefore red blood cell and haemostasis 
components contributes to coagulopathy development (Hewson 1985).   
Part of the body’s normal initial physiological response to haemorrhage is 
an attempt to increase intravascular fluid by movement of extracellular fluid 
into the vasculature, mounting to a natural dilution of clotting factors (Carey 
1973).  
 
Colloid resuscitation in order to increase plasma volume effects clotting in a 
number of ways.  It not only dilutes clotting factors but can also have a 
direct impact on the fibrinolytic system producing a pro-fibrinolytic state.  
Dilution of α2-Antiplasmin reduces its inhibitory effect on plasmin, leading to 
an increased fibrinolysis.  This can be exacerbated by additional dilution of 
another fibrinolytic inhibitor thrombin activatable fibrinolysis inhibitor (TAFI) 
(Bolliger 2010).  A Cochrane Review on colloids (Perel 2013) looked at 65 
trials involving colloids and found there was no justification for their use 
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compared to crystalloids with no evidence that they reduce the risk of death.  
Although for most there was no evidence of increased harm – save 
hydroxyethyl starch which might increase mortality – their expense 
precludes justification for their use.  
 
Crystalloid resuscitation also causes a diluent effect on factors and like 
colloids can also potentially produce a pro-fibrinolytic state (Bolliger 2010).  
As the amount of crystalloid resuscitation increases so does the 
coagulopathic effect, so that up to 70% of patients will have a coagulopathy 
and reduced platelet count if they receive 4000ml of fluid (Maegele 2007). 
 
Dilution with crystalloids, colloids and even plasma will also reduce 
haematocrit and haemoglobin.  
 
 
4.11.3  Anaemia 
 
Reduced haematocrit due to dilution, through either the normal 
physiological response to blood loss or as a consequence to iatrogenic 
means, has an important effect on haemostasis.  Margination of cells 
particularly platelets improve platelet/endothelial cell interaction and 
adherence.  This interaction and adherence is a key component of the 
normal function of coagulation.  In anaemia the reduced haematocrit impairs 
this effect (Valeri 2007), reducing the interaction between platelets and 
endothelium and having a negative impact on clotting.    
 
 
4.11.4  Hypothermia 
 
Defined as the reduced body core temperature of below 35°C, hypothermia 
has been found historically in nearly 50% of trauma patients on arrival to 
Emergency Departments particularly if scene times were prolonged (Helm 




Enzyme function is affected by many conditions, one of which is 
temperature, the extremes of which reduce enzyme function.  Haemostasis 
is reliant on clotting factors, all of which are enzymes in their activated form.  
It is unsurprising to find therefore that haemostasis is impaired in 
hypothermic patients.  Enzymes do not function at lower temperatures and 
the activity of proteases, particularly important for activation of clotting 
factors decreases as temperature drops (Reed, 1990).  The activation of 
factors involved in initiation of coagulation diminish linearly with 
temperature; FVIIa activity (key in the initiation of coagulation) is only 80% 
effective at 33°C (Meng 2003).  
 
The effect of low temperatures has an even greater impact on platelets, the 
activation of which is a key component of the amplification phase of 
coagulation.  Wolberg (2004) found that not only enzyme activity was 
reduced but platelet function, in particular aggregation and adhesion were 
diminished to 60% of normal at 33°C.  The threshold for these temperature 
effects on platelets (and enzyme function) appears to be 34°C.  
 
Conventional laboratory tests of coagulation – activated partial 
thromboplastin time (aPTT) and prothrombin time (PT) – have been shown 
to be prolonged in hypothermic patients (Rohrer 1992, Staab 1994) but 
more recently studies on visco-elastic tests (thromboelastography TEG® 
and rotational thromboelastometry ROTEM®) have yielded more 
information at different temperatures.  Watts (1998) found once patient 
temperatures dropped below 34°C although PT and aPTT were unchanged, 
TEG maximum amplitude (MA, which is a measure of clot strength, 
determined by platelet or fibrinogen function) diminished and this was 
attributed to platelet function.  Dirkmann (2008) found results that supported 
Watts; using ROTEM, they discovered that platelet function was primarily to 
blame for haemostasis failure in hypothermia.  The maximum clot firmness 
(MCF, the equivalent to TEG® MA) a reflection of platelet function was 
reduced.  They also found at the lower temperature of 30°C clotting time 
(CT, a measure of initiation of clot) was prolonged, a reflection of reduced 
activation clotting factors.  Dirkman also found that acidosis acted 
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synergistically with hypothermia and although there were little effects at 
normothermia, the combination of both acidosis and hypothermia worsened 
MCF and CT illustrating reduced platelet function and diminished enzyme 
efficiency.  Martini (2009) looked at the non platelet effects of cold and 
acidosis, and found they also both effected thrombin generation and 
fibrinogen metabolism  
 
In all, hypothermia in trauma has been found to be related to injury severity 
and is an independent risk factor for death, in one study reaching a mortality 
of 100% when core temperatures were below 32°C (Jurkovich 1987).  
 
 
4.11.5  Acidosis  
 
Tissue hypoperfusion in trauma causes hypocoagulation by different 
mechanisms.  It is the initiator of the protein C pathway to coagulopathy 
(ATC).  It also causes hypoxia of tissues, the result of which is an acidosis, 
which has a separate impact on coagulation.  Although in Dirkman’s in vitro 
trial (2008), acidosis only had an influence on coagulation in hypothermic 
conditions, a number of other studies have found that it can significantly 
affect haemostasis in normothermia.  Although these studies generally 
investigated acidosis in isolation and not in the context of haemorrhage and 
hypoperfusion, the results remain relevant.  Acidosis has been found to 
inhibit the propagation phase of thrombin generation and accelerates 
fibrinogen degeneration (Martini 2009).  While each clotting factor can be 
affected differently by acidosis, calcium (a crucial clotting enzyme co-factor) 
availability is significantly reduced (Martini 2007).  Platelet internal structure 
is altered and their ability to change shape is reduced at pH less than 7.4 
(Djaldetti 1979).  By pH 7.0 haemostatic platelet functions are completely 
down regulated (Etulain 2012), with one study finding platelet count reduced 
by 40% at pH 7.1 potentially due to some impact on aggregation, but in 




In Martini’s animal model (2007) the effects of a pH of 7.1 were manifold: 
PT and aPTT were both prolonged (by approximately 20%); TEG Maximum 
Amplitude was reduced by 20%; there was 50% inhibition of thrombin 
generation and fibrinogen degradation was accelerated by 1.8 fold.  
 
The majority of the aspects of this resuscitation-associated coagulopathy 
can be avoided by using good resuscitation regimes.  Acidosis is the 
exception to this as it will be pathologically produced by the body’s reaction 
to trauma and the consequent hypoperfusion.  Usefully, acidosis can be 
measured with base excess, which is a useful marker of both physiological 
compromise and response to resuscitation. 
 
Longer term the effect of trauma on the casualty moves away from 
coagulation and more towards inflammation.  There is a correlation between 
inflammatory changes, sepsis and the endothelium being instrumental in the 
causation of ATC.  An analysis of a subset of patients in the PROPPR 
(Pragmatic, Randomised Optimal Platelet and Plasma Ratios) trial (Wei 
2018) found that evidence of glycocalyx disruption (measured by Syndecan-
1) after massive transfusion was associated with developing sepsis.  This 
supports previous work by Johansson’s team (Ostrowski 2012b) who 
investigated a biomarker of endothelial activation (soluble vascular 
endothelial growth factor receptor 1 – sVEGFR1) in trauma patients, the 
presence of sVEGFR1 previously having been found to have a strong 
association with severe sepsis (and mortality) (Shapiro 2010).  The 
presence of sVEGFR1 correlated with glycocalyx degradation (syndecan-1 
presence) and the presence of hyperfibrinolysis and APC, but also evidence 
of inflammation (Interleukin-6).       
 
So the glycocalyx is not only influential in the pathophysiology of ATC, but 
studies exist that provide evidence of a number of uniting factors; tissue 
destruction, endothelial damage, coagulopathy, inflammation and higher 





4.11.6  Immune System Activation    
 
The immune system mediated “inflammatory response” is to limit damage or 
more accurately limit additional damage and promote healing.  Traumatic 
injury is often followed by a systemic inflammatory response (SIRS) (Lenz 
2007, Tsukamoto 2010), yet despite the reason for its presence (to limit 
damage) it is also commonly associated with poor outcomes after trauma 
(Napolitano 2000).  
 
Cytokines (small proteins involved in cell signalling and key to modulating 
the balance of the immune system) are raised within 30 minutes of injury 
and remain elevated for days (Gebhard 2000, Frink 2007).  The presence of 
cytokines in trauma patients is associated with an increased mortality rate, a 
higher rate of sepsis and elevated incidence of multiple organ failure 
(Hranjec 2010, Jastrow 2009, Patrick 1999).   
 
It has been found that injured cells release endogenous molecules termed 
danger-associated molecular pattern (DAMP) molecules, or alarmins, which 
are the signalling mediators of the “sterile” inflammatory response after 
trauma (Rider 2017).  These molecules (including High Mobility Group Box 
Protein – HMGB) interact with the innate immune cell receptors to trigger 
cytokine production (Matzinger 2002).  
 
Inflammation has also been attributed to many other factors involved in 
trauma patients, including surgery and blood transfusion (Sihler 2010, 
Tschoeke 2007).  These are complicating and arguably iatrogenic factors 
but it is useful to attempt to separate these different components from each 
other and trying to elucidate their individual effect on outcome and mortality.  
The alarmins related inflammatory response found rapidly after time of 
injury are those pertinent to the immediate ATC.  The degree to which they 
are the cause of multiple organ failure is more difficult to elucidate.  By the 
temporal evidence of SIRS in early trauma patients and its close association 
with the timing of ATC presentation, alarmins and their relationship to initial 




There is a close relationship between the inflammatory system and 
coagulation pathways; inflammation leads to an activation of coagulation, 
but coagulation also modulates the inflammatory system (Petäjä 2011).  It is 
pro-inflammatory cytokines - identified early in trauma patients - in addition 
to other mediators that have been identified to contribute to activate the 
coagulation system and down regulating anticoagulant pathways (Levi 
2010).  
 
Tissue Necrosis Factor alpha (TNFα) and Interleukin 1b (IL-1b) induce 
Tissue Factor (TF) expression on endothelial cells (Levi 2002), a vital 
component to coagulation initiation.  TNFα and IL1b are pro-inflammatory 
cytokines and in addition to other interleukins (6 and 12) not only increase 
TF expression, but also increase thrombin production.  Thrombin can in turn 
through a positive loop pathway induce further production of TNFα and IL-6 
and IL-1. 
 
Animal studies carried out on a blast/haemorrhage model at Dstl have 
studied the initiator to this cytokine release – alarmins - in particular HMGB1 
and cytokines themselves.  They found in a hypotensively resuscitated 
animal there was an increase in HMGB1 expression, supporting the 
observations that they are key to initiating the inflammatory response 
(Kirkman 2011b).  In a consequent porcine haemorrhage and blast injury 
model investigating resuscitation strategies, those animals resuscitated to a 
normal blood pressure after a set period of hypotensive resuscitation 
(compared to a complete hypotensive resuscitation) had improved survival, 
a comparatively better base deficit and lower IL-6 levels, suggesting that the 
tissue hypoxia (a trigger for ATC) was improved with a higher blood 
pressure and this led to modulation of the inflammatory response after injury 
(Doran 2012). 
 
The role of the immune system in trauma is complicated especially when 
relating its interaction with the coagulation system.  The evidence suggests 
trauma activates both and their consequent reactions can be detrimental. 
	
	 89	
There appears to be a role for immune-modulation and certainly the 
alarmins seem to be a potential target for such treatment.   
 
 
4.12  Coagulation Summary  
  
Coagulation in trauma and the coagulopathy that appears in the trauma 
patient is complex and as yet not completely understood.  Hypoperfusion, 
causing tissue hypoxia and impacting particularly the vascular endothelium, 
appears to be the key initiator of the Acute Traumatic Coagulopathy (ATC).  
ATC has a number of different components one of the most important being 
fibrinolysis.  Hyperfibrinolysis has one of the highest mortality rates.   
 
It is clear that a third of all civilian trauma patients arrive at hospital 
coagulopathic and this correlates with worse outcomes.  These rates of 
coagulopathy appear to be higher in the military population.  Adequate and 
correct resuscitation of these casualties is clearly important in avoiding the 
later resuscitation associated coagulopathy.  It is also vital to be able to both 
determine the presence of coagulopathy within these patients early in order 
to individualise their treatment and identify those at higher risk of death. 
This is not only a measurement of their coagulation status but also 
assessment of other aspects of the patient’s physiology that may result from 
injury and are a potential driver for coagulation (and immunology) 
abnormalities, such as oxygen delivery.  The next chapter discusses 










5.1  Introduction 
 
There is a large variety of medical equipment and instrumentation that can 
assist the clinician in the management and diagnosis of a patient’s 
condition. In a trauma patient there are minimum standards of treatment 
and equipment recommended for use by National and International bodies 
to ensure the patient is cared for appropriately.  These range from 
International guidance from the World Health Organisation (Mock 2004) to 
UK hospital guidelines from the National Institute for Health Care 
Excellence (NG40) to the direct guidance to the clinician on matters such as 
minimum levels of monitoring for an anaesthetised patient from the 
Association of Anaesthetists of Great Britain and Ireland (AAGBI 2015).   
 
After initial assessment and resuscitation in the Emergency Department, 
potentially including radiographic investigation, the commonest journey the 
trauma patient will take is to the Operating Room (OR) for Damage Control 
Surgery and Damage Control Resuscitation as discussed in more detail in 
Chapters 2 and 6 of this thesis.  The anaesthetist becomes the principal 
clinician in charge of resuscitating the patient in the OR and relies on certain 
equipment to guide patient therapy.  There are many demanding clinical 
issues requiring attention, but two lie at the forefront of the resuscitating 
physicians’ mind; adequacy of resuscitation and presence of coagulopathy.  
Adequacy and response of the patient to resuscitation is estimated by the 
presence of metabolic acidosis.  Inadequate resuscitation will lead to hypo-
perfusion of organs and particularly peripheral tissues with resultant 
anaerobic metabolism leading to acidosis.  Arterial blood gases are 
accepted as the most useful measurement for this.  Various assays within 
this aid treatment, but it is the standard base excess that is judged to be the 
most useful assay in metabolic acidosis (Park 2008) and used by the 
majority of anaesthetists as a guide to resuscitation management.   
	
	 91	
The presence of coagulation abnormality is measured by a number of 
different assays available within the laboratory and at point of care. The 




5.2  Acid Base Balance 
 
Negative base excess or base deficit is one of the most readily described 
parameters in trauma patients with evidence of tissue hypoperfusion or 
shock. In trauma, tissues and organs have a reduced blood supply, 
secondary to the cardiovascular and humoral responses to that blood loss.  
This is principally because of arterial vasoconstriction reducing blood flow 
and hence oxygen delivery.  The hypoperfused cells in the tissue 
consequently lack adequate oxygen to meet metabolic demands and resort 
to anaerobic metabolism for less efficient energy production resulting in the 
conversion of glycogen or glucose to lactate.  This production of lactic acid 
results in a metabolic acidosis.  The swiftest compensatory mechanism is 
through respiratory compensation with hyperventilation excreting carbon 
dioxide, resulting in a low arterial carbon dioxide in the spontaneously 
breathing patient.  Base excess represents the concentration of titratable 
acid needed to normalise the pH of one litre of blood to normal physiological 
values.  Decreased base excess represents the presence of unmeasured 
anions, which in trauma is assumed to be lactate related.  
 
In trauma patients a negative base excess or base deficit is used as a 
measure of tissue hypoperfusion in particular when related to trauma 
induced coagulopathy.  In trauma patients a base excess of less than -6 
mEq/l is accepted as evidence of hypoperfusion (Brohi 2007a, Curry 2012).    
 
The presence of a base deficit in trauma patients is related to increased 
mortality.  Studies as far back as Vietnam (Simmons 1969) found this, as 
have more recent ones in the civilian population.  Frith et al (2010) carried 
out a retrospective study of over 3000 patients from 5 International trauma 
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centres and found that as base deficit increased, so did mortality with a 
correlation between injury severity, shock and the presence of a 
coagulopathy.  Mutschler et al (2013) also performed a retrospective 
analysis of the German trauma registry and determined that as base deficit 
worsened, mortality increased.  He demonstrated that a base deficit of 
between -6 and -10 mM had a mortality of 23.9%, whereas a base deficit of 
less than -10 mM had a mortality of 51.5%. 
 
In addition to mortality, there is an association between base deficit and 
coagulopathy.  In civilian trauma patients a link has been shown to occur 
between level of base excess and development of Acute Traumatic 
Coagulopathy (ATC).  Brohi (2007) and Frith (2010) showed that as base 
deficit increased, this correlated with a prolongation of activated partial 
thromboplastin time (aPTT) and prothrombin time (PT). 
 
Thus, measurement of base excess is important for the assessment of 
trauma patients as it indicates not only the presence and level of 
hypoperfusion, but identifies patients that are at risk of developing a 
coagulopathy (ATC) and are in a higher mortality risk group. 
 
Base excess along with lactate levels, pH and various other key 
measurements are standard in an arterial blood gas.  There are numerous 
laboratory instruments that do these assays as well as smaller instruments 
that can be held in theatre and emergency departments.  Smaller apparatus 
also exist and the UK Defence Medical Services use a handheld device 
called i-STAT manufactured by Abbot and can give laboratory quality results 




5.3  Assessment of Coagulation  
 
Clotting can be assessed by a number of measurements, either through 
whole blood assessment or of individual aspects of the haemostatic system.  
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The resuscitating clinician requires an assay that gives the most information 
rapidly to aid a rapidly changing physiological response to the initial 
traumatic injury and response to resuscitation events.  Various methods of 
assessment are discussed below and related to their degree of practicality 




5.4  Routine Laboratory Testing 
 
Laboratories offer a number of tests for the different aspects of the 
coagulation pathway. These can be divided into tests of: whole blood, 
plasma, platelets and fibrinogen. These are discussed in more detail with 




5.5  Whole Blood Tests 
 
The formation of a clot is dependent on the interaction of all the factors of 
haemostasis, in particular the cellular components.  A test that considers all 
these aspects together is arguably a more suitable investigation of the 




5.5.1  Bleeding Time 
 
This is probably one of the oldest tests of haemostasis, (De Caterina 1994) 
and unusually for modern laboratory test is completed in vivo. It requires 
minimal additional equipment. It has been deemed as an excellent 
screening test for platelet function, traditionally described as the vascular 
platelet phase of haemostasis (Raber 1990). It is also dependent on an 
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intact vasospastic response in small vessels in addition to an adequate 
number of functionally active platelets.  
 
The test is performed with a standard incision on the forearm 5cm below the 
antecubital fossa, after a blood pressure cuff has been inflated to 40mmHg. 
Blood can be absorbed off the skin, but no direct wound pressure is 
allowed. The time is measured from the moment of incision to the moment 
bleeding stops.  The time varies depending on the type of blade that makes 
the incision, the direction of the incision and location on arm.  Bleeding 
normally stops within 7 to 9 minutes.  
 
Bleeding time is no longer practiced routinely due to the large number of 
variables and lack of standardisation and arguably ethical questionability in 
the face of alternatives.     
 
 
5.5.2  Activated Clotting Time (ACT)      
 
For this test, fresh whole blood is added to a test tube containing a 
negatively charged surface (using kaolin, celite or glass) (Horton 2013) and 
is placed into a warmed rotating device. A proximity switch is activated once 
a small magnet within the test tube is displaced by sufficient clot formation. 
It was traditionally used to test the adequacy of heparin, but it can be 
prolonged by platelet dysfunction, “intrinsic” clotting factor deficiencies, low 
fibrinogen and hypothermia (Horton 2013).  
 
ACT and Bleeding Time give a global picture of clotting function and to 
some extent the clot quality, however despite this advantage they are 
actually not as clinically useful as the alternatives.  Any abnormal result 
does not give specific information on which particular aspect of haemostasis 






5.6  Plasma Tests 
 
Two of the commonest investigations for haemostasis requested nationally 
are the activated partial thromboplastin time (aPTT) and prothrombin time 
(PT).  Originally designed for investigating inherited haemostasis disorders, 
such as the Haemophilias, they are now used in routine screening of 
patients with suspected bleeding disorders or peri-operatively.  They were 
designed around measuring the speed of coagulation and historically tested 
what was traditionally described as the two pathways of coagulation – 
intrinsic and extrinsic. 
 
 
5.6.1  Activated Partial Thromboplastin Time (aPTT) 
 
Originally termed the kaolin-cephalin clotting time, as kaolin and cephalin 
were originally used as activators, this was a test of the “intrinsic” clotting 
factor pathway.  This test uses centrifuged plasma taken from a citrated 
blood sample.  Calcium is added (to reverse the citrate effect) and a number 
of activators are used to initiate coagulation.  These activators include 
kaolin, but silica, celite and ellagic acid have also been used.  The term 
“partial” represents the lack of tissue factor used.  The time to form a clot is 
measured optically and is normally 30 to 50 seconds (depending on the 
laboratory set up and what activator is used). This is a measurement of the 
time for a clot to form (initiation) and gives no information on clot strength or 
stability. It will be prolonged in deficiencies of the “intrinsic” pathway factors 
(FVIII, FIX, FXI, FXII) and the final common pathway (FII, FV and FX).  It is 
typically used to measure the effects of heparin.  Inaccuracies occur and 









5.6.2  Prothrombin Time (PT) 
 
PT is an assay of the “extrinsic” pathway.  It has a derivative called the 
International Normalised Ratio (INR), which is the ratio of the patient’s 
prothrombin time to a normal PT result.  A normal range is 12-13 seconds 
and the INR is a ratio of result to normal range (normally 0.8 to 1.2), so that 
an INR of 1.0 is therefore a normal result, >1.2 is a prolonged time to 
coagulation and <0.8 is an indication of clotting occurring more rapidly than 
normal. 
 
The PT test is similar to aPTT, except it uses tissue factor as the activator 
(normally thromboplastin from brain tissue; Laffan 2017).  The PT is the 
time taken for the clot to form and like aPTT is not a reflection of clot 
strength or stability. PT will be prolonged in deficiencies of the “extrinsic” 
system (FVII) and the final common pathway (FII, FV and FX).  It is typically 
used to measure the effects of Warfarin and other factors that impact on 
Vitamin K production/function.  INR is the standard test for Warfarin therapy 
and standardised internationally after the World Health Organisation 
regulated the preparation of the thromboplastin activator (Poller 2012).  
 
Although the most common laboratory tests undertaken, these standard 
haemostatic measurements have two main failings; prolonged time to obtain 
results from the laboratory and a reliance on a historical and arguably 
outdated understanding of haemostasis.   
 
The wider acceptance of the cell based model of coagulation and the pivotal 
role of platelets within this means these plasma based studies are less 
appropriate for the assessment of haemostasis in a trauma patient.  They 
provide information on the initial aspect of coagulation; initiation up to fibrin 
formation and do not make any assessment of clot strength or stability. 
 
Although laboratory platelet tests exist, they are predominantly 




5.7  Platelet Tests 
 
5.7.1  Platelet Count 
 
Platelets are a key aspect of haemostasis and the formation of an adequate 
clot.  A minimum number of platelets are required to form a normal clot and 
European and UK Defence guidelines state that in trauma for a bleeding 
patient platelet count should be kept greater than 1000x109/l (Spahn 2013, 
JSP 99, 2012).  Platelet counts can be done manually using a 
haemocytometer, but it is more common for laboratories to use an 
automated analyser.  These are normally flow cytometers that count all 
blood cells (including red cells, leukocytes and platelets) concurrently.  The 
problem with this assay is that it is merely a measurement of quantity not 
quality, nor function.  Abnormal platelet activity and function has been found 
to occur after trauma in spite of a normal platelet count (Doran 2010, 
Davenport 2011, Jansen 2013) and it is this measurement that is also 
needed in the management of a trauma patient. 
 
 
5.7.2  Platelet Function 
 
Historically the Bleeding Time was used as a test for platelet function 
(despite being a test of more than this function of homeostasis) and was 
replaced in the 1960s by light transmission aggregometry.  Born used light 
transmission aggregometry to test the ability of platelets to aggregate in 
response to external agents in vitro (Born 1962).  In the 1980s platelet 
aggregometry in whole blood (Cardinal 1980), the study of activated 
platelets ex vivo using flow cytometry (Michelson 2006) and other 
measurements of specific platelet compounds and nucleotides were 
available (Holmsen 1966).  
 
The recent increased use of antiplatelet drugs in patients with their higher 
risk of bleeding, especially during trauma and surgery has led to the need 
for platelet function tests use in the peri-operative setting.  Newer, simpler 
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instruments that are point of care (POC) have led to improved diagnostic 
capabilities available to clinicians.  
 
Multiple Electrode Aggregometry (MEA; Multiplate®, Dynabite, Munich) was 
introduced in 2005.  It operates on the basis of whole blood impedance 
aggregometry, using the fact that platelets become sticky upon activation 
and adhere and aggregate onto metal sensor wires.  The change in 
resistance of these sensor wires is measured, providing a continuously 
recorded impedance proportional to the number of platelets adhering to 
them (Pape 2010).  The changes in impedance are plotted against time with 
the area under the curve produced providing the highest diagnostic power 
(Figure 5-1A).  The main limitation to MEA is the time required to obtain 
results; the tests takes 20 minutes to perform, however an additional 30 
minutes of resting post-sampling of blood is recommended (Jámbor 2009). 
 
TEM International, who produce ROTEM® delta (a viscoelastic analyser 
that is discussed in more detail in section 5.11.2) manufactured an 
integrated module that can be added to its machines, ROTEM® platelet.  It 
also uses whole blood impedance aggregometery and can run concurrently 
to whole blood viscoelastic testing (Görlinger 2007).  It has ready-made 
agonists and reagents that are ready to use with automated pipetting.  It 
produces a curve and the result is calculated automatically using the Area 
Under the Curve (AUC) and can give data about platelet function within 10 
minutes (Figure 5-1B).  It has been shown to detect the effects of anti-
platelet drugs (Tóth 2006, Jámbor 2009) in addition to the early effects of 
trauma and sepsis on platelet function (Adamzik 2012, Kutcher 2012).  
 
Haemoscope Corporation developed TEG® platelet mappingTM initially for 
monitoring anti-platelet therapy (Bowbrick 2003, Agarwal 2006).  Two 
coagulation assessment curves are produced by the instrument and 
compared; the first a kaolin-activated test curve reflecting maximal platelet 
function and the second curve is produced with the addition of FXIIIa 
(activating clotting factor), reptilase (a snake venom enzyme with similar 
activity to thrombin) plus one of a number of additives - ADP (adenosine 
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diphosphate) or AA (arachidonic acid) (both aggregating agent agonists).  
The activation and aggregation of platelets is quantified by measuring the 
difference in maximum amplitude (graph width) between unstimulated 
samples (forming weak fibrin-only clots) and samples with agonists added 
forming stronger clots containing fibrin and activated/aggregated platelets 
(Pluthero 2005).  These additional additives reduce platelet function and 




A            B 
 
 
Figure 5-1A. Typical MEA graph of impedance termed as Aggregation against time (min).  
Area under the curve (AUC) produces the indication of platelet function. 
Figure 5-1B. Typical ROTEM® platelet graph measuring impedance (Ohm) against time 
(min).  AUC is a measure of overall platelet aggregation and Maximum Slope (MS) 
describes how quickly the platelets aggregate.  
 
 
Platelets have a significant role in clotting, wound healing and inflammation.  
In particular their function and activity is being better understood particularly 
after trauma using the newer viscoelastic additional point of care 
aggregation tests, chiefly ROTEM® (Ganter 2008, Doran 2010, Solomon 
2011).  Viscoelastic tests and particularly rotational thromboelastometry can 
also produce an indicator measurement of platelet function and is discussed 
below in section 5.11.2.  Integral to platelet number and function is their 
relationship to fibrin.  There are a number of laboratory tests that investigate 




5.8  Fibrinogen Tests  
 
5.8.1  Fibrinolysis 
 
The occurrence of fibrin degradation products (FDPs) are used to illustrate 
the presence and quantity of fibrinolysis, with one specific FDP commonly 
being measured – the D-dimer.  The FDP assay uses antibodies to these 
products with a test based on agglutination.  D-dimer (the most commonly 
measured FDP) levels are normally less than 500ng/ml.  A result of greater 
than 500 are abnormal but do not indicate a specific disease state, although 
an increase is an indication of; 
- fibrinolysis,  
- DIC,  
- conditions associated with increased activation of procoagulant and 
fibrinolytic mechanisms such as recent surgery or presence of 
thromboembolism 
- other conditions such as pregnancy, malignancy and liver disease 
(Bates 2001, Schouten 2013) 
 
Testing of overall fibrinolysis can also be measured by a euglobulin lysis 
test that can illustrate a hyperfibrinolytic state, particularly in patients with 
deficiencies of the controlling enzymes of fibrinolysis – PAI-1 (plasmin 
activator inhibitor-1) and alpha 2 antiplasmin.  There is some evidence that 
measurement of individual proteins can be useful such as PAI-1 and TAFI 
(thrombin activatable fibrinolysis inhibitor), but lack of standardisation 
relegates these methods to research as a whole (Longstaff 2017).  
Viscoelastic instruments can also detect fibrinolysis to some extent and is 
discussed in section 5.11. 
 
 
5.8.2  Fibrinogen Levels 
 
If fibrinogen levels are found to be low on arrival at hospital, this is an 
independent predictor of both massive transfusion requirement and death in 
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severely injured trauma patients (Schöchl 2011, Hayakawa 2015, Inaba 
2013, Flocard 2012, Rourke 2012).  Its timely measurement is imperative to 
allow correct management of patients’ transfusion requirements and is a 
useful prognostic guide.   
 
There are a number of different assay methods described for measuring 
fibrinogen levels.  Estimations derived from prothrombin time (PT-Fg) are 
not recommended due to lack of standardisation and numerous variables. 
Clotable protein assays are very accurate but time consuming and 
technically difficult.  Immunological assays including enzyme-linked 
immunosorbant assays (ELISAs) have accuracy, but have some variability 
and lack standardisation.  
 
Clauss fibrinogen assay appears to be the most reliable method for general 
use in laboratories and remains the gold standard as it measures fibrinogen 
function directly (Mackie 2003).  It requires a plasma sample to be added to 
a high concentration of thrombin and the clotting time measured and 
compared to a calibration curve of clotting times from samples of known 
fibrinogen concentrations and the fibrinogen level is extrapolated from that, 
giving a result in g/l.  The normal range is 1.5 to 4.0 g/l and guidelines 
suggest in trauma patients their fibrinogen should be kept within this range 
(Spahn 2013).  Unfortunately it can take 30 minutes or more to get the 
results of these assays.   
 
As the early evaluation of fibrinogen is key (Schöchl 2009, 2011, 
Theusinger 2015, Kashuk 2010b) for management of trauma patients other 
more rapid techniques have taken precedence.  Viscoelastic methods have 
become widely used for early fibrinogen level evaluation in trauma patients. 
Thromboelastometry, especially, has been shown to be of considerable use 
(Schöhl 2009, 2011, Levrat 2008, Theusinger 2011, 2015).  The viscoelastic 






5.9  Coagulation Tests in Trauma Management 
 
The key problem with management of the bleeding trauma patient and their 
blood component transfusion requirements is the lack of a rapid and 
validated coagulation test (Toulon 2009, Segal 2005).  The coagulation 
tests mentioned so far are of limited value for a number of reasons.  
 
Timing is arguably the principal cause for their failure.  Laboratory tests in 
platelet poor plasma require standardised processing, which leads to a 
delay in the results being available to the clinician for 30 (Toulon 2009) to 
45 minutes (Doran 2010).  This is an unforgivable delay as the 
coagulopathy observed in trauma changes rapidly and a historical result is 
consequently of little use to the physician looking for guidance on 
transfusion therapy (Brohi 2009, Segal 2005, Curry 2012).  
 
PT and aPTT provide incomplete information on clot initiation (Mann 2003c) 
and will only detect a reduction in clotting factors of around 40% (Shapiro 
1942, Proctor 1961).  Both of these tests do not quantify the relative activity 
of pro-coagulants versus anti-coagulants since neither assay discriminates 
if a deficient clotting factor is counter balanced by a corresponding anti-
coagulant protease (Tripodi 2009).  
 
Platelet count is often initially normal in trauma and does not calculate 
platelet dysfunction which is common in trauma secondary to the trauma 
induced coagulopathy and corresponding physiological derangement (Hess 
2008).  
 
Fibrinogen levels calculated via Clauss Fibrinogen is a non-functional test 
and makes no assessment of the cross-linking of polymerised fibrin by 
FXIII. It can take 30 minutes to get a result.  
 
Finally, there is no laboratory test that examines the relationship between 
clot production and propagation versus clot lysis or one that determines an 
assessment of clot strength. Reduced clot strength is a common 
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pathological consequence of trauma and an inability to measure it will 
hinder a physicians ability to adequately resuscitate a trauma patient. 
 
In short there are no laboratory tests that can determine the elements of 
ATC within a useful timeframe in order to aid blood component therapy or 
help predict the need for massive transfusion (Kashuk 2010a, Dzik 2004).  
The historical diagnostic indicators for the management of major 
haemorrhage were based on the need for fresh frozen plasma 
administration.  An INR1 of greater than 1.5 (Stainsby 2006, Rossaint 2010) 
was initially used for diagnosis of coagulopathy in trauma.  More recent 
work has reduced this to a level of greater than 1.2 as a more realistic 
diagnostic level for ATC as a PT ratio of greater than 1.2 in trauma patients 
was associated with higher transfusion requirements and worse outcomes 
(Frith 2010).  
 
For the management of a trauma patient therefore the weight is against the 
majority of diagnostic tests described so far.  The reluctance to use them in 
the trauma patient have been described by a number of authors (Counts 
1979, Ciavarella 1987, Yuan 2007) especially when used as an aid to guide 
transfusion therapy in the face of rapid blood loss.  There is recognition by 
some that they have limitations when screening for, or detecting 




5.10  Modern Whole Blood Testing 
 
What is needed for trauma patient bleeding management is a test that is 
rapid and complete (assessing all aspects of whole blood clot formation, 
stability and breakdown) using a machine that is mobile and robust enough 
to be used in the patient’s location wherever in the hospital environment 






and platelets have in clot formation, stability and strength.  This need for a 
global clotting assessment in the trauma patient has initiated a renewed 
interest in viscoelastic coagulation testing (Johansson 2009a) in trauma 
patients.  It is a method that has been used for considerable time in NHS 
hospitals for guiding transfusion therapy in elective surgery where blood 
loss is significant – cardiac surgery (Avidan 2004), hepato-biliary and 
transplant surgery (Kang 1985) and obstetrics (Rai 2003) – and the move to 




5.11  Viscoelastic Coagulation Testing 
 
Viscoelastic point of care testing produces information on all phases of 
coagulation, providing an understanding into the interactions between the 
plasma and cellular components of whole blood in addition to the activity of 
the fibrinolytic system (Levy 2010).   
 
The principle method of viscoelastic tests consists of a rotating system 
moving a pin in a cup.  Depending on the manufacturer, either the pin or the 
cup can be the mobile rotating component.  When the system is measuring, 
a torsion wire usually suspends the pin in the cup.  Whole blood is added to 
the cup and additive reagents to the whole blood initiates clot formation.  As 
the clot forms it entraps the pin and changes movement in the pin.  The 
motion is restricted as the clot strengthens and becomes less restrained as 
the clot is lysed.  The change in movement is interpreted by the machine’s 
software and a graph is produced to reflect the developing clot, which can 
be related to the clotting process (Figure 5-4). 
 
There are two main manufacturers of devices that measure the viscoelastic 
properties of blood samples on the market.  Both produce equipment that 
assess the viscoelastic properties of blood and provide a graphical 




5.11.1  TEG® 5000 Thromboelastograph® Haemostasis Analyzer 
System 
 
The first method; Thromboelastography or TEG®  (Haemoscope 
Corporation, Niles, IL, USA) was originally developed in Germany by 
Hellmut Hartet who used it for research and illustrating the haemostatic 
function for whole blood samples (Hartert 1948).  The modern version is 
















Figure 5-2. TEG® 5000 (from www.haemonetics.com). 
 
 
TEG was used in the Vietnam War to guide blood transfusions (Hardaway 
1988) and in the civilian population Kang pioneered its use to guide blood 
transfusion in orthotopic liver transplantation (Kang 1985) and increase 
efficiency of blood component use.  The use of TEG in haemostasis 
assessment and informing blood product use has subsequently been 
investigated in cardiac surgery (Shore-Lesserson 1999, Spiess 1995, 
Avidan 2004), obstetrics (Rai 2003) and inherited coagulation abnormalities 
Sorensen 2005).  By the late 1990’s, TEG had been used in trauma patients 
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to guide their resuscitation using blood products, and assess coagulation 
(Kaufmann 1997).  Successive studies on civilian and military trauma 
patients has confirmed the value of TEG and other viscoelastic testing 
products in goal directed targeted blood product resuscitation (Johansson 
2009a, 2012a, Holcomb 2012, Plotkin 2008, Kashuk 2010a, Tapia 2013).   
 
In addition further studies have confirmed their value in trauma patients 
requiring blood product resuscitation and guiding the use of adjunctive 
haemostatic resuscitative agents including fibrinogen concentrate, activated 
recombinant Factor 7 (rFVIIa), Prothrombin Complex Concentrate (PCC) 
and the antifibrinolytic tranexamic acid (TXA) (Schöchl 2010, Theusinger 
2012, Woolley 2013, Ziegler 2013, Hauser 2012, Branco 2014, Hunt 2015). 
 
The TEG® 5000 uses a whole blood sample that is heated at 37°C in a 
warmed cup and coagulation is activated using additional compounds (e.g. 
tissue factor, kaolin, etc.).  The cup containing the blood sample is 
oscillated.  The pin placed within the cup is attached to a torsion wire 










Figure 5-3. TEG pin and cup arrangement (from www.haemonetics.com).   
 
 
As the oscillating clot forms around the pin, an electro-mechanical 
transducer measures the movement in the torsion wire attached to it and 
produces a graphical representation of the movement – a 
thromboelastograph (Haemonetics 2011).  This graphical output illustrates 
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clot strength on the y-axis measured in millimeters, against time on the x-


















TEG provides continuous monitoring of the clotting process: initiation, 
amplification and propagation (kinetics) and fibrinolysis, generating values 
related to each step (see Table 5-1) and allowing interpretation of the 
relevant haemostatic process. 
 
Kaolin (and Calcium) are the main initiating compounds used in TEG.  Other 
additives can be used to look at certain aspects of the clotting system.  
Fibrinogen function can be measured using a glycoprotein IIb/IIIa inhibitor, 
abciximab.  This inhibits platelet function and the assessment of the clot and 
the contribution of fibrinogen to it can be subsequently assessed by 
measuring the Maximum Amplitude (MA; Figure 5-4) in comparison to a 
normal Kaolin sample (Harr 2013).     
 
Platelet function can also be studied using TEG® platelet mappingTM, a 
modified thromboelastography using platelet mapping, which measure the 
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ability of a platelet agonist (thromboxane A2) to activate arachidonic acid 
and adenosine diphosphate to stimulate a fibrin-platelet clot independent of 
thrombin (Bochsen 2007; more details in section 5.7.2).  
 
 
5.11.2  ROTEM® delta Haemostasis Analyser  
 
The ROTEM® delta is the main piece of equipment produced by Tem 
International and is the current equipment used by the British Defence 















Figure 5-5.  ROTEM® delta (from www.rotem.de) 
 
 
Thromboelastometry is based on the principles of thromboelastography but 
differs from it in a number of ways.  In parallel with the latter a pin is placed 
in the whole blood sample, which itself is placed in a cup.  However in 
thromboelastometry it is the pin that is rotated and rather than a tension 
wire, a light source is used.  The light is directed at a mirror on the pin and 
reflected onto a detector (Figure 5-6).  As the clot forms around the pin, its 
movement is reduced and this change is detected by the detector and 
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interpreted by the data processor that converts this into a graphical 
representation, the thromboelastometric curve (Figure 5-7).  The software 
determines certain parameters from this curve, which are displayed 


























Figure 5-7.  Temogram curve displaying measured parameters (from www.rotem.de) 
 
The ROTEM® delta has four channels which are temperature adjusted and 
independent of each other.  The plate beneath the channels is warmed to 
37°C and includes a warmed trough to hold blood sample tubes.  There is a 
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reagent tray, an integrated personal computer with attached touchscreen 
and a software assisted automatic pipette.  The four channels allow for 
concurrent specimen testing for additional aspects of the hemostasis 
pathway using additional assays other than kaolin (Larsen 2011).  For the 
basic test, termed EXTEM, the sample is recalcified with the addition of 
calcium chloride and tissue factor is added to activate or initiate clotting. 
 
The parameters used by ROTEM® are similar to those used in TEG and 
can be interpreted to provide information on clot initiation, quality and lysis.  
The curves and measurements produced by both machines are extremely 
similar in both normal and abnormal circumstances and consequently in the 
next sub chapter describing interpretation of the graphs, only temograms 
will be used.   
 
Both methods demonstrate haemostatic integrity and measure the ability of 
whole blood samples to form a clot in addition to the details of clot formation 
or “clot firmness” during the transition of blood from a fluid to a semi-solid 
state.  They have shown good correlation with thrombin generation assays 
(Rivard 2005, Johansson 2008).  
 
Although the curves and parameters measured by the two instruments are 
similar it is difficult to directly compare traces from the two devices due to 
different amounts of sample used, different activators utilised, distinctive 
cup and pin size and the variability in reference ranges (Nielsen 2007).  In 
one study looking at the use of both in trauma patients the only parameter 
comparable was clot amplitude (MA in TEG or Maximum Clot Firmness in 
ROTEM) (Hagemo 2010).  While the values of the parameters are not 
exactly the same and have differing names – their interpretation is similar 







































As in the TEG where differing compounds added to the activators can 
examine different aspects of the haemostasis system, so does the ROTEM 
system.  The difference being 4 channels can be run concurrently in 





Assay Additives Clinical Use 
EXTEM Calcium Chloride 
Recombinant Tissue  
  Factor 
Polybrene 
Assesses deficiencies of factors 
involved in “extrinsic” pathway 
FIBTEM Calcium Chloride 
Recombinant Tissue   
  Factor 
Polybrene 
Cytochalasin D  
Assesses fibrin polymerisation 
APTEM Calcium Chloride 
Recombinant Tissue  
  Factor 
Polybrene 
Aprotinin 
Verifies effect of anti-fibrinolytic drug if 
given 
INTEM Calcium Chloride 
Ellagic Acid 
Assesses deficiencies of factors 
involved in “intrinsic” pathway 
HEPTEM Calcium Chloride 
Ellagic Acid 
Heptase 
Determines Heparin and Protamine 




Table 5-2.  Commonly used ROTEM delta assays 
 
 




Similar to the laboratory test of prothrombin time, these assay are activated 
by recalcification (using the star-tem assay containing 0.2mol/l calcium 
chloride) and the addition of thromboplastin (ex-tem reagents, i.e. 
recombinant tissue factor and phospholipids).  The traditional thought was 
that the extrinsic pathway initiates coagulation and initial thrombin 
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generation/clot formation in this test is reliant on FVII, FX, FV, FII and 
fibrinogen.  The addition of polybrene - an inhibitor of heparin - enables the 
use and interpretation of these tests in patients who are treated by heparin. 
Clot strength is reliant on fibrinogen formation, platelet number and function 




This modified EXTEM assay contains the additional platelet inhibitor 
Cytochalasin D, which affects platelet activation and shape, in addition to 
the expression and activation of GlycoproteinIIb/IIIa (fibrinogen) receptors.  
Platelet contribution to clot strength (as measured by Maximum Clot 
Firmness (MCF)) is removed from this assay, meaning the clot formation in 
this test is based purely on fibrinogen concentration, polymerisation and 
strength, providing the user with a measurement of fibrinogen function.   
 
The clot strength aspect of this test (MCF) can also be directly compared to 
the MCF in EXTEM, which is a reflection of both fibrinogen and platelet 
count/function.  The difference in clot strength between EXTEM and 
FIBTEM therefore allows for estimation of the platelet portion of clot 




This is the third extrinsic test in the group and includes an antifibrinolytic 
drug. This was Aprotinin (hence the nomenclature APTEM) but has been 
replaced by Tranexamic Acid.  The inclusion of this drug allows for testing of 




The “intrinsic” pathway, similar to the activated partial thromboplastin time 
laboratory test, is tested by this assay.  It uses ellagic acid as an activator.  
The initial thrombin generation and clot formation is deemed to be 
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dependent on FXII, FXI, FIX, FVIII, FX, FV, FII and fibrinogen.  As in 
EXTEM clot strength is a reflection of both fibrinogen and platelets.  It does 




In combination with INTEM this assay – now containing a heparin inhibitor; 
heparinase – can be used to reveal residual heparinisation or protamine 
overdose.  
 
Both TEG and ROTEM are capable machines, useful for near patient 
testing of coagulation, but they both have strengths and weaknesses 
depending on user need.  Clinicians in general favour one over the other, 
whilst researchers see use in both.  Of interest are the new developments in 
the area with other manufacturers producing competing products.  The 
majority of investigations completed on trauma patients or on animal 




5.12  Viscoelastic Interpretation  
 
As discussed above TEG traces are very similar to EXTEM traces and the 
interpretation of the graphs produced for each are similar.  ROTEM traces 
are discussed below, but the analysis of TEG mirrors that of EXTEM traces.  
 
When using thromboelastometric viscoelastic testing to aid resuscitation 
management of trauma patients INTEM traces offer no additional 
information to EXTEM and FIBTEM (Doran 2010) – in this study INTEM 
trace abnormalities were also shown on EXTEM traces and they concluded 
there is no need for an additional test (INTEM) unless the patient is on 
Heparin.  It is general practice within the Defence Medical Services to run 
EXTEM and FIBTEM tests together for trauma patients.  These two tests 
will provide information on overall clot dynamics (initiation and amplification) 
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as well as clot strength and stability (propagation).  Fibrinogen levels can be 
assessed from the FIBTEM trace in addition to an estimate of platelet 
function.  Normal traces are illustrated below in Figure 5-8.  The pictorial 
representation of the results makes the test ideal for patient management in 
busy Emergency Rooms and Operating Rooms during on going Damage 
Control Resuscitation and Surgery.  Any staff can learn the fundamentals of 
interpretation and highlight abnormalities to otherwise busy clinicians.  The 
results can be incorporated into ongoing resuscitation management, 
particularly assisting in decision making on type and quantity of blood 
component therapy and its speed of administration.   
 
 
5.12.1  Abnormal Temograms 
 
Viscoelastic testing is a comprehensive test and there a large number of 
abnormalities it can elucidate.  Examples of their interpretation can be 
gained from the Tem International education website 
(https://learning.rotem.de/en/interpretation/) and the Haemonetics website 
(https://teg.haemonetics.com/en/teg-5000-thrombelastograph).  Some 
abnormalities are more commonly observed in Acute Traumatic 




5.12.2  Prolonged Clotting Time 
 
Clotting Time is the initial time it takes for the clot to start forming (and the 
graph amplitude to reach 2mm).  It is dependent on the presence of 
adequate clotting factors.  Figure 5-9 illustrates an EXTEM trace with 
prolonged Clotting Time.  The initial green line observed on the EXTEM 
trace is prolonged and there is a delay until the clot starts to form 
(appearance of pink thickening trace).  The treatment of a patient with this 












Figure 5-8.  Normal Temogram.  
Normal EXTEM and FIBTEM  
Traces.  EXTEM CT 43-82secs,  
EXTEM MCF 52-70mm, EXTEM  
















Figure 5-9.  Temogram of  
prolonged CT.  The 
EXTEM CT is prolonged 
(> 82 secs) which is 
mirrored by the FIBTEM 
CT.  This is illustrative of 








5.12.3  Maximum Clot Firmness 
 
Maximum Clot Firmness (MCF) is a measurement of clot strength or 
stability.  It is the maximum width the temogram achieves and is a reflection 
of the interaction between platelets and the fibrin mesh.  It is the widest that 
the blue part of the trace achieves.  
 
An abnormally low EXTEM MCF (<52mm) means the coagulation 
abnormality is secondary to fibrin(ogen) or platelets; with either being low in 
quantity or quality/function.  A low EXTEM MCF (width) needs to be 
assessed with the corresponding FIBTEM MCF.  The FIBTEM MCF (width) 




Fig 5.10.  Temogram of low EXTEM MCF.  If EXTEM MCF is low (<52 mm) and FIBTEM 
MCF is normal (7-24mm), suggesting a deficiency in platelet number or function or FIBTEM 





If the FIBTEM MCF is normal, it indicates that fibrinogen and the fibrin 
system is normal and the deficiency in coagulation causing the low EXTEM 
MCF is therefore due to platelet number or function (Figure 5-10). 
 
If the FIBTEM MCF is low (<7mm) then fibrinogen levels are low (Figure 5-
10).  This may be the cause of coagulation abnormality.  However little 
assessment can be made on platelet number/function.  They may also be 
low (in number or function) but the low fibrinogen levels are hiding their 
accurate interpretation.   
 
 
5.12.4  Fibrinolysis 
 
Abnormal clot breakdown is measured by a number of lysis markers, the 
main one being Maximum Lysis (the maximum amount of clot broken down 






Figure 5-11.  Temogram of  
hyperfibrinolysis.  EXTEM (and  













It is normal to observe some lysis and a value of less than 15% is 
considered to be normal.  More than 15% is hyperfibrinolysis and some 
authors describe a condition of “fulminant hyperfibrinolysis” as being more 
than 50% in 30 minutes (Schöchl 2009).  Figure 5-11 illustrates an example 




5.13  Limitations to Visco-elastic Testing   
 
5.13.1  Initiators 
 
TEG® traces are activated using kaolin, but some investigators have used 
celite, tissue factor or a combination of kaolin and tissue factor (Shore-
Lesserson 1999, Avidan 2004, Kashuk 2010a).  ROTEM uses standard 
activators (recombinant tissue factor) and this has been shown to reduce 
the discrepancies encountered in TEG (Nielsen 2007).  Some investigators 
have found that analysis with kaolin was unable to distinguish 
coagulopathies caused by dilution from that of coagulopathies caused by 
thrombocytopenia, but ROTEM tests could readily distinguish them (Larsen 
2011).  This potential error caused by TEG analysis could lead to incorrect 
platelet use.  
 
 
5.13.2  Clinical 
 
The chief constraint of viscoelastic tests is their insensitivity to the effects of 
anti-platelet drugs (cyclooxygenase-1 [COX-1] inhibitors like Aspirin and 
Adenosine Di-Phosphate [ADP] P2Y12 receptor inhibitors like Clopidogrel; 
Lang 2006, Görlinger 2007).  This limitation is caused by the high quantity 
of thrombin produced in viscoelastic tests which stimulate platelets via 
protease-activated receptor (PAR) 1 and 4; a thrombin-receptor platelet 
activating pathway (Kalantzi 2012).  As thrombin is a strong platelet 
activator, the inhibition of the other (arachidonic acid and ADP) pathways 
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have no effect on viscoelastic tests.  Clinicians should be cognisant of this 
when faced with a haemorrhagic trauma patient with normal coagulation 
tests (Kembell-Cook 2005). 
 
The UK military in Afghanistan discovered a temporal problem with 
rotational thromboelastometry.  If citrated blood samples are left standing 
for an hour before being processed EXTEM MCF improves from abnormal 
to normal (22mm compared to 54mm), showing a spontaneous 
improvement in coagulation with time.  FIBTEM MCF did not change, 
suggesting it was platelet function that improved in a citrated blood sample 
over time once blood was removed from the patient (Jansen 2013). 
 
 
5.13.3  Experimental 
 
One of the key advantages of ROTEM clinically is that the pipetting system 
is guided by the ROTEM software and performed with an automated pipette 
drawing and discharging the correct volume of fluid.  For an investigator 
though this is a disadvantage.  Having a more utilitarian pipette system such 
as found in TEG enables certain variables to be better investigating and 
allows flexibility of testing that is often necessary in research.  Different 
initiators, their volume, and their concentrations can all be more easily 
investigated with TEG.  It is for this reason that despite the considerable 
weight of support for the use of ROTEM argued in the next sub chapter, it 
was TEG that was predominantly used for the coagulation tests in this 




5.14  Use of ROTEM and TEG in Trauma 
 
ROTEM with its touchscreen, software assisted automatic pipette is very 
user friendly.  The software guides the user though the measurement 
process with pictures and instructions and a support menu for result 
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interpretation.  Mounted on a wheeled trolley, all these factors reduce inter-
user variability (Anderson 2014) and enable it to be used in a number of 
different environments by different operators.  
 
In comparison to TEG the technical modifications, and in particular the 
stability of the pin and cup system, of ROTEM make the device less 
susceptible to vibrations and movement and their interference with the 
Temogram.  It also allows continuous electronic quality control of the pin 
movement, therefore reagent quality control (QC) is only necessary once a 
week compared to daily QCs needed for other machines.  These factors 
mean clinicians in a number of different environments generally favour 
ROTEM.  It has been adopted by the UK Defence Medical Services (Doran 
2010) and has been used in a number of other austere or outdoor 
environments (Modesti 2011, Tarmey 2012, Benson 2014).  It has been 
found to be particularly useful in trauma compared to conventional tests 
(Haas 2015).   
 
Despite the perceived advantages many have observed first hand, the use 
of viscoelastic tests in the management of a haemorrhagic trauma patient’s 
resuscitation has not been supported by large reviewing organisations such 
as the Cochrane Library.  That group’s recent review of the use of 
viscoelastic tests (Hunt 2015) for diagnosing trauma-induced coagulopathy 
found little evidence on the accuracy of both TEG and ROTEM and advised 
they should only be used for research.  Since that review more evidence 
has come to light, although the number of randomised control trials are 
lacking.  Other single centre and larger reviewing bodies argue against the 
Cochrane authors suggestions and are more supportive of its use in trauma 
patient management.   
 
Many centres now suggest ROTEM use is a vital aspect of trauma patient 
resuscitation principally for managing their coagulopathy.  Single centre 





minutes predict coagulation status in ballistic military trauma casualties 
(Woolley 2013) and a prospective cohort study from London in over 800 
civilian trauma patients found that ROTEM CA 5 was a valid marker for 
Acute Traumatic Coagulopathy and a predictor of massive transfusion 
(Davenport 2011b).  
 
A more recent review that included more evidence than the previous 
Cochrane review (Veigas 2016) found that abnormal temogram amplitudes 
(MCF, CA 5, CA 10) in EXTEM and FIBTEM were capable of diagnosing 
Acute Traumatic Coagulopathy; predict the need for massive transfusion 
and predict mortality.  In addition they found the presence of fibrinolysis was 
also strongly associated with mortality and suggested that “ROTEM® 
parameter thresholds to guide blood component transfusion could be 
clinically useful.” 
 
The French Group on Perioperative Haemostasis went further to declare 
that for “the clinical use of these techniques in the setting of emergency and 
perioperative medicine….viscoelastic tests must be included in algorithms”.  
(Roullet 2018).  
 
Many US and UK trauma centres now use viscoelastic testing and ROTEM 
probably has the majority vote from many clinicians due to its robustness, 
ease of use and more readily available detailed results.  It is the main stay 
of my clinical practice in both civilian NHS and military austere 
environments. 
 
Over the past few years other companies have entered the market and the 
manufacturers have developed newer models in the competition to provide 








5.15  Viscoelastic Equipment Development 
 
Single use reagents (lyophilised) were developed a few years ago for use 
with ROTEM delta removing the need for multiple pipetting into multiple 
different containers of liquid initiators/reagents (Rahe-Meyer 2009).  This 
made the ROTEM even more user friendly but unfortunately eliminated the 
flexibility that can benefit research. 
 
In the last few years both companies have developed a cartridge system, 
removing the need to pipette completely.  Haemeonetics have developed 
the TEG®6s.  This uses a different method for clot strength measurement; 
the resonance method.  An unmetered citrated blood is loaded onto the 
cartridge.  This sample is exposed to a fixed vibration frequency with LED 
illumination of the blood meniscus.  The detector measures meniscus 
motion and the resonance frequency is identified.  The information is 
converted, by the machine’s software, into a conventional TEG readout.  
The cartridge contains a number of tests within it that will complete 4 tests 
including the whole coagulation process and fibrinogen.  There is an 
additional platelet function cartridge.  Information and publications on its 
performance capability are beginning to come to light (Gill 2017, Meledeo 
2018) with mixed reviews.  Gill (2017) found it did not perform well under a 
considerable vibration challenge.  On the contrary Meledeo (2018) put it 
under a similar test, in addition to others including a direct blow.  His group 
compared it to the TEG5000 and ROTEM delta and found it was an 
improvement over the other systems, stating it was robust and capable 
enough for austere military deployments.  
 
Tem International has also produced a cartridge system, which is based on 
their rotational thromboelastometric measurement methodology.  A citrated 
blood sample tube is inserted into the cartridge, which is then tested by the 
ROTEM sigma.  Each cartridge contains EXTEM, INTEM, FIBTEM with 
either APTEM or HEPTEM.  A number of trials investigating its use are 




5.16  Equipment Summary 
 
Acid base balance is easily measured by a number of blood gas analysers 
and small accurate machines exist within the market already.  They are 
readily used to aid resuscitation strategies. 
 
Haemostasis can be measured by a myriad of methods.  Time constraints in 
damage control resuscitation require rapid results and for this reason near 
patient, point of care testing has greater advantages.  Of the few on the 
market the robustness, completeness of results and ease of use make the 
ROTEM® delta the UK Defence Medical Services’ first choice.  Clinicians 
look forward to how the new lighter, more practical machines will fare and 
await initial investigation results with interest.  
 
Injury mechanism and the appropriate resuscitation regimes have been 
discussed in earlier chapters.  The coagulation abnormalities and how to 
measure them in these trauma cases have now been discussed in detail.  
The fluids used in resuscitation and associated adjuncts and how they 










6.1  Introduction 
 
The ideal fluid to resuscitate a severely injured, hypotensive trauma patient 
needs to be safe, easy to dispense and easy to look after.  It should expand 
blood volume, increase oxygen delivery, and improve haemostasis, in 
addition to not increasing bleeding.  No such fluid exists.  The alternatives 
all have their own advantages and disadvantages.  This chapter will discuss 
in detail those fluids and some specific adjuncts that are commonly used in 




6.2  Non-Blood Component Fluids 
 
For decades the preeminent internationally recognised trauma course, run 
by the American College of Surgeons, was the Advanced Trauma Life 
Support ® course.  It has historically educated thousands of doctors and 
allied health practitioners that the initial resuscitation fluid of choice in 
trauma patients with clinical evidence of blood loss was 2 litres of 
crystalloid, only very recently reducing this to 1 litre (ACS 2012).  Recent 
European guidelines still advised that in the management of haemorrhage 
in patients having suffered trauma, it should be crystalloids that are applied 
initially (Rossaint 2010).  These recommendations also stated consideration 
could be given to hypertonic solutions, although previous recommendations 
have stated that the type of fluid was not important as long as the 
appropriate volume was given (Nolan 1999).  For those many decades that 
the ATLS® course taught that crystalloids were the fluid of choice, there has 
been an ongoing debate as to what the appropriate fluid choice should be 




6.2.1  Crystalloids  
 
There are significant advantages to crystalloids: cheap, easily available 
Worldwide, recognisable by all health professionals, with a long shelf life 
and logistically the easiest fluid to manage.  Paramedics can administer 
them without a Doctor’s prescription - covered by National guidelines 
(AACE JRCALC 2016) and local Patient Group Directives.  The majority of 
them are easily transportable in sealed bags and very stable at a range of 
temperature extremes, and regularly warmed to 40°C (Lindoff 2002).  Some 
studies have shown they have a beneficial effect on mortality if given (in 
certain volumes) in the pre-hospital environment (Hampton 2013).  Readily 
transportable and with a logistical ease of care outside the hospital 
environment, both civilian and military, crystalloids have been the bedrock 
of fluid resuscitation in trauma patients for decades.   
 
Although they initially appear to be the panacea for trauma resuscitation 
fluids recommended by distinguished International organisations, there exist 
a number of problems with their use as resuscitation fluids in trauma.  
Isotonic crystalloid fluids such as normal (0.9%) saline and Hartmann’s 
Solution (known as Ringers Lactate in USA) distribute quickly to the 
interstitial space.  In the hypovolaemic trauma patient any resuscitation fluid 
of choice should replace lost blood and remain in the vascular space, yet 
crystalloids fail to achieve this.  They move relatively freely in the 
extracellular space and redistribute rapidly into the interstitial space so that 
at 30 minutes after transfusion only 16% of the volume of infused fluid 
remains within the intravascular space (Watenpaugh 1998) in a healthy 
patient.  In a hypovolaemic, injured patient this is unlikely to be any better.  
Many disease states, including sepsis and trauma, cause vascular 
endothelial glycolcalyx disruption (Kolorava 2014, Pierce 2014).  As the 
glycocalyx is the key structure limiting free fluid across the vascular space 
(Lee 2010), if it is compromised, there will be increased loss of fluid from the 
vascular space.  This suggests crystalloids may spend even less time in the 
intravascular space in a trauma casualty, although there are suggestions 
that in some cases of hypovolaemia this may not be the case (Drobin 1999).  
	
	 127	
Brisk redistribution is only one of the many shortcomings crystalloid has as 
a trauma resuscitation fluid.  Maegele’s study of over 17,000 trauma 
patients in Germany showed the greater the amount of crystalloid given pre-
operatively in trauma casualties the more coagulopathic they were, with an 
incidence of over 40% if more than two litres of fluid was given, up to an 
incidence of over 70% if over 4 litres of crystalloid was given (Maegele 
2007).  Although this is a significant finding to observe a direct correlation 
between amount of fluid given and level of coagulation abnormality, this 
study raises a key question: is the correlation between volume of fluid given 
and coagulopathy a direct one?  The coagulopathy was measured by the 
presence of a platelet count of less than 100,000 µl-1 and a prothrombin 
time test (Quick’s value) of less than 70%.  These could have been caused 
by dilution of platelets and clotting factors.  Or was there a direct 
pathophysiological effect on coagulation from some aspect of the content or 
physical property of the crystalloids?   
 
Severely injured patients are more likely to be coagulopathic through a 
separate pathophysiological process (Brohi 2008, Frith 2010).  Severely 
injured patients are also more likely to receive more fluid when conventional 
resuscitation goals are followed in order to maintain physiologically normal 
cardiovascular observations pre-operatively.  Rather than fluid having a 
direct action on clotting or by dilution of factors and platelets; coagulopathy 
and fluid volume may be independent reflections of injury severity and not 
directly interrelated. 
 
The relationship is unlikely to be binary and it is probable that both injury 
severity and volume of fluid are influencing the coagulation abnormality.  
Within a set injury severity the greater volume the patient received the 
worse their coagulopathy was, suggesting that the direct relationship 
between injury severity and coagulopathy is accentuated by volume of fluid 
given. What is clear though, direct causation aside, is that there is a 




While there have been studies that have shown pre-hospital crystalloid 
administration has beneficial results, this is not guaranteed.  Hampton and 
the PROMMTT (Prospective Observational Multicenter Major Trauma 
Transfusion) Study Group found in just over a thousand patients that pre-
hospital crystalloids of 700ml (median) conveyed a survival benefit 
(decreased in-hospital mortality) (Hampton 2013).  However there is 
confounding evidence that suggest that this is not assured.  One particular 
study showed any greater amount of crystalloid given can increase the odds 
ratio for mortality by over 2, if one and half litres of crystalloid is given to a 
trauma patient (Ley 2011).  Ley et al found in his retrospective study of over 
3000 patients that as the amount of crystalloid given in the Emergency 
Department increased so did the odds ratio for mortality.  It rose to 2.6 for 
three litres given and his findings were further compounded by age, where 
those patients suffering from trauma over the age of seventy had an odds 
ratio for mortality of over 8.  
 
Crystalloids, the ATLS and European resuscitation guidelines first line 
panacea for trauma resuscitation, have the advantage of being easy to 
manage and handle, but they do not remain intravascular for long, probably 
causes a worsening coagulopathy and increases mortality in trauma 
patients. This suggests they are not the best fluid to use.  On balance it 
appears that they have their uses.  In a constrained environment where 
alternatives are realistically unavailable either by logistical challenge (e.g. 
temperature constraints or resupply times) or by qualification constraints of 
medical personnel, where the alternative is no fluid for resuscitation there is 
a clear and valid argument for their use.  If alternatives exist, then the 
weight of argument is against them in the trauma patient group.  Valid 
alternatives do exist.  Colloids are one of them, and in common with 
crystalloids, are another class of fluid that has a low logistical burden.  What 







6.2.2  Colloids 
 
Colloids are homogenous, non-crystalline compound fluids that consist of 
particles that are molecularly large which can’t be separated by filtration or 
centrifuge. They can be protein or non-protein derived and their principal 
argument for use is the comparatively increased time they remain within the 
intravascular space (Huskisson 1992, Hillman 1997).  
 
Protein derived colloids include human albumin, which is derived from 
human plasma.  It was shown in one meta-analysis to increase mortality 
(Cochrane Injuries Group Albumin Reviewers 1998), although another study 
found otherwise in critically ill patients, but as it is expensive they suggested 
there was no advantage to its use over crystalloids (Finfer 2004).  The 
SAFE (saline versus albumin fluid evaluation) group found trauma 
casualties had an increased relative risk of death if they received albumin.  
A subsequent follow up study (Myburgh 2007) confirmed this higher 
mortality was attributed to patients with traumatic brain injury. 
 
Non-protein colloids include synthetic hydroxyethyl starches, modified 
gelatins and dextran solutions.  The latter are branched polysaccharides 
synthesised by the activity of Leuconostic mesenteroides on sucrose 
mediums.  Generally the two derived products are Dextran 40 and 70, the 
nomenclature of which originates from the molecular weight (MW) of the 
polysaccharides – 40,000 Daltons (Da) and 70,000 Da.  It is the larger, 
Dextran 70, that has been more commonly used in resuscitation (Salmon 
1993), especially as Dextran 40 has been associated with renal failure, 
particularly in the presence of hypovolaemia (Haljamae 1997).  Both 
compounds have been shown to reduce platelet adhesiveness and enhance 
fibrinolysis and have been associated with significant number of 
anaphylaxis (Nolan 2001), so that now both are rarely used in the UK.   
 
Gelatins are derived from bovine collagen and have an intravascular space 
half-life time of up to 4 hours (Sadler 1987).  The collagen is modified to 
increase molecular size and hence improve intravascular retention.  The 
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most widespread are Haemaccel (a Urea-bridged gelatin of 24 500 Da 
derived from cattle bone) and Gelofusine (a 22 600 Da compound derived 
from calf skin collagen which has undergone thermal degradation).  Most of 
the gelatins are less than 20 000Da and are excreted rapidly through the 
kidneys, although intravascular persistence is still up to 4 hours (Sadler 
1987).  They are the most likely of the colloids to cause anaphylactic 
reactions (Laxenaire 1994) and some in vitro studies have shown that they 
impair clotting (Mardel 1998, Evans 1998) in contrast to one in vivo study 
which showed that post-operative thromboelastographic coagulation 
measurements showed hypercoagulability in patients who received gelatin 
(Karoutsos 1998). 
 
Hydroxyethyl starches (HES) are branched amylopectin polymers, which 
can be broken down by serum amylase.  Substitution of certain 
hydroxyethyl groups for hydroxides can increase the time the compound 
remains within the intravascular space (Treib 1996).  The compounds are 
described by molecular weight (kDa) and degree of substitution (ratio); 
hetastarch 450/0.7 has a MW of 450kDa and a substitution of 0.7.  The 
latter is related to not only prolonged intravascular time, but also other 
characteristics including side effect profile (Jungheinreich 2005).  They are 
generally divided into high, medium and low molecular weights (Petroianu 
2000).  Considerable work has gone into the development and investigation 
of (HES) over the last few decades; especially after some of the original 
data on outcome benefits were falsified (Shafer 2011).  Most of the 
subsequent work has been predominated by safety and its use in sepsis.  
 
High molecular weight HES had been shown to reduce Factor VIII (clotting 
factor 8) and von Willebrand factor and will consequently cause a 
coagulopathy (Petroianu 2000, Treib 1998) to a greater proportion than 
would be expected by simple plasma dilution.  Molecular weight has been 
considered a key factor in determining the blood coagulation effects of HES 
(Treib 1998) with lower molecular weight HES being considered to have 
less effect on coagulation (de Jongee 2001) but their disadvantage has 
been their shorter intravascular presence.  Recent studies have shown that 
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there is an additional direct inhibition of platelet function occurs through 
binding of HES to the platelet surface (Deusch 2003).  Contrary to previous 
beliefs this was found to be with a lower molecular weight HES (200kDa).  
Madjdpour et al (2005) looked at molecular weight specifically in an animal 
model.  Using both traditional laboratory and thromboelastographic 
measurement of coagulation they found that all molecular weight HES 
caused a coagulopathy immediately after infusion and sometimes lasting up 
to 4 hours afterwards.  This was evident in all results including Prothrombin 
Time (PT), Activated ProThromboplastin Time (aPTT), von Willebrand 
Factor (vWF) activity, Thromboelastography (TEG®) Maximum Amplitude 
(MA) width and K time.  
 
The US military community has used HES for many decades and up to one 
litre of Hextend was recommended for use in the Tactical Combat Casualty 
Care Guidelines in 2002 (Holcomb 2003), with greater volumes not being 
recommended secondary to coagulation concerns.  Its heat tolerance, price 
and prolonged duration of action won over counter-arguments for its use in 
the logistically challenging military pre-hospital environment, yet there was 
still concern amongst pre-hospital providers as almost 50% still used 
crystalloids in preference (McSwain 2011).  More recent US military 
guidelines have retained its use in preference to crystalloids (Butler 2014). 
 
Its use in civilian trauma has been reviewed in a number of retrospective 
studies.  The Ryder Trauma Centre in Miami found no difference in mortality 
for those receiving HES, but did find higher rates of ICU admission, blood 
product transfusion, sepsis and ARDS (Ogilvie 2010).  Shock Trauma in 
Baltimore (Lissauer 2011) found patients receiving HES had a higher in-
hospital mortality, higher blood product utilisation and higher incidence of 
acute kidney injury compared with saline.  Both of these studies have their 
potential problems as found in many retrospective studies, particularly with 
selector and survivor bias with some lack of clarity on the mechanism of 
injury (in the Shock Trauma study 85% of HES patients had blunt trauma).  
The Ryder group (Allen 2014) looked at the potential difference between 
mechanism of injury in trauma casualties in receipt of a single bolus of HES 
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(1410 patients) and found that in blunt trauma HES was an independent risk 
factor for both acute kidney injury and death, but not in penetrating trauma 
(although the numbers in the latter group were small).  A follow up study by 
the same authors (Allen 2016) found again there was no difference in a 
penetrating injury group (816 patients), although all deaths in the first 24 
hours were excluded. 
 
To date the Fluids in Resuscitation of Severe Trauma (FIRST) Trial (James 
2011) is the main randomized controlled trial examining the effects of HES 
in trauma.  No difference in mortality was observed, but penetrating trauma 
patients appeared to fare better compared to those injured from blunt 
trauma who required more blood products if they received HES.  There are 
many critics of this trial and it is injudicious to draw conclusions from it for 
many reasons; no intent to examine mortality, coagulation or renal failure 
and the fact that it was manufacturer sponsored.  Another prospective study 
is ongoing and its results are awaited – TETHYS, PragmaTic, prospEctive, 
randomized, controlled, double-blind mulTicentre, multinational study on the 
safety and efficacy of a 6% HydroxyEthylStrach (HES) solution versus an 
electrolyte solution in trauma patients. 
 
The most significant work on HES has been on critically ill and septic 
patients.  Although HES has been found to have a beneficial effect in septic 
patients and in acute inflammation (Schmand 1995, Dieterich 2007) through 
immunomodulation, there are concerns over their effect on renal function, 
coagulation and mortality.  After Boldt’s retraction of over 90 publications 
(Wilkes 2013) a number of trials were published – 6 S (Perner 2012), 
CHEST (Myburgh 2012), CRYST-MAS (Guidet 2012) and VISEP 
(Brunkhorst 2008) – that linked HES with adverse outcomes, suggesting 
that the use of HES is harmful in septic or critically ill patients increasing 
their risk of mortality and renal failure.  The US Food and Drug 
Administration (FDA 2013) has now advised health professionals against 
their use in these patient groups and the European Medical Agency has 




The Cochrane Collaboration has reviewed the use of all colloids in patients 
who had suffered trauma, burns or surgery (Perel 2013).  They identified 65 
trials and examined 56 that had mortality data where crystalloids were 
compared to colloids.  They found “no evidence from RCTs that 
resuscitation with colloids reduces the risk of death compared to 
crystalloids”, there was “no improvement in survival”, they were “more 
expensive” and concluded that it was “hard to see how that their use in 
these patients can be justified”.  These are strong comments that have had 
widespread repercussions certainly in the NHS where colloids are now a 
rarity.  There is little suggestion in the summary that their use increases risk 
to the patient and all colloids are bracketed together despite some clear 
differences between them, making it seem that the accountants are the 
driver for fluid choice decision-making.  
 
The weight against HES use is certainly significant, but there appears to be 
evidence that it may be of limited use in particular environments.  Despite 
evidence of its detrimental effect on coagulation, in the penetrating military 
casualty treated by a health professional with a poor logistical supply, there 
is support for its limited use if there are no alternatives.  In all other 
situations however it would be hard to justify its use. 
 
Largely this gives any clinician a dilemma. Crystalloids and colloids are both 
easy to transport to the patient in the civilian pre-hospital environment and 
the battlefield.  There is good argument to suggest crystalloids is preferred 
to some colloids but is there strong enough argument to avoid their use 




6.2.3  Hypertonic Saline  
 
Hypertonic solutions have a greater solute concentration than the cell 
cytosol.  When infused they create an osmotic draw that pulls water from 
intra-cellular to extra-cellular space and into the interstitial and finally intra-
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vascular space, thus increasing intra-vascular volume (Cross 1989).  This 
ability to potentially rapidly restore tissue perfusion with a smaller volume 
has attracted many clinicians involved in resuscitation.  
 
In animal studies of haemorrhagic shock hypertonic fluids have been shown 
to decrease inflammation (Angle 1998, Deitch 2003), organ injury (Smith 
1985) and mortality (Traverso 1987) and so it was hoped the same benefit 
would be seen in humans. 
 
Patients who have suffered traumatic injuries have been shown to 
experience complications secondary to immune dysfunction such as multi-
organ failure and sepsis (Maier 2000, Rotstein 2003).  Hypertonic solutions 
have been shown to have beneficial immunomodulatory effects on 
haemorrhage induced leukocyte activity (Junger 1997, Kolson-Petersen 
2004), in addition to decreasing neutrophil activation (Angle 1998), 
stimulating lymphocyte proliferation (Loomis 2001) and anti-inflammatory 
cytokine production (Gushchin 2002).  One human studies has mirrored 
these experimental studies; in trauma patients admitted to an American 
trauma centre and treated with either a small bolus (250ml) of hypertonic 
saline or normal saline (Rizoli 2006).  Subjects receiving the hypertonic 
saline showed reduced neutrophil activation, reduced pro-inflammatory 
tumour necrosis factor production and increased anti-inflammatory 
interleukins.  These immunomodulatoary effects were shown to outlast the 
transient cardiovascular effects raising the possibility that hypertonic saline 
may attenuate multi-organ failure after traumatic injury. 
 
One particular concern for hypertonic saline (HTS) has been its effect on 
coagulation and the potential to increase bleeding following its 
administration.  Increased bleeding has been observed in various animal 
trauma and haemorrhage models.  They have predominantly been large 
vessel injury models with uncontrolled haemorrhage and resulted in 
increased bleeding from injured vessels, haemodynamic decompensation 
and increased mortality (Gross 1989, Matsuoki 1995, Krausz 1992, 
Solomonov 2008).  There has been criticism of the models used and their 
	
	 135	
relevance to human trauma; furthermore other studies have disputed these 
findings in similar animal studies (Elgjo 1996) and those with organ injury 
(Varicoda 2003).  In vitro studies illustrated a prolongation of PT, aPTT and 
time for platelet aggregation when greater than ten percent of plasma 
volume is replaced by HTS (Reed 1991, Wilder 2002), meaning concerns 
on its effect on coagulation will remain.  
 
The fundamental attraction of hypertonic solutions was their ability to 
expand plasma volume by more than the volume infused (Kramer 1989).  
Animal haemorrhage models illustrated it improved cardiovascular 
parameters (arterial pressure and cardiac output) (Kramer 2003, Wade 
1997) and led to 100% survival in dogs (Velasco 1980).  Similar findings 
were found in sheep (Nakayama 1984, Smith 1985) but were noted to be 
transient.  Most human studies have been inconclusive; although showing 
an improvement in mean arterial pressure (MAP) and reducing the volume 
of other fluids required in subjects’ resuscitation, mortality rates are not 
affected (Younes 1992). 
 
There has been significant interest in the use of HTS use after traumatic 
brain injury where it was shown to more effectual at reducing cerebral 
oedema than mannitol (Himmelseher 2007).  Human studies have shown it 
reliably and safely reduces raised intracranial pressure (ICP) in patients with 
acute traumatic injury (Fisher 1992, Härtl 1997) and in some cases it has 
lowered ICP in patients refractory to other therapeutic approaches (Kerwin 
2009).  Despite this some studies have found that the trauma casualty with 
head injury and low blood pressure there was no significant improvement in 
neurological outcome or survival at 6 months (Cooper 2004).  Pre-hospital 
studies have shown greater benefit with increased blood pressure and 
survival in some groups (Vassar 1993). 
 
This continued controversy over hypertonic fluids led the Resuscitation 
Outcome Consortium (ROC) to conduct two separate multicenter, 
randomized, blinded trials in America and Canada studied the use of HTS in 
pre-hospital resuscitation; one on hypovolaemic shock in trauma patients 
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and one on traumatic brain injury (TBI).  The TBI trial was stopped for futility 
reasons as those patients with TBI, but not in hypovolaemic shock, had no 
difference in 28-day survival and 6-month neurological outcome (Bulger 
2010).  Bulger and colleagues also stopped the hypovolaemic trial early 
over potential safety concerns when in one patient group (no blood 
transfusions received) HTS resuscitation had a higher 28 day mortality 
(12.2%) compared to normal saline (4.8%; Bulger 2011).  Although the 
authors noted that overall, in all groups (including those that received blood 
transfusions), there was no significant difference for the 6 hour (in the 
hypovolaemic study) and 28 day (both studies) survival and argued that the 
role of HTS, particularly in the pre-hospital environment, remained extant 
(Dubick 2013). 
 
Although there is significant evidence of the benefits from HTS from 
experimental injury and animal models, there is little evidence that this 
translates to human casualties with haemorrhagic shock.  While coagulation 
and increased bleeding has been a potential problem in animal studies this 
has not translated across to human studies.  The greatest concern is from 
the more recent studies that have shown increased mortality.  Some have 
argued that this mortality increase could have been secondary to fluid 
overload in patients with pre-existing co-morbidities (Dubick 2013).  A 
second explanation has suggested that clinical misinterpretation of patient 
colour and cardiovascular parameters subsequent to receiving HTS have 
led those patients to be mis-managed (Holcroft 2011).  If either of these last 
explanations is correct and can be overcome, then it suggests that there is 
a role for HTS in the pre-hospital and military environment. 
 
The transient response to initial resuscitation with HTS led to the 
development of a combined hypertonic saline with a colloid in order to 
attempt to retain more fluid within the intravascular space – Hypertonic 






6.2.4  Hypertonic Saline Dextran 
 
The benefit of using small volumes of fluid for resuscitation that is 
equivalent to a much larger volume of conventional fluids is logistically 
attractive to both the military and civilian pre-hospital practitioner.  The 
intention of adding Dextran, a polysaccharide, to hypertonic saline in the 
production of hypertonic saline (HSD) was to increase the duration of intra-
vascular expansion.  250ml of HSD is comparative to 3 litres of normal 
saline for plasma volume expansion (Dubick 2003).  Animal and human 
studies have shown similar benefits to HTS in improving organ blood flow 
(Kreimeier 1990) and modulating the immune response (Rotstein 2000, 
Rizoli 2006, Bulger 2007).  Animal studies have also found that 
haemodynamics improved for longer compared to HTS (Wade 1989).  
Results on survival however have been varied with head injured sub-groups 
having a tendency to improved survival with HSD (Vassar 1993, Mattox 
1991, Younes 1997), as did one penetrating torso trauma group (Wade 
2003).  Wade’s group completed a number of meta-analyses finding that 
HSD had a survival benefit for the treatment of traumatic hypotension 
(Wade 1997a), in TBI (Wade 1997b), and overall HSD was found to have a 
30-day survival benefit compared to conventional crystalloids (Wade 
1997c).  This data (from predominantly retrospective studies) has not led to 
the widespread use of HSD though.  A Cochrane review in 2004 found there 
was insufficient data to be able state whether hypertonic crystalloid is better 
than isotonic fluids for trauma resuscitation (Bunn 2004).  One prospective 
trial was carried out subsequent to that review.  
 
The multi-centre trial investigating HTS for the Resuscitation Outcomes 
Consortium (ROC) mentioned previously (Bulger 2011) also looked at HSD. 
Their findings were similar with no difference in mortality except for the 
group not receiving blood transfusions that had an increased mortality of 
10% in the HSD group compared to 4.8% in the normal saline group.  Again 
they mused on potential reasons for this including poor recognition of the 
actual level of hypovolaemia in patients resuscitated with HSD and fluid 
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overloading patients with unidentified co-morbidities tipping them into heart 
failure (Dubick 2013).  
 
Due to the uncertain relationship between HSD (and to some extent HTS) 
and increased mortality these are not in common use in UK civilian practice.  
The military (and pre-hospital) situation remains extant though where a 
limited fluid resuscitation with uncertain resupply chain in a population with 
predominantly penetrating trauma means that in America it is of use.  The 
data is probably too inconclusive to support general use except in certain 
military situations.  
 
Early blood product use has predominated a significant proportion of 
research both human and animal in the last two decades on trauma 
resuscitation.  Different protocols and strategies have attracted a number of 
different nomenclatures including, and not exclusively, hypotensive, 
haemostatic and damage control resuscitation.  These have been discussed 
elsewhere in more detail (Chapter 2) but their main constituents include 
blood and blood components.  Large volumes of these can be required in 





6.3  Blood and Blood Components 
  
In the UK, after donated blood is collected it is divided into a number of 
different components.  The need to maximize the length of storage of the 
blood donated, and its constituent parts have historically driven this 
process.  Although exceptions occur, the commonest components produced 
by the NHS Blood and Transplant are Red Cells (also known as Packed 
Red Blood Cells - PRBC), Fresh Frozen Plasma (FFP), Platelets and 
Cryoprecipitate (The Red Book, 2013).  Whole Blood (also known as Fresh 
Whole Blood - FWB) has been used uncommonly in UK practice, but has 
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seen increased use in the USA in both civilian and particularly military 
environments.    
 
 
6.3.1  Packed Red Blood Cells 
 
Packed Red Blood Cells (PRBCs) are one of the most commonly used 
blood components.  PRBCs are prepared from whole blood by 
centrifugation or by apheresis collection.  Typically, one unit of PRBC is 280 
+/- 60ml volume, of which the Haemoglobin (Hb) content is greater than 
40g.  Anticoagulation is achieved by the collection into citrate-phosphate-
dextrose.  Additives are used to prolong the components shelf life of 35 
days at 4 +/- 2°C (The Red Book, 2013).  In the USA adenine is combined 
to the collected agents and used for storage as CPDA (citrate, phosphate, 
dextrose and adenine).  In the UK the currently used additive solution is 
Saline Adenine Glucose and Mannitol (SAGM) which allows for 35 days 
storage at 1–6°C.  Leucodepletion is carried out on the starting whole blood 
material or on the final PRBC component and there must be less than 1 x 
106 leucocytes per unit.  Leucodepletion was introduced in 1999 in the hope 
of reducing the risk of vCJD transmission with secondary effects being the 
reduction in other adverse effects such as non-haemolytic reactions and 
graft-vs-host disease (McLellan 2003).  
 
Haemorrhage causes loss of erythrocytes, the only oxygen carrying cell 
within the vasculature and vital for its transport to the rest of the body. 
Replacement is essential.  Early transfusion of PRBC increases cardiac 
output and preserves oxygen carrying capacity (Dutton 2006).  There is a 
lack of generalized agreement on when PRBCs should be given.  In critical 
care the evidence suggests a restrictive transfusion policy is best for that 
patient group  (7-9 g/dl) (Hébert 1999).  In trauma patients there are a 
number of recommendations; The British Committee for Standards in 
Haematology (BCSH) 2006 guidelines on management of massive blood 
loss recommend keeping a target of Haemoglobin (Hb) of greater than 
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8g/dl, but the more recent 2014 guidelines recognise that haematocrit and 
haemoglobin concentrations may be initially misleading after major blood 
loss and clinical criteria and observations should predominate, stating that 
red cells should be given if the Hb is falling (BCSH 2014, Hunt B 2015).  
The Joint UK Blood Transfusion and Transplantation Services Professional 
Advisory Committee advice keeping Hb at between 8-10g/dl as part of their 
“Massive haemorrhage toolkit” for Transfusion management of Massive 
Haemorrhage in Adults (JPAC 2013).  The most recent European guidelines 
on management of bleeding recommend a target Hb of 7 to 9 g/dl (Rossaint 
2016) and the British military’s Clinical Guidelines for Operations suggest 
keeping Haematocrit above 0.3 (CGO, JSP 999, 2012). 
 
Haemostasis is affected by the heamorheological effects of red cells.  An 
increase in the haematocrit-related blood viscosity has a beneficial physical 
effect on interaction between platelets and endothelium (Turrito 1980).  Red 
cells preferentially move down the centre of blood vessels causing 
margination of platelets positioning them in a preferential site close to the 
vessel wall (Flamm 2012).  Despite this, over transfusion of PRBCs 
producing a consequential high haematocrit can have a detrimental impact 
on haemostasis.  Although normally the pressure exerted by the centrally 
flowing red cells progressively aids platelet adhesion, as haematocrit rises 
from low (10%) to normal levels (35.8%), at higher haematocrit levels 
particle crowding impedes the formation of aggregates (Goldsmith 1995).   
 
In anaemic patients initiation of coagulation has been found to be mildly 
impaired as measured by a prolonged rotational thromboelastography time 
for clot initiation.  Correction of anaemia in these patients by red cell 
transfusion led to a return of clotting time to normal, but led to a reduction in 
clot strength (Roeloffzen 2010), possibly secondary to the detrimental effect 
of high haemotocrit on platelet function.  
 
In addition to these rheological effects, red cells have other direct and 
indirect actions on haemostasis.  Their presence appears to be a key part of 
haemostasis; structurally abnormal red cells present in in stored blood have 
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a greater strength of adhesion to the endothelium (Sparrow 2015) and 
under conditions where red cell damage can occur such as oxidative stress 
and inflammation (both potentially occurring in the trauma patient) red cells 
can expose phosphotidylserine, producing an active surface for prothrombin 
activation (Shi 2006).  The fibrin system is a key aspect of haemostasis and 
particularly the coagulopathy found in trauma.  Red cells have been found 
to have a protective effect against fibrinolysis as they have been discovered 
to decrease fibrin permeability in a dose dependent manner and increase 
resistance to lysis (Wohner 2011).  
 
These haemostatic effects are multiple, but predominantly dependent on 
certain pathological conditions.  The most likely effect of red cells is 
probably rheological and their interaction with platelets, illustrating a minimal 
level of Hb and haematocrit is needed for platelet function, but too high a 
haematocrit is detrimental - an observation that fits well with the majority of 
Hb guidelines.  
 
There are potential risks with red cell transfusion; from mild reactions, 
allergic reactions, exposure to blood borne infections, ABO incompatibility, 
haemolytic transfusion reactions and death.  Massive transfusions carry 
additional risks and have been associated with electrolyte abnormalities, 
renal impairment, increased incidence of ARDS and multi-organ failure, 
increased ICU stay, hospital stay and increased mortality (Claridge 2002, 
Malone 2003, Charles 2007, Marik 2008, Chaiwat 2009, Fredericks 2017).  
It is imperative therefore that the transfusion is guided appropriately and 
links in with the whole resuscitation process and other components such as 
fresh frozen plasma (FFP). 
 
 
6.3.2  Fresh Frozen Plasma 
 
Fresh frozen plasma (FFP) is prepared from a single unit of whole blood or 
plasma collected by apheresis into a citrate-containing anticoagulant 
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solution.  It needs to be ABO compatible with AB being the universal donor 
type used.  After donation it is frozen within 8 hours and can be stored at  
-25°C for up to a 36 months.  It contains all of the clotting factors, some 
fibrinogen (up to 900 mg/unit), electrolytes and other plasma proteins 
including physiological anticoagulants (O’Shaughnessy 2004).  Before 
administration to patients it needs to be thawed.  Methods for thawing are 
water bath systems or microwave oven most commonly.  The UK Defence 
Medical Services use a third method that is a dry tempering system 
(SAHARA-III).  Once thawed the UK Blood Transfusion Services require 
transfusion within 4 hours, or if that is to be delayed it should be kept at 4°C 
for up to 24 hours.  FVIII activity will decline at 24 hours by up to 28% 
(Blood Transfusion Task Force 2004).  The timeline for use can be 
extended up to 72 hours, at which point 40% of FVIII activity is lost, 
although the activities of all other factors (including FII and FV) are normal 
(approximately 20% loss, Shehata 2001).  At 5 days FVIII has lost 60% 
activity, FV has lost 34% activity and the remainder less than 30% of activity 
is lost (Blood Transfusion Task Force 2004).   
 
Risks of transfusion are similar to PRBC and include infectious disease 
transmission (ranging from 1:7.8 million for HIV to 1:153,000 for Hepatitis B; 
O’Brien 2007), transfusion associated cardiac overload, transfusion-related 
acute lung injury, acute haemolytic reactions and anaphylaxis (Callum 2005, 
Popovsky 2006).  
 
FFP is a blood component that has been available since World War 2 
(Emerson 1945).  It was initially used as a volume expander but this has 
developed into the management of bleeding and prevention of haemostatic 
abnormalities in bleeding and coagulopathic patients.  The proof of its 
efficacy in the management of massive haemorrhage in a trauma casualty 
is disappointingly lacking (Stanworth 2004) and it has been used to treat 
trauma hemorrhage for many years but with very limited knowledge of its 
utility and application.  Inadequate transfusion is potentially associated with 
poor outcomes and undoubtedly blind over-transfusion can result in 
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additional donor exposure with increased rates of sepsis and multi-organ 
failure (Watson 2009, Norda 2006).  
 
Despite this it has been widely recommended for use in major haemorrhage 
simultaneously with PRBC (Holcomb 2007) at either specific doses of 10-
15ml/kg (Rossaint 2010) or to achieve a lab coagulation level of no more 
than 1.5 times normal (PT and aPTT) (Stainsby 2006).  Other guidelines 
and recommendations counsel that it should be transfused in a specified 
ratio to PRBC.  These vary according to continent and military or civilian 
use; USA civilian (Hess 2006), USA military (Borgman 2007), UK military 
circles (CGOs 2012) and European guidelines (Rossaint 2016).  However 
some key guidelines from noteworthy International bodies do not specify a 
particular ratio; Europe (NICE 2015, Kanani 2017) and USA (ASA 2006, 
Iorio 2008).    
 
The National Institute for Health and Care Excellence (NICE) is an 
executive non-departmental public body of the NHS that provides guidance, 
advice and information services for health and other professionals.  It 
produces key guidelines on a variety of subjects.  It has produced 
guidelines for the use of FFP in major haemorrhage and advises FFP 
should be given; if there is bleeding in excess of 150ml/min or 50% blood 
loss of total blood volume in under 3 hours or (bleeding) leads to a systolic 
BP of less than 90 or a HR of more than 110 in adults (NICE guideline 
(NG24) 2015). 
 
This reason many guidelines don’t state a ratio is that there is on going 
debate on this issue.  However despite the paucity of supporting evidence 
for its use FFP is required in trauma resuscitation and is beneficial to the 








6.3.3  Packed Blood Red Cell: Fresh Frozen Plasma Ratios 
 
One ongoing debate amongst physicians dealing with trauma casualties 
concerns the amount of plasma used in resuscitation and its quantity 
compared to packed blood red cells.  I had experience of a crystalloid only 
based approach in MedSTAR, the Washington DC trauma centre in the late 
1990s, but at that time it was rapidly being replaced by a blood component 
resuscitation policy.  As a trainee deploying to Afghanistan in 2008 I was 
instructed into the 1:1 ratio of FFP to packed cells of all ballistic trauma 
casualties who had suffered major blood loss, especially if there was on 
going bleeding.  There was no access to point of care coagulation 
(viscoelastic) testing and this empirical ratio had at that time what was 
deemed strong supportive data.  It was being used elsewhere - by both our 
fellow American military colleagues in Iraq and Afghanistan and it was in 
use at the Baltimore Shock Trauma Centre where a number of our 
physicians had just completed Fellowships. 
 
This empirical ratio used in resuscitation of trauma casualties had support 
from a number of papers.  Modeling had an important initial influence with 
one computer model of exsanguination (Hirschburg 2003) calculating the 
possible changes in coagulation subsequent to blood loss.  It predicted that 
the optimal FFP:PRBC ratio of 2:3 would be needed to replenish clotting 
factors.  Another mathematical model (Ho 2005) predicted a similar ratio (1 
to 1.5 FFP to 1 unit if PRBC) would be needed to prevent a dilution 
coagulopathy in patients with ongoing blood loss. 
 
Subsequent to these there were a lot of both military and civilian 
retrospective studies on early empirical ratio haemostatic resuscitation 
(Spinella 2008a, Cotton 2008, Gunter 2008, Maegele 2008, Johansson 
2009b, Dente 2009, Teixeira 2009, Zink 2009, Snyder 2009, Savage 2014).  
In summary these papers showed that there was a significant association 
between higher ratios (of FFP to packed cells) and a lowering of mortality in 
significantly bleeding trauma casualties.  These mortality reductions ranged 
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from 15 to 62% and were from predominantly civilian trauma centres in the 
USA and Europe. 
 
Some studies have observed optimal outcomes may be at plasma ratios of 
greater than 1:1 (Teixeira 2009, Kashuk 2008, Gunter 2008) and some use 
these as evidence of the benefit of higher ratios.  Gunter (retrospective 259 
patients) found a reduction in 30-day mortality if patients received a 
plasma:PRBC ratio of 1:1.5.  Teixeira (retrospective 383 patients) found the 
best relative risk of death was in patients who received a ratio of less than 
1:2.  Kushuk probably discovered the more convincing evidence towards 
higher ratios (retrospective 133 patients) finding the median ratio of 
survivors was 1:2 compared to 1:4 (non-survivors), but stated that 1:2 was 
the threshold for survival inferring a higher ratio is better.  They also 
discovered that a 1:1 ratio gave patients the best improvement in 
coagulopathy. 
 
The arguably pivotal study and a critical report for military resuscitators, was 
from Borgman et al based in Iraq (Borgman 2007) who looked at massive 
transfusions in 246 military combatants.  All of these casualties had 
received more than 10 units of components in 24 hours.  Their FFP to 
packed cell ratios were divided into three groups; 1:8, 1:2.5 and 1:1.4.  They 
found a 55% absolute reduction in mortality between the highest and lowest 
ratios.  Yet they also identified that the median time to death was much 
longer (38 hours) in the high ratio group compared to only 2 hours in the low 
ratio group.  A number of those authors investigated civilian trauma in their 
home trauma centres on return from their military deployment (Holcomb 
2008).  They found a similar survival advantage in the high ratio group, but 
again a markedly dissimilar time to death (35 hours compared to 4).  
Although the first paper was used as a particular support to the resuscitation 
of military ballistic casualties, the authors disclosed that there was a 
survivorship bias.  The patients, who died early, did so before they were 
able to get more plasma and hence their ratios were high.  In contrast a 
patient with less shock and less physiologically challenged by their injuries 
survived long enough to get more FFP and as a result of having lesser 
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injuries their plasma ratio was higher (Magnotti 2011), suggesting injury 
severity was the cause of mortality difference, not ratio. 
 
Two authors specifically looked at this survivorship bias (Scalea 2008, 
Snyder 2009).  As in the other papers, both found that high ratios had a 
better survival. Scalea in a prospective study of 806 patients used stepwise 
regression analysis on their data and when early deaths were excluded, 
they found no survival benefit for higher ratios.  However their mortality was 
surprisingly low (only 6%) and various amounts of data is missing that 
would enable a more detailed review of their findings, including intensive 
care admission times.  When Snyder treated the ratio as a time-dependent 
variable they also found that the survival advantage of high ratios was lost. 
 
The only other prospective study at that time was the London group 
(Davenport 2011c) who investigated the haemostatic effect of different 
ratios during resuscitation.  It was a small study on only 50 patients in which 
the authors stated a ratio of 1:1 had no advantage over a ratio in the range 
of 1:2 to 3:4 for conveying haemostatic advantage.  The results initially 
seem pertinent, but closer inspection reveals that the median amount of 
FFP received in the first 12 hours was only 4 units, suggesting that a 
significant number of massive transfusions did not take place.  No actual 
results for coagulation were presented, only the difference before and after 
treatment, making it impossible to determine how many were actually 
coagulopathic.  Thromboelastometric graph width, termed Maximum Clot 
Firmness (MCF), is predominantly a reflection of clot strength determined by 
platelet quantity and quality in addition to fibrinogen.  MCF is typically one of 
the first abnormalities seen in coagulopathic trauma patients and their 
results here were not particularly conclusive; the maximum difference in 
mean value variation between all groups was 8mm, producing changes 
reported to be in the region of 38%, yet a normal MCF is in the region of 
40mm.  Initial Clotting Time (CT) is a better reflection of the presence and 
activity of coagulation factors and as such a better reflection on FFP 
requirement.  The CT significantly improved in both low and mid ratio 
groups.  With these minimal differences in a patient group that did not 
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receive massive transfusions, it is difficult to agree with their maxim that 
hemostatic effects are maximal at a 1:2 ratio. 
 
In 2010 I deployed to my second Operational deployment to Afghanistan.  
At this time our resuscitation strategies were becoming well established.  
My work was predominantly on the Medical Emergency Response Team; 
the helicopter based pre-hospital team that collected patients from the front 
line.  Injuries in that year were significant in severity and explosive, ballistic, 
multiple amputations unfortunately predominated.  We had just established 
the ability to provide blood components to the aircraft with an assured cold 
chain and on each trip we took 4 units of packed cells and 4 units of FFP.  
Severely injured casualties was resuscitated with a 1:1 ratio and 
coagulation was measured on admission using rotational 
thromboelastometry.  A prolonged Clotting Time, indicating lack of clotting 
factors and by inference inadequate FFP, was a rare result to find with 
these casualties.  Was this a reflection of an already adequate resuscitation 
reducing the coagulopathy of trauma?  Was there scope for less FFP to be 
given?   
 
These are difficult questions to answer however the use of ROTEM in 
trauma (as described in the Chapter 5) must be remembered.  Certainly the 
definition and diagnosis of Acute Traumatic Coagulopathy (ATC) has 
differed temporally and between centres and authors.  Historically the lab 
parameters of PT and aPTT were used, however ROTEM (and TEG) are 
now well established as having primacy in ATC diagnosis.  Throughout the 
literature describing ATC diagnosis on admission it is not CT that is used, 
but MCF, A5 or A10 – all graphical measurements of graph height – a 
reflection of clot strength, not lack of clotting factors.  These parameters 
were shown to be predictive of need for Massive Transfusion prediction 
(Leemann 2010, Davenport 2011b, Schöchl 2011, Tauber 2011, Brockamp 
2012, Maegele 2012, Mutschler 2014) and hence are used as an indicator 
of the presence of ATC.  This suggests our findings of a CT within the 




reflection of our FFP transfusion policy and its adequacy, both in ratio and 
quantity.  
 
It would be difficult to determine the effect of our pre-hospital resuscitation 
without pre-hospital blood results, but the question of the amount or ratio of 
FFP remains.  If a normal CT is found in ATC, then it is natural to question 
the necessity of needing FFP at all.  The evidence for its use has certainly 
been previously questioned (Stanworth 2007), but the weight of evidence 
that it is beneficial to the trauma casualty remains (Snyder 2009, Johansson 
2012b, Savage 2014).  More recent studies on plasma only resuscitation 
have shown its benefit (Sperry 2018) with a likely effect of plasma on the 
pathophysiological mechanism behind the cause of ATC (Peng 2013, Pati 
2016). 
 
My third deployment to Bastion in 2014 had me based in the military 
hospital at Camp Bastion.  Pre-hospital resuscitation was continuing in a 
similar manner to two years previously.  In the hospital we continued to use 
an empirical ratio of 1:1, which remained throughout the initial resuscitation 
phase and into the operating theatre, lasting at times many hours in the 
operating room.  Rotational thromboelastometry was available and used on 
all patients on admission and into the operating room.  It was used for goal 
directed therapy guiding the use of additional components (cryoprecipitate 
and platelets) and adjuncts (such as Tranexamic Acid) but it was not used 
particularly for determining FFP use.  These protocols were supported by 
guidance from the Surgeon General’s office, advised by his experts (CGOs, 
Massive Transfusion Protocol 2012).  This continuation of the use of 
empirical ratio throughout resuscitation despite the ability to use goal 
directed therapy for all products could attract criticism from some quarters, 
but our data suggested otherwise.  Evidence of haemostasis benefit is 
lacking, but evidence of the impact of our resuscitation methods on the 
whole patient pathway is clear.  The survival of our patients improved with 
these changes in management with the 50% survival NISS value being 32 
in 2003 rising to 60 in 2012 (Penn-Barwell 2015).  This improvement in 
survival was secondary to a multitude of factors but included “massive 
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transfusions….at approximately a 1:1 ratio with early platelet 
administration….guided by near-patient thromboelastometry”.  This aspect 
of continued resuscitation within the operating theatre at an empirical ratio 
was shown to improve physiological parameters significantly throughout 
their period in surgery.  Indicators of injury severity and degree of 
physiological damage before and after surgery illustrate how well their 
damage control resuscitation improved their circumstance, including clotting 
status; pH improving from 7.19 to 7.45 and PT reducing from 18secs to 
14secs (Morrison 2013a).  
 
Certainly one concern with the potential over use of FFP is the additional 
donor exposure with the risk of increased sepsis and multi-organ failure 
(Watson 2009, Norda 2006) and TRALI (Transfusion Related Acute Lung 
Injury; Inaba 2010a), but these findings have not been found in the military 
population (Starkey 2013).  
 
A multi-centre study involving 16 trauma centres recruited 452 massively 
bleeding trauma patients and looked at transfusion rates over the first 6 
hours.  FFP to packed cell ratios were divided into less than 1:4, more than 
1:1 and a group between these ratios.  They concluded early high FFP to 
red cell (and high platelet to red cell) ratios improved survival. Although 
limitations were evident in the study particularly in the difference in head 
injuries between the groups, this still provided good evidence that reaching 
high ratios within the early hours of admission is associated with a reduction 
in mortality (Zink 2009).  A recent observational study associated early 
plasma administration with improved 30-day survival (del Junco 2013, 
Holcomb 2013) and a prospective multicentre study involving patients’ 
receiving massive transfusion showed that the high FFP (and platelet) to 
red cell ratio was associated with a survival benefit even when time 
dependency was accounted for (Brown 2013).  
 
The PROMMT (Prospective, Observational, Multicenter, Major Trauma 
Transfusion) study looked at timings and ratios from over a thousand 
patients admitted to 10 US trauma centres.  Patients with lower ratios 1:1 
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compared to 1:2 or greater) had a decreased 6-hour and 24-hour mortality, 
but this did not extend beyond this time (Holcomb 2013). 
 
One of the most recent and rational studies was the Pragmatic Randomized 
Optimal Platelet and Plasma Ratios (PROPPR) trial (Holcomb 2015b, 
Baraniuk 2014).  Nearly 700 randomised trauma patients who were 
suspected to have or had sustained massive blood loss reported that there 
was no difference in overall survival between early administration of plasma, 
(platelets) and packed cells in a 1:1:1 ratio compared to 1:1:2.  However the 
patients in the high ratio group (1:1:1) achieve haemostasis and fewer 
experienced death due to exsanguination by 24 hours.  Importantly there 
were no differences between the groups in safety and side effects. 
 
Further support to higher plasma ratios is given by some recent papers on 
plasma only resuscitation.  The Prehospital Air Medical Plasma (PAMPer) 
trial found those patients receiving plasma only resuscitation in the pre-
hospital environment, compared to conventional regimes, had a significantly 
lower mortality (Sperry 2018) with minimal adverse effects.  This further 
supports those investigations that found that plasma had a beneficial effect 
on the vascular endothelium in minimizing its damage (Peng 2013), 
inflammation and permeability (Pati 2016) in haemorrhagic shock  
 
There is consequently still no clear evidence that one ratio is better than the 
other.  There is certainly evidence that one is no worse than the other.  
Military resuscitation physicians lean towards resuscitating with higher FFP 
ratios.  Seminal papers, albeit retrospective, have shown the benefit of this 
and personal experience has proven its worth supported by the evidence 
that our trauma management methods as a whole are excellent.  
Importantly there is little proof that it does harm, both in our population and 
in a civilian population. 
 
Another component of considerable value and to some extent included in 




6.3.4  Platelets 
 
Platelets are produced in two ways; derived from whole blood donations or 
from direct apheresis.  The standard adult dose of platelets is generally 
derived from a unit of donated whole blood.  A unit is centrifuged and the 
buffy coat (fraction of an anticoagulated that contains white blood cells and 
platelets) from four such units are pooled together from four ABO identical 
donors and then resuspended - after leucocyte depletion - in the plasma of 
one of the donors (male, to reduce the risk of transfusion-related acute lung 
injury (TRALI)).  This produces a pooled platelet component, typically of 
300ml volume, containing a platelet count greater than 240 x 109  (JPAC 
2013).   
 
In apheresis, blood is removed from the circulation, anti-coagulated and 
separated into components. The apheresis platelets are leucodepleted and 
typically have a volume of 180ml with a similar platelet count to pooled 
platelets.  
 
Both types can be stored up to 5 days at 20 to 24°C with gentle agitation 
with some Blood Services able to extend this to 7 days if they have 
automated bacterial screening.  Risks of transfusion remain extant with 
acute non-haemolytic transfusion reactions like TRALI remaining low (Eder 
2007) and the potential for transfusion transmissible infections with 
haemolytic reactions a potential secondary to the level of plasma contained 
within. 
 
Thrombocytopenia is considered a late event in haemorrhage seen only 
after a loss of 1.5 blood volumes (Hiipala 1998).  It is rarely found on patient 
admission, with one study finding less than 5% of trauma patients having 
platelet counts of less than 100 x 109/l (MacLeod 2003).  Platelet count is 
typically normal during early, otherwise proven, traumatic coagulopathy 
(Hess 2009, Brown 2011, Floccard 2012), although patients with a higher 




Admission platelet count is considered a good indicator of outcomes, it is 
inversely related to injury severity and there is an association between 
platelet count and both morbidity (Schnuriger 2010) and mortality (Van Beek 
2007, Hess 2009, Brown 2011).  One large study found platelet counts can 
reduce significantly after hospital admission, which is important when you 
consider that a low platelet count in trauma has been shown to predict an 
increased mortality risk (Stansbury 2013).  
 
The antithetical relationship between mortality and platelet count is not just 
confined to abnormal counts but encompasses the lower extents of the 
normal range.  Although platelet counts can be normal in proven 
coagulopathy of trauma, even this is associated with a high mortality 
(Stansbury 2013, Brown 2011).  
 
The interpretation of this data suggests that adequate platelet numbers are 
not a vital aspect of ATC, though there is a relationship between them and 
both ATC and mortality.  This suggests that it is not quantity, but quality that 
is key. 
 
More recent work has concentrated more on platelet function rather than 
quantity. Abnormal platelet function has been identified as a part of the 
acute coagulopathy of trauma (Wohlauer 2012) with a decreased platelet 
aggregation correlating to mortality (Jacoby 2001, Kutcher 2012).  Wohlauer 
suggested there was a role of early platelet transfusion in trauma 
resuscitation.   His team, using TEG platelet mapping, found that platelet 
function was abnormal within 30 minutes of injury before significant fluid and 
blood component administration.  
 
There have been a number of studies investigating the effect of platelet 
transfusion in trauma patients, although it is a challenge to determine the 
exact influence of platelets alone from these, as a significant number use 
predefined ratios with other blood components. One retrospective study of 
over nearly 700 military trauma patients (Perkins 2009) found a higher ratio 
of platelet to red cell transfusion (greater than 1:8) had a higher survival 
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(95%) compared to the lower ratios (less than 1:16 survival of only 36%) at 
24 hours and at 30 days (75% survival in higher ratio compared to 43%).  In 
a similar retrospective study at a Level 1 trauma centre in USA (Inaba 
2010b), 657 trauma patients were identified who had received a massive 
transfusion where mortality at 24 hours was found to be lowest in the high 
ratio group (greater than 1:6) compared to the lowest (lower than 1:18).  A 
review of platelet to red cell ratio in early resuscitation of trauma patients 
run by Hallet (2013) included 7 observational studies with over 4,000 total 
patients.  Although they could not support specific ratios, they found that in 
studies looking at patients requiring a massive transfusion a lower mortality 
was observed with higher ratios.  This supports Johansson’s earlier review 
(Johansson 2012b), which also included plasma, but looked specifically at 
patients receiving massive transfusions (which they identified as more than 
10 units in 24 hours).  They included 16 studies, with a total of just fewer 
than 4,000 patients and produced a meta-analysis of these, concluding for 
platelets the higher the ratio the lower the mortality.  One recommendation 
of these papers was a prospective, randomized controlled trial (RCT) should 
be carried out.  Holcomb (2013) carried out a prospective cohort study to 
answer this need – the Prospective, Observational, Multicenter, Major 
Trauma Transfusion (PROMMT) study.  Looking at specific timings, they 
found higher platelet ratios achieved in the first 6 hours conferred a 
decreased chance of death by a factor of 3, although this did not exist at the 
30-day mortality mark.  
 
A more recent study was the Pragmatic Randomized Optimal Platelet and 
Plasma Ratios (PROPPR) trial (Holcomb 2015b, Baraniuk 2014).  Their 
patients in the high ratio group (1:1:1 of PRBC: platelets:plasma) achieved 
haemostasis and fewer experienced death due to exsanguination by 24 
hours with no differences between the groups in safety and side effects.  A 
subsequent study on the impact of platelets in these patients found that 
those patients who received early platelet transfusion had improved 
haemostasis, fewer deaths from exsanguination and were associated with a 
significantly decreased 24-hour and 30-day mortality (Cardenas 2018).  The 
majority of studies appear to directly favour a higher platelet ratio, which 
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clinicians need to keep in mind early in their casualty’s resuscitation as 
platelets commonly take some UK Blood Services a period of time to 
provide.  In addition, once transfused it is not infrequent to find they take 
time to start functioning normally.  
 
In fitting with this, there is some commonality in guidelines on timing and 
quantity of platelets requested.  One adult therapeutic dose (one apheresis 
pack or 4 pooled units) of platelets are recommended to be given in both 
the UK (BCSH 2014, Hunt B 2015) and in Europe (Rossaint 2016), with the 
latter stating up to 8 pooled units can be given.  Both recommend keeping 
patient circulating platelet levels above 50 x 109/l, however the UK 
guidelines recognise that many NHS hospitals don’t keep a stock of their 
own platelets and so recommend clinicians should order platelets early in 
major haemorrhage, when the count has fallen to 100 x 109/l.  British 
military guidelines also recommend this higher level in their massive 
transfusion policy (CGOs 2012).   
 
Platelets work hand in hand with fibrinogen and their interaction ensures the 
stability and strength of clot formation.  Fibrinogen is key in activation and 
ensuring correct function of platelets and hence effective haemostasis.  Its 
provision should have a key part to play in resuscitation.  It is available in a 




6.3.5  Cryoprecipitate 
 
Cryoprecipitate is the cryoglobulin fraction of plasma that is obtained from 
fresh frozen plasma (FFP).  FFP is thawed to 3°C, spun in a centrifuge at 
that temperature producing the cryoglobulin at the base, which is then 
frozen rapidly.  It should contain at least 140mg per unit of fibrinogen in the 
UK (JPAC 2013) and Europe (Council of Europe 2006).  It is usually 
prepared as a pool of multiple donors, typically being from five single units.  
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The risks and side effects are similar to other blood components including 
TRALI (Chapman 2009), TACO (Transfusion Associated Circulatory 
Overload; SHOT 2012) and infectious diseases.  The latter is probably 
higher than FFP, as a common adult dose of cryoprecipitate is from 5 to 10 
pooled units of FFP from multiple donors (JPAC 2013).  This would suggest 
that it carries a higher risk of viral transmission per dose (Callum 2009). 
 
Fibrinogen was identified as one of the first haemostasis proteins to fall 
during substantial haemorrhage in 1995 (Hippala 1995) and has been 
acknowledged as an important aspect of traumatic coagulopathy 
(Davenport 2011b).  Hippala originally found a low fibrinogen was 
associated with an increased transfusion requirement and an increased 
mortality.  In 2012 Rourke at al found in a prospective analysis of over 500 
patients that coagulopathic patients had significantly lower fibrinogen levels 
upon arrival and that low fibrinogen (less than 1.5 g/l) on admission was 
found to be an independent predictor of mortality at 24 hours and 28 days 
(Rourke 2012).  Measurement of fibrinogen (usually Clauss Fibrinogen) is 
not a normal coagulation measurement when patients arrive at an 
Emergency Department.  It was useful therefore that it was noted that a fall 
in fibrinogen levels was shown to be associated with a rising base deficit, a 
low systolic blood pressure and a higher injury severity in Rourke’s study.  
Another project found quantitative results illustrating similar correlations, the 
chance of low fibrinogen (less than 1.5 g/l) being 73% if Hb was less than 
10 g/dl and 63% if Base Excess was less than -6.   
 
It is common for trauma centres in USA and UK to use thromboelastometry 
to assess initial coagulation in trauma on arrival.  Schohl found, in trauma, a 
FIBTEM MCF of 7mm correlated with a fibrinogen of 1.5 g/l (Schohl 2011) 
and Rugeri found in civilian trauma patients that were “coagulopathic” had a 
median fibrinogen level of 0.9 g/l and FIBTEM MCF of 6mm (Rugeri 2007).  
Others have found similar results (Rourke 2012) suggesting 
thromboelastometry can estimate fibrinogen levels in a clinically useful time, 
identifying those patients early (who have a higher mortality) and enabling 
adequate directed resuscitation. 
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There is clinical data to suggest the benefits of fibrinogen replacement in 
increasing survival (Stinger 2008, Curry 2014, Curry 2015) and reversing 
traumatic coagulopathy (Rourke 2012).  Rourke found that those trauma 
patients receiving a cryoprecipitate transfusion (2 pools, 10Units) 
maintained their Fibrinogen levels.  Those patients who did not receive 
cryoprecipitate had fibrinogen levels that steadily dropped into the level that 
correlated with a higher mortality risk (Rourke 2012).  A feasibility study 
looking at early administration of cryoprecipitate in transfusion protocols 
found that those patients who receiving cryoprecipitate had a mortality of 
10% compared to 28.6% for patients resuscitated with a standard 
cryoprecipitate free transfusion protocol.  A couple of military studies had 
similar findings for their ballistics combat trauma casualties.  MATTERS II 
was a retrospective look at cryoprecipitate in association with Tranexamic 
Acid (TXA) use, which found those patients receiving cryoprecipitate had a 
slightly lower mortality compared to those who did not (21.4% compared to 
23.6%) and when given with TXA the additive survival benefit meant 
mortality rates were halved (11.6%; Morrison 2013b).  Another study of 
trauma patients at an American Army combat hospital found that a high 
ratio of fibrinogen to red cell transfusion was independently associated with 
improved survival to hospital discharge (Stinger 2008), stating the ratio 
could be achieved by transfusing 2 (10 Unit total) pooled bags of 
cryoprecipitate for every 10 Units of red cells.  The PROMMT authors found 
little evidence to support use of cryoprecipitate, however very few of their 
patients actually received it.  They did note though that it took over 2 hours 
for patients to get their first cryoprecipitate transfusion (Holcomb 2013), 
similar to the ACIT study where it was noted that patients did not generally 
receive any cryoprecipitate until after 6 units of red cells (Khan 2014).  
Another UK study found it took 103 minutes (median) to receive 
cryoprecipitate (Rourke 2012), however a feasibility trial, CRYOSTAT by the 
same authors, attempted to drive the inclusion of cryoprecipitate into normal 
massive transfusion protocols had better success and the majority of 





The amount and threshold of replacement is not well documented, there are 
various guidelines with little data to support the findings, however it is 
interesting to note that one study found that a 0.5g dose of fibrinogen 
(noting one unit of cryoprecipiate is likely to have 0.14g of fibrinogen and a 
5U pool 0.7g) would increase a FIBTEM MCF by 1mm (Gorlinger 2012).  
Doses recommended are from 5 pooled units (CGOs 2012) to 15-20 units 
(Rossaint 2016 European guidelines). 
 
There are a number of guidelines on using cryoprecipitate as a fibrinogen 
replacement, many of which recommend administration once plasma 
fibrinogen levels drop below 1.0 g/l-1 (Levy 2013).  Recent evidence as 
described above suggests a higher level should be targeted (Thomas 2010, 
Fries 2010).  The European guidelines on management of major bleeding in 
trauma (Rossaint 2016) now recommend a level of 1.5 to 2 g/l or a 
viscoelastic sign of fibrinogen dysfunction as the threshold for treatment, 
whereas the UK Defence Medical Services state a threshold of 1.5 g/l 
(CGOs 2012).  
 
The evidence suggests lower levels of fibrinogen are an indicator of worse 
outcome (Rourke 2012, Hippala 1995, Schöhl 2010), the time to give 
cryoprecipiate is usually delayed (Holcomb 2013) but fibrinogen 
supplementation in the form of cryoprecipitate is beneficial (Stinger 2008, 
Curry 2014, 2015).  Rather than waiting for levels to drop before requesting 
cryoprecipitate, the argument for earlier pro-active treatment of an adequate 
dose is growing stronger and personally I would look to request at least a 10 
unit pool on patient admission and confirmation of their need for a massive 
transfusion and then conduct a viscoelastic test to determine if more is 
needed.  Cryoprecipitate is not the only form of fibrinogen supplementation. 
 
 
6.3.6  Fibrinogen Concentrate  
 
Fibrinogen concentrate (FC) is produced from pooled human plasma and 
stored as a lyophilised powder at room temperature (Rahe-Meyer 2011).  It 
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can be reconstituted rapidly with sterile water, ready for transfusion 
(Fenger-Erikson 2009).  Viral infection risk is minimal as viral inactivation by 
exposure to solvent or pasteurisation occurs in the manufacturing process 
(Pereira 2007).  Unlike cryoprecipitate, the concentration of fibrinogen is 
standardized and there is no requirement for cross matching (Fenger-
Erikson 2009).  It has been shown to be at least as efficacious, if not better 
than cryoprecipitate in increasing plasma fibrinogen levels.  One study 
showed 2 g of FC would increase plasma fibrinogen by 0.44g/l, compared to 
only 0.26g/l after a 10U cryoprecipitate infusion (~1.8-2.2 g of fibrinogen).  
Some have deemed it better than cryoprecipitate; in one study 7 out of 64 
episodes of cryoprecipiate infusion was followed by a drop in fibrinogen 
(Theodoulou 2012).  
 
Although there are a number of manufacturers, the majority of studies have 
been one particular formula  - Haemocomplettan, known as RiaSTAP.  Low 
fibrinogen levels in trauma are discussed in detail above and the need for 
supplementation remains extant.  Those studies investigating 
Haemocomplettan as the source of fibrinogen supplementation in cases of 
severe bleeding have found similar results; its use is associated with an 
improvement in coagulation parameters (Danes 2008, Fenger-Erikson 
2008, Thorarinsdottir 2010), there is a direct relationship with plasma 
fibrinogen levels and survival (Danes 2008) and its use reduces transfusion 
requirements (Fenger-Erikson 2008, Thorarinsdottir 2010).  One study 
(Schöchl 2010) specifically looking at goal directed resuscitation in trauma 
using fibrinogen concentrate found actual mortality was less than expected; 
24.4% compared to a predicted mortality of 33.7% (calculating using 
Trauma Injury Severity Score [TRISS]) and 28.7% (using the Revised Injury 
Severity Classification [RISC]).  Despite these favourable results, a meta-
analysis carried out in 2017 on 7 observational, mostly retrospective studies 
found no effect on mortality with the administration of FC in trauma, noting 
though that there were no RCTs and their findings were due to a lack of 




There have been some trials subsequent to this review. The FiiRST trial 
was a feasibility trial looking at 6g of FC given successfully within an hour of 
hospital arrival (Nascimento 2016).  Fibrinogen levels were higher and 
remained so for up to 12 hours, but there was no difference observed in 
mortality.  This is not surprising though as neither group received massive 
transfusions, there was no difference in the amount of blood components 
each group received and both groups received similar amounts of 
cryoprecipitate.  The RETIC trial (Innerhoffer 2017) investigated the use of 
FFP versus coagulation factor concentrates.  They used fibrinogen 
concentrate predominantly but the trial was abandoned due to the large 
numbers from the FFP group needing rescue therapy (additional blood 
component resuscitation out with the study protocol), but this in itself was an 
interesting finding.  52% of the FFP group needed rescue versus only 4% 
receiving FC and the number needing massive transfusion was also greater 
in the FFP group (30%) versus 12% in the other.  Despite this study being 
stopped early their findings suggest that FC should be looked at in a 
favourable light. 
 
One more recent trial (Yamamanto 2017) undertook a retrospective look at 
giving FC pre-emptively in trauma patients rather than waiting for threshold 
results.  Nearly 60% of the patients that had an ISS of greater than 26 had 
received 10U red cells and were found to have had low fibrinogen.  The 48 
hour mortality of those with ISS greater than 26 was 8.6% in the pre-
emptive FC group compared to 22.9% in the other group.  For the more 
severely injured casualties this difference was greater; those patients with 
an ISS of greater than 41, the pre-emptive FC group had a mortality of 20% 
compared to 50% in the other group.  Although this is a retrospective study 
it was one of few to illustrate mortality benefit of giving fibrinogen 
concentrate early and most definitely leads to the question of whether it 
could be taken into the pre-hospital environment (both civilian and military). 
 
Another lyophilised product in use by the British and American military and 




6.3.7  Freeze Dried Plasma 
 
Freeze dried human plasma (FDP) otherwise known as lyophilised plasma 
(LP) was first introduced in World War II for use in resuscitation.  Plasma 
was converted into a fine lightweight powder in significant quantities to 
answer the high demand under difficult logistical conditions allied with the 
need for large volumes in a combat setting.  Disappointingly there were high 
rates of viral disease transmission secondary to pooling of plasma units and 
inadequate screening and the concept was abandoned (Inaba 2011).  
Modern screening methods have significantly reduced the risk of virus 
transmission have meant the concept of lyophilised plasma has re-emerged 
as primarily a logistically superior alternative to FFP.   
 
The two main manufacturers are from France producing FLyP  (French 
Lyophilised Plasma) and Germany producing LyoPlas N-w.  The latter is 
used by the British market including the Defence Medical Services.  LyoPlas 
production is typical with FFP being thawed and transferred to a glass bottle 
in sterile conditions with filtration eliminating any blood cells.   
 
LP has been repeatedly tested for functional comparison to FFP.  
Investigations after World War II demonstrated its haemostatic function was 
similar as measured by prothrombin time (Oktavec 1954).  In vitro assays of 
dried porcine plasma and FFP showed similar coagulation profiles (FII, FVII 
and FIX, PT, aPTT and fibrinogen in addition to thromboelastograhy 
assessments) (Shuja 2008, Spoerke 2009).  In vivo studies using swine 
models of polytrauma and haemorrhage demonstrated that FDP clotting 
factor levels were comparable to FFP with only a 14% drop in coagulation 
factor activity (Spoerke 2009, Lee 2013). 
 
Similar animal trauma models have illustrated it was equally effective as 
FFP in reversing coagulopathy and improving physiological markers as well 
as survival which increased from 15% to 100% (Shuja 2008).  In addition to 
coagulation benefits Spoerke et al (2009) also establish that LP reduced IL-
6 levels.  Levels of IL 6, 8, TNF are found to be increased in trauma and are 
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predictors of death (Martin 1997), SIRS (Giannoudis 2008), injury severity 
(Gebhard 2000) and multiorgan dysfunction (Kobbe 2008), so the authors 
suggested this secondary effect (to the use of ascorbic acid in its 
manufacturing process) was a further advantage (Hamilton 2011). 
 
There is very little substantial prospective evidence of the efficacy of LP or 
FDP in a human population.  The military however have been using it for 
some time, acting on the significant animal data, bringing it into use to meet 
the logistical demands of treating troops deployed long distances from 
medical support.  At present it is used by Dutch, French, Israeli, German 
and UK armed forces (personal communications).  US forces have just 
received FDA approval.  Most studies have therefore been military based.     
 
A recent prospective study conducted by the French military at the Role 3 
Hospital in Kabul, Afghanistan reported on the use of LP in 87 military and 
civilian casualties (Martinaud 2011).  They reported an overall mortality of 
10% among those patients who received LP, with 67% of these patients in 
shock when treatment was initiated.  This study noted a significant decrease 
in Prothrombin Time (PT) after LP administration in the 36 patients with 
complete data sets.  Though this study was small and many patients were 
lost to follow-up, there were no reported complications attributable to LP 
administration.  The French military have probably the greatest amount of 
experience and regularly extol the virtues of LP and its significant shelf life 
(2 years); its ease of time to use (3 minutes to rehydrate) and that at the 
end of its shelf life it still has similar clotting factor and fibrinogen activity to 
FFP (Daban 2009, 2010, Bux 2013).  A further French study, again from 
Kabul, looked at 72 transfusion episodes of which 63 received LP (average 
of 3 units).  They found a significant improvement in PT back to normal 
levels with LP, prior to surgical intervention (Patrick 2011).    
 
This small evidence supports the animal model evidence that LP has a use 
in patients suffering severe trauma and haemorrhagic shock and backs 
those growing number of medical providers who have been using it in the 
civilian pre-hospital environment Internationally.  An Israeli retrospective 
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study (Shlaifer 2017) on 109 casualties over a 3-year period (83% 
penetrating, 50% multiple severe injuries) receiving FDP, showed that it was 
both easy and feasible to use in this environment.  A French retrospective 
study has shown trauma patients can receive plasma in a 1:1 ratio with 
greater rapidity if LP is used instead of FFP (Nguyen 2018).  The 
Norwegians have used LP in their pre-hospital HEMS service and published 
a 12-month review of its use (Sunde 2015).  Only 16 patients received it, 
having received mixed trauma and being hypotensive (Systolic BP < 
90mmHg).  They reported no transfusion related complications.  These 
studies show the feasibility of using LP in the pre-hospital environment but 
more prospective studies are needed to evaluate clinical effectiveness and 
outcomes following LP transfusion.     
 
There has been only one study published so far; the Traucc trial was a 
prospective, randomised trial comparing FLyP to FFP in trauma patients in 
a French hospital.  One of their primary outcomes was the incidence of 
coagulopathy and fibrinogen levels (Garrigue 2017).  The investigators 
found in the 48 patients enrolled that those in receipt of FLyP had higher 
fibrinogen concentrations and a more rapid improvement in their 
coagulopathy compared to FFP.  They also noted that FLyP patients 
received plasma more rapidly (15 minutes compared to more than 90) and 
as a consequence achieved a 1:1 ratio in significantly less time. 
 
Lightweight, easily transportable, simply stored for long periods of time; the 
superior logistical reasons for using lyophilised plasma are clear.  The 
additional in vitro and animal model and limited human in vivo evidence that 
it functions as well as FFP makes lyophilised plasma a viable component to 
use in a trauma patient.  Unfortunately its limited availability and cost reduce 
any physicians ability to use it.  These latter reasons are the principle 
rationalisation for its use only in austere situations in the British military – in 
the pre-hospital environment or with Units who provide small surgical teams 





6.3.8  Whole Blood 
 
There has been a resurgence in the interest in using Whole Blood (WB), 
both stored (SWB) and fresh (FWB), for trauma in recent years.  It has had 
a long history of use in the military environment since World War I 
(Stansbury 2017), and many argue that it is a logistically easier and less 
wasteful option as it contains all the elements of blood components, but in a 
smaller volume of anticoagulant.  A recent review (Spinella 2016) indicated 
that its use in hemorrhage, results in outcomes as favourable if not better 
than component therapy resuscitation.  Retrospective military studies on the 
use of FWB on combat casualties have shown it is independently 
associated with improved survival in Iraq (Spinella 2009) and Afghanistan 
(Nessen 2013).  The advantage of refrigerated storage for one product 
compared to multiple storage options for components, including agitation 
requirements for stand-alone platelets means WB has a significant logistical 
advantage (Cap 2018).  Concerns over infection and grouping mismatch are 
valid, with 2 infections and one transfusion associated graft versus host 
fatality in 10,000 FWB transfusions on US personnel (Gilstad 2012).  Its use 
is increasing with at least 5 US and Norwegian trauma centres using WB for 
trauma resuscitation using group O blood with low titres (less than 50 anti-A 
and anti-B; Yazer 2018) with a number of larger studies beginning to look at 
the feasibility and potential advantages of using it (LITES 2018) 
 
UK military experience so far has been sporadic and has centred on 
emergency donor panel provision in response to patient extremis or when 
platelet provision was inadequate or non-existent.  WB has considerable 
potential, particularly in the pre-hospital environment and in austere military 
environments. 
 
Unfortunately within the UK at present NHS Blood and Transplant (NHSBT) 
does not supply WB as standard. Despite this, requests from the UK military 
and other agencies have had recent impact, and the London HEMS are at 
present undertaking a study on its use for pre-hospital trauma resuscitation 
(LAA News 2018). 
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6.4  Transfusion Adjuncts 
 
6.4.1  Tranexamic Acid 
	
Hyperfibrinolysis is found in severely injured patients and is associated with 
increased mortality (Kashuk 2010a).  The Clinical Randomisation of an 
Antifibrinolytic in Significant Haemorrhage 2 (CRASH-2) (CRASH-2 
collaborators, 2010, 2011) brought Tranexamic Acid (TXA), an anti-
fibrinolytic, into the International sphere.  The investigators appraised the 
use of TXA in trauma within 8 hours of injury in a large, international multi-
centre trial of over 20,000 patients.  They demonstrated that administration 
of TXA in trauma reduced death from 16.0% to 14.5% and death from 
hemorrhage from 5.9% to 4.9%.  They found no increase in fatal or non-
fatal vascular occlusive events.  Importantly for bleeding deaths, early TXA 
was better, with less than 1 hour being more protective than 1 to 3 hours.  
Of concern was TXA given after 3 hours was associated with increased risk 
of death. 
 
Despite these significant and important results there has been criticism from 
a number of quarters, particularly in America and Australia (Pusateri 2013, 
Mitra 2014).  In CRASH-2, 98% of the patients were recruited from 
developing countries where trauma patient treatment is considerably 
different (rudimentary pre-hospital and emergency medicine care, minimal 
blood supply, limited imaging access and basic operative and postoperative 
care facilities) to developed countries.  There is little evidence that the 
patients were bleeding at the time of randomization; only half (50.4% in TXA 
group, 51.3% in placebo group) of the patients received blood transfusions 
and less than half the patients had a surgical intervention (47.9% in TXA 
and 48.0% in the placebo group) so many question if some groups of 
patients recruited to CRASH-2 would be expected to actually benefit from 
TXA.  Particularly when there was no reporting of the total number with 
hypotension, or haemorrhage.  It is reasonably likely that patients with 
massive haemorrhage may not have made it to some of the hospitals 
involved in the study.  Finally the mortality of recruited patients is 
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significantly higher than that found in major trauma centres in USA, UK and 
Australia.  Hence criticism is understandable, especially from physicians in 
developed countries where the trauma population is appreciably different 
from the groups described above (Cap 2011, Napolitano 2013). 
 
The UK military have used TXA extensively in Afghanistan for ballistic 
casualties and found in a retrospective study that TXA use was associated 
with improved survival (OR 7.3; 95% CI 3.02 to 17.32), although unlike 
CRASH-2 there was no difference in mortality at 24 hours, it was found to 
be thereafter (Morrison 2012).  The reason for this is unclear.  Of concern 
though, was that the patients receiving TXA had a higher rate of pulmonary 
embolism (PE) and deep vein thrombosis (DVT) (2.7% and 2.4%) compared 
to those who did not receive TXA (0.3% and 0.2%).  It is highly likely that 
this thrombus incidence is even higher as under reporting of PEs was 
discovered in the UK Hospital in Afghanistan at that time; actual incidence 
9.3% in a retrospective study compared to 3.2% diagnosed at injury, with a 
positive association between pulmonary thrombus and DVT, amputation 
and TXA use (Lundy 2013).   
 
A number of studies in developed countries have investigated the impact of 
TXA use in developed countries.  The Ryder Trauma Center reviewed 1217 
patients over 4 years and compared those who had received TXA to those 
who had not (Valle 2014).  They found that in patients with the highest injury 
acuity TXA was associated with increased mortality (27% vs 17%, p<0.024).  
The Texas Health Science Center in Houston investigated 1032 patients 
over a 4-year period who had evidence of hyperfibrinolysis on 
thrombolealstography.  In-hospital mortality was higher in the TXA group 
(40% vs 17%, p<0.0001; Harvin 2015).  Another prospective study from 
London investigated the implementation of TXA use in their massive 
transfusion protocol.  Of 385 patients, 160 (42%) received TXA within 3 
hours.  Those receiving TXA were more severely injured and coagulopathic 
on arrival.  TXA was found to have no influence on outcome and in 
multivariate analysis was protective for mortality in “shock” patients only 
(Cole 2015).  All of these studies support the notion that the CRASH-2 trial 
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results should not be blindly followed and physicians must question its use 
in a well developed trauma centre with ready access to blood components 
and near patient coagulation testing particularly in the more severely injured 
group, and especially when the theory of distinct fibrinolysis phenotypes is 
considered (Moore 2015).  
 
Despite these misgivings its use is common in the pre-hospital environment 
across the World.  The USA, French, British and Israeli military and the 
British, Norwegian and Israeli civilian ambulance services use TXA as part 
of their resuscitation protocols.  The Germans have found evidence that 
TXA given in the pre-hospital environment improved survival (Wafaisade 
2016) although there were some limitations to the study; timings of TXA not 
documented, no TXA algorithm, and cause of death not documented.   
 
Most guidelines produced recommend the use of TXA at the doses used by 
the CRASH-2 collaborators; 1g bolus to be given within 3 hours of injury, 
followed by a 1g infusion over 8 hours.  This is recommended by the British 
(CGOs 2012) and US military guidelines (Joint System Control 
Resuscitation Clinical Practice Guideline; Damage Control Resuscitation 
2011) where a pre-hospital TXA bolus is advocated.  Civilian guidelines are 
similar in Europe (Rossaint 2016) where the first dose is recommended en 
route to the hospital.    
 
Elsewhere guidelines are a little more cautious; the International Trauma 
Life Support states “consideration should be given to administration of 
TXA….in those patients who show signs of hemorrhagic shock” (Alson 
2014).  A document endorsed by the American College of Surgeons 
Committee on Trauma and American College of Emergency Physicians on 
pre-hospital use of TXA (Fischer 2016) stated that there was a lack of data 
and recommended any TXA administration be monitored. 
 
There is some convincing evidence for the use of TXA, however this is not 
without flaws and more relevant and robust data relevant to developed 
country civilian and military patients is lacking.  Military data suggests it has 
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potential but the one retrospective study played down significant potential 
side effects and had insufficient data on timings and doses of TXA given.  
Many clinicians look forward to the results of two on going prospective pre-
hospital studies; STAAMP (Study of Tranexamic Acid during Air Medical 
Prehospital Transport) (Brown 2015c) in America and PATCH (Pre-hospital 
Antifbrinolytics for Traumatic Coagulopathy and Haemorrhage) (Mitra 2014) 
in Australia.  
 
 
6.4.2  Recombinant Activated Factor Seven 
 
Initial investigations into the use of recombinant activated factor VII (rFVIIa) 
were promising.  An early, randomised controlled trial in trauma patients 
found reduced PRBC usage and reduced ARDS incidence with no increase 
in adverse thrombotic events (Boffard 2005).  A military retrospective study 
on ballistic trauma casualties found a reduction in PRBC transfusions 
(Perkins 2007) and another found reduced 30-day mortality, again with no 
increase in thrombotic events (Spinella 2008b).  However there was 
growing evidence that it was not an uncomplicated treatment option, with 
the greatest concern being over thrombo-embolic events.  Greater 
experience and larger numbers of patients exposed to it resulted in a 
number of studies illustrating these concerns; it is found to be related to 
deaths from thromboembolic events (MacLaren 2005, O’Connell 2006, 
Thomas 2007), there is a lack of evidence to support its use in penetrating 
trauma (Duchesne 2008) and it has been shown to potentially cause an 
increased incidence of multiple organ failure (Wafaisade 2013).  A recent 
randomized controlled trial was terminated early (secondary to a futility 
analysis) due to unexpected low mortality (Hauser 2010).  Mortality was 
higher (but not significant) in penetrating trauma for those receiving rFVIIa, 
but there was no increased incidence of thrombotic events, a factor also 
found in an earlier study (Boffard 2005).  Other studies in the pre-hospital 
space have found little difference with its treatment (no effect on mortality) 




The evidence is confounding and contradictory.  The US Food and Drug 
Administration (FDA) does not approve it for use in trauma and the 
European guidelines on trauma (Rossaint 2016) recommend that it should 
only be considered if all other attempts to control bleeding by conventional 
measures have failed, a similar position to British military guidelines (CGOs 
2012).  Consequently it is rarely used, as for rFVIIa to work adequately the 
patient should not be acidotic or hypothermic and should have adequate 
platelet and clotting factor levels – an unlikely situation if all other 





6.5  Resuscitation Fluid Summary 
 
Previous chapters have discussed in detail the expected injuries in civilian 
and military trauma and the physiological outcome of those injuries.  
Clotting and how it is affected by trauma has been considered with 
particular attention to the Acute Traumatic Coagulopathy.  The resuscitation 
methods for these patients has also been examined; methodology (Damage 
Control Resuscitation) and investigation aids (near patient coagulation 
assessment).  Finally the different fluids, including ratios of blood 
components, and their adjuncts used in trauma casualty resuscitation has 
been considered within this chapter.   
 
Whilst there is clear evidence that early use of blood products with a high 
ratio of plasma (and platelets) has benefits in severely injured casualties, 
the objective evidence is limited to early in-hospital use.  Recent UK military 
practice advanced the use of blood products to the pre-hospital environment 
based principally on clinical “common sense” and risk balance 
considerations.  Nonetheless early use comes at a logistical cost and some 
clinical risk.  The purpose of the study described in this thesis was to 
investigate the potential impact of pre-hospital blood components on 
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7.1  Introduction 
 
The military in-hospital Damage Control Resuscitation practices in 
Afghanistan involved early aggressive use of blood products for perceived 
morbidity and mortality benefit (Holcomb 2007, 2008, Borgman 2007, Penn-
Barwell 2015).  The UK extended this practice into the pre-hospital 
environment in 2008 with the UK helicopter based Enhanced Medical 
Emergency Resuscitation Team (MERT-E) carrying four units of PRBC and 
thawed FFP. 
 
Concern over the logistical burden of supporting this capability, the potential 
high blood component wastage and increased risk of transfusion related 
reactions (secondary to the difficult environment it was being used in) meant 
that the unproven clinical benefits were questioned. 
 
This study was proposed to provide an objective evaluation of the presence 
of any additional benefit of pre-hospital vs early in-hospital administration of 
blood products.  This would then inform the decision of whether or not to 








Animal models of haemorrhage are broadly divided into two; controlled and 
uncontrolled.  Each has its strengths and weaknesses, and each can be 




list is not designed to be exhaustive, but simply to provide an overview and 
relevant examples.  Uncontrolled haemorrhage is induced by causing a 
vascular lesion and allowing blood loss to simply occur.  A variety of injuries 
have been used, including aortotomy and liver injury, depending on the 
animal species being used and the question being investigated.  This type 
of model has an advantage of being sensitive and appropriate to assess 
treatments and devices designed to stem the initial haemorrhage.  The 
disadvantage of this model is the resulting widely differing volumes of blood 
loss between individuals, and therefore a high degree of underlying 
variability in studies designed to assess treatments once the haemorrhage 
has occurred (e.g. fluid therapies). 
 
Controlled haemorrhage can be induced by removal of a set volume of 
blood or by removing blood so as to reach a predetermined blood pressure.   
This approach has the advantage of minimising the variability of the initial 
haemorrhagic insult and physiological response (from haemodynamic, 
autonomic and metabolic perspectives) for studies investigating e.g. 
resuscitation strategies.  A disadvantage, if this is the sole approach taken 
to the haemorrhage, is that it will not be sensitive to problems of re-bleeding 




Several models have used measures such as haemodilution and exchange 
transfusion to induce a coagulopathy (Sena 2013, Koko 2017), but this is 
not a coagulopathy akin to human Acute Traumatic Coagulopathy.  Few 
previous large animal models studies have developed an endogenous 
coagulopathy due to combined injury and shock alone, as humans do. 
 
Brohi’s group recently reviewed available animal models used to investigate 
trauma induced coagulopathy (Frith 2012).  They identified 23 models using 
5 species.  Pigs were the predominant large animals used.  The Animal 
(Scientific Procedures) Act 1986 necessitates that the species to be used is 
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the lowest possible on the hierarchy of sentience.  With the majority of these 
studies a certain volume of blood is required for measuring the necessary 
assessments.  It is crucial that the volume of blood sampled for 
animal/investigation assessment has little impact on the investigation itself, 
necessitating a certain size of animal.  This means that the species used is 
most commonly the pig. 
 
The few studies on pig hemostasis have only been conducted in 
predominantly physiologically normal animals.  Generally they have been 
found to be hypercoagulable relative to humans, with viscoelastic tests 
showing a quicker clot formation (shorter Clotting Time [CT] and Clot 
Formation Time [CFT]; Siller-Matula 2008) and a similar (comparable 
Maximum Clot Firmness [MCF]; Kessler 2011) or a more stable clot (wider 
MCF; Siller-Matula 2008).  Conventional laboratory tests have not generally 
shown a difference in results (similar PT and aPTT; Siller-Matula 2008) 
between the two species.  Platelet Count has been noted to lie in the upper 
end of the human normal range and Fibrinogen levels are at the lower end 
of the normal range (180 mg/dl; Siller-Matula 2008).  The model remains 
relevant though as it is valid to investigate the change from the normal 
coagulation of that animal and compare any coagulopathy to normal porcine 
ranges. 
 
There have been very few models of military injury to investigate the 
effectiveness of pre-hospital resuscitation, as it needs to include other 
aspects of military injuries to reproduce the pathophysiological response to 
ballistic penetrating injuries or blast injuries.   
 
With very few ballistic models, no injury induced coagulopathy models and 
few pre-hospital resuscitation models existing; the development of a model 







7.1.2  Requirements of Model 
 
To assess the impact of pre-hospital blood components in Afghanistan, the 
model needed to reflect the type of typical ballistic casualty that was being 
transported by the MERT-E and undergoing Damage Control Resuscitation 
and Surgery in the military hospital at Camp Bastion.  These casualties 
were severely injured, coagulopathic, acidotic, hypotensive casualties, and 
had received little medical care prior to that provided by the MERT-E.  The 
requirements of the model would need to include; 
 a. Severe injury including blast. 
 b. Significant blood loss. 
 c. Acidosis (hypotensive shock). 
 d. Coagulopathy induced by injury similar to ATC. 
 e. Limited resuscitation prior to expert pre-hospital medical care. 
 f. A pre-hospital phase of similar duration to Afghanistan. 
 
This would reflect a typical trauma patient that a clinician, either pre-hospital 
or in-hospital, would be particularly concerned about and pose the crucial 
question on fitness for definitive or damage control surgery. 
 
 
7.1.3  Dstl Animal Model 
 
The Defence Science and Technology Laboratory (Dstl) at Porton Down 
had already completed a significant amount of work on the study of 
resuscitation in ballistic casualties using animal models.  A porcine model of 
severe, survivable battlefield injury had been developed previously to 
evaluate pre-hospital resuscitation strategies.  It was developed to test the 
effect of resuscitation on mortality and in particular shock (arterial base 
excess [ABE] and lactate, rather than coagulation (Garner 2009, 2010, 
Doran 2012). 
 
The model used terminally anaesthetised Large White pigs that were 
surgically prepared, including line insertion and splenectomy.  Pigs’ spleens 
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are invested with smooth muscle and the organ acts as a reservoir for a 
significant amount of blood (Hannon 1985).  This smooth muscle contracts 
during the sympathetic response to haemorrhage; squeezing blood into the 
circulation producing an autotransfusion, making its removal essential in 
order to more accurately mirror human physiology.  The animals were 
wrapped in a Kevlar blanket before exposure to an explosive charge with no 
casing in order to reduce variability by preventing secondary and tertiary 
blast injury.  Removing a fixed volume of blood through a preplaced cannula 
induced shock and this was then converted to an uncontrolled haemorrhage 
with a Grade IV liver injury (i.e. involving disruption of 25-75% of the liver 
parenchyma; Moore 1995) that allowed an element of uncontrolled bleeding 
with the possibility of re-bleeding.  The controlled haemorrhage was 
intended to reduce variability in the amount of blood that would be lost, 
especially between the blast and sham blast groups. 
 
 
7.1.4 Animal Model for Shock, Haemorrhage and Acute 
Coagulopathy of Trauma 
 
Several modifications to this original Dstl model were required for the 
proposed study of pre-hospital blood components.  Ballistic injury, either 
from bullets or from fragment injuries in an explosion usually leads to 
widespread tissue damage extending a considerable distance away from 
the wound-track of the projectile.  This tissue damage causes release of 
mediators which can impact on clotting as the body responds to a large 
volume of damage to macro and, in particular, micro-vasculature.  This 
aspect was replicated in a controlled, reproducible manner in the current 
study as blunt injury to muscle using a captive bolt pistol.  The modifications 
in summary were: 
  
a. Injury and haemorrhage were adjusted to induce a 
coagulopathy at a time point corresponding to hospital admission.  
 b. The endpoints of the trials were to be based on coagulation 
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 parameters rather than mortality. As such, it was necessary for the 
 animals to survive until the end of the investigation.  
 c. The liver injury had face validity as a potentially survivable 
 wound capable of re-bleeding, but was removed in order to reduce 
 lethality of the model. 
d.  Since tissue injury can alter the response to haemorrhage 
(Rady1993) and is a crucial part of ATC development (Frith 2010), a 
limb injury (intended to mimic the tissue damage resulting from a 
fragmentation ballistic injury) was included.  
 e. Changes in the operational scenario in Afghanistan meant that 
 evacuation times were now much shorter and the timing of 
 interventions in the model needed to reflect this.  
 
This current study was designed to extend this earlier research and 
investigate the use of pre-hospital blood products in an animal model of 
blast, tissue injury and haemorrhagic shock.  The study was also designed 
to investigate the effects of injuries from both explosive events and non-





7.2  Hypothesis  
 
The use of blood components (PRBC:FFP) – compared to the use of saline 
– in the pre-hospital phase of a simulated patient journey, will attenuate 
trauma induced coagulopathy and over all shock burden at the decision 







7.3  Outcomes 
 
7.3.1  Primary Outcome 
 
Coagulation status as measured by Thromboelastography, 30 minutes into 
the In-Hospital Phase  
 
7.3.2  Secondary Outcomes 
 
Overall coagulation status at end of In-Hospital Phase; burden of shock as 
measured by base excess at the end of the early In-hospital phase 
(characterised by degree and trend of change of base excess) and total 
volume of fluids used in resuscitation. 
 
 
7.3.3  Tertiary Outcome 
 





7.4  Study Design 
 
The study was conducted on terminally anaesthetised Large White pigs (i.e. 
anaesthesia is induced at the onset of the study, and the animals are 
maintained under anaesthesia throughout until they are euthanased 
humanely with an overdose of anaesthetic at the end).  The study was 
carried out in accordance with the Animals (Scientific Procedures) Act 1986.   
 
This was a prospective, randomised, controlled trial comparing early 
(simulating pre-hospital) vs later (simulating immediate in-hospital) 
administration of blood components (packed red blood cells and plasma) on 
the pre-operative coagulopathic and physiological state of battlefield injury 
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casualties.  Two models of severe battlefield injury – blunt tissue damage 
plus haemorrhagic shock in the presence and absence of blast – were 
studied in terminally anaesthetised pigs. 
 
Efficacy of treatment was assessed at 30 minutes after hospital admission 
(having received 60 minutes of pre-hospital and 30 minutes of in-hospital 
resuscitation).  This corresponds to an early in-hospital clinical decision 
making point on the need to perform abbreviated damage control surgery 
e.g. limb amputation, or whether the patient is fit enough to withstand a 
more complete procedure e.g. limb salvage.   
 
The main ideology behind the experimental protocol was to mirror the 
medical capabilities and the timelines that existed at that time in 
Afghanistan.  This would include: 
 
 a. Wounding Phase.  Injury and haemorrhage (with or without 
 blast).   
b. Shock Phase.  This corresponds to the presence of a basic 
pre-hospital medical capability such as a stand-alone medic who 
would  only give crystalloids if blood pressure was too low 
(hypotensive  resuscitation) – 30 minutes duration. 
c. Pre-Hospital Phase.  A MERT-E (Medical Emergency 
Response Team – Enhanced) stage followed where Damage Control 
Resuscitation could take place with blood components or saline, still 
aiming for hypotensive resuscitation – 60 minutes duration. 
 d. Early In-Hospital Phase represented the time it would normally 
 take to resuscitate, obtain a Computer Tomography scan, diagnose 
 and decide on surgical plan for the patient.  Blood components were 
 used for resuscitation in all groups.  The end of this phase was the 
 Primary Outcome time point – 30 minutes duration.  
e. Late In-Hospital Phase with continued blood component 
resuscitation up to a maximum of 6 units of each blood component.  
This corresponded to a surgical intervention stage, but no surgery 
occurred in our model  
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7.5  Experimental Protocol 
 
The animals were randomly allocated to one of four treatment groups as 
illustrated in Table 7-1.   
 
Injury.  All groups received a blunt tissue injury and haemorrhage. Group 1 
and 2 received a Primary Blast Injury, Group 3 and 4 did not (Sham Injury).   
 
Treatment.  In the Pre-Hospital Phase the groups’ treatment diverged.  
Group 1 (Blast) and 3 (Sham) received pre-hospital blood components in 
contrast to saline used in the other two groups.  The same clinically relevant 
blood pressure targets were used throughout.  All groups converged at the 
Early In Hospital Phase where all groups received blood component 
resuscitation.  
 












7.6  Licensing and Animal Husbandry 
 
The entire study was carried out in accordance with the Animals (Scientific 
Procedures) Act 1986.  Prior to commencing the study, the programmed 
work underwent Local Ethical Review (Dstl Porton Down) and gained a 
United Kingdom Home Office Project Licence (PPL 30/3004).  Immature 
female Large White pigs were sourced from a commercial supplier, whose 
animals’ are classed as Specific Pathogen Free.  The animals were 
acclimatised at Dstl Porton Down for at least 7 days prior to the study and 
were attended to twice daily being fed and watered ad libitum (16% protein 
home-milled coarse mix).  The animals were weighed three times per week 
and on the afternoon before a trial.  Mean trial-day weights were 52.2 ± 0.4 
kg (mean ± SEM).  Feeding was discontinued 18 hours before planned 




7.7  Blood bank  
 
Blood was collected by exsanguination from terminally anaesthetised 
female Large White pigs.  Anaesthesia and carotid line insertion were 
carried out as detailed in section 7.9.1 and 7.9.2.  For blood collection 
anaesthesia maintenance was inhalational using Isoflurane.  Standard units 
of blood were collected from a carotid cannula into a citrate, phosphate and 
dextrose (CPD) blood collection bag (RCB434CCL, Pall Medical, UK), with 
each unit collected over 5-7 minutes from the carotid cannula and mixed 
continually during collection.  There were pauses between bag collections 
resulting in an overall bleeding rate of 22.5mL/min.   
 
The blood was processed according to standard UK blood transfusion 
protocols (“Red Book”, NHSBT 2013) to separate the red blood cells from 
the plasma, which was leucodepleted, while the packed red cells were 
stored in saline, adenine, glucose and mannitol solution (SAG-M).  The 





























Figure 7-1. Experiment Protocol and timeline.  Black bordered boxes show the clinical phases.  Orange bordered boxes 
represent key timelines.  Four groups of animals (1 - 4) are displayed and diverge at the simulated pre-hospital phase where 
casualties may be treated by the MERT-E.  In hospital phase is divided into early and late phases separated by the primary 
outcome (coagulation assessment with TEG) and represents the decision point for surgical intervention.  Treatment is identical 
for all groups during the in-hospital phases. Ratios indicate ratio of PRBC to FFP. 
Time points:  These are forwarded by the induction of anaesthesia and surgical preparation of the animal (including 
splenectomy).  B1 to B3 - baseline measurements after completion of surgical preparation and transportation.  Blast/Sham - 
samples taken 5 min after exposure to blast (immediately before injury).  Injury - samples taken after musculoskeletal injury and 
controlled haemorrhage.  S15 - samples taken after 15 min of shock. S30 - samples taken after 30 min of shock and is the start 
of resuscitation (equivalent to R0).  R30, R60 etc - samples taken 30, 60 etc min after onset of resuscitation.  R90 coincides with 
the “decision on surgery” clinical event; this time point was used for the primary endpoint of the study. This is 90 minutes after 






Collected units of blood were processed within 90 min of collection.  The 
resulting units of PRBC were stored at 4°C (LabCold Blood Bank, UK) and 
used within 14 days of collection.  The plasma was fast-frozen (MP1100 
Plasma Freezer System, Thermogenesis, US), stored at -30°C (LabCold 
Plasma Freezer, LabCold, UK) and used within 6 months of collection.  The 
Fresh Frozen Plasma (FFP) was thawed at 37°C in a dry tempering device 
(Sahara III Maxitherm, Sarstedt, Germany) immediately before use.  Prior to 
use all donor products were forward and reverse matched to recipient 
blood.  In addition, since PRBC and FFP from different donors were used 




7.8  Initial Anaesthesia and Surgical Preparation  
 
7.8.1  Anaesthesia 
 
The study was conducted under terminal anaesthesia, i.e. anaesthesia was 
induced and maintained throughout the study, followed by humane killing at 
the end with an overdose of anaesthetic without recovery of consciousness. 
 
Induction and Intubation 
 
Sedation was achieved with 5ml of Midazolam Hydrochloride (approx. 
0.1mg/kg) via intramuscular injection.  Once sedated, anaesthesia was 
induced by inhalation of Isoflurane 5%, driven by a 1:1 ratio of Oxygen (O2) 
and Nitrous Oxide (NO) via a nose cone.  Endotracheal intubation with a 
size 8.0 silicone oral/nasal tube (Vygon, France) followed induction.  
Aspiration, chest wall movement and end-tidal Carbon Dioxide (ETCO2) 
monitoring (Propaq 106 EL, Dräger Medical) confirmed correct tube 
position.  The endotracheal tube was then secured with strong adhesive 





Maintenance of Anaesthesia in Operating Theatre 
 
Once intubated, the animals were moved to the operating theatre, where 
anaesthesia continued with Isoflurane (1-2%) and a mixture of O2 and N2O 
(ratio 1:2) (Blease Frontline Plus 690).  The animals were then ventilated 
(Blease Frontline Manley MP3 Anaesthetic Ventilator) for the duration of the 
surgical procedure.  Monitoring comprised of a Propaq 106 EL (Dräger 
Medical) monitor for continuous 3-lead ECG, End Tidal CO2 and rectal 
temperature measurements.  Once central venous access was secured at 
surgery, inhalational anaesthesia was replaced by an intravenous (IV) 
infusion of Alfaxalone (Alfaxan®, Jurox Pty Ltd) – at a starting rate of 
approximately 1ml/kg/hr using a syringe driver (IVAC Medical Systems™ 
P2000) and titrated to maintain surgical anaesthesia.  Total Intra-Venous 
Anaesthesia (TIVA) continued for the remainder of the experiment.  At the 
end of surgery mechanical ventilation was discontinued and the animals 




Warming pads, a silver-foil blanket, a wool blanket and a portable electric 
heater were all used to maintain the animal’s normal rectal temperature of 
38.5°C.  If the temperature rose above 39°C, the animal was fanned and 
cooling pads applied.  Resuscitation fluids were heated by being transfused 
through a fluid warming device (Belmont® Rapid Infuser RI-2, Belmont 
Instrument Corporation).  Core body temperature was measured by a rectal 




7.8.2  Surgical Preparation 
 
After intubation, surgical fields were shaved and prepared with Pivodine 
Iodine (Betadine®, Purdue Pharma) antiseptic. The animal was placed 
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supine, covered with a large sterile surgical drape, cut to expose the neck, 
abdomen and left groin.  
 
Vascular Access in the Neck 
 
Both carotid sheaths were exposed via a midline neck incision. The left 
internal carotid artery and internal jugular vein were cannulated with Portex 
8 French lines (Hythe, UK), flushed and sutured in position (Figure 7-2).  A 
pulmonary artery catheter (744MF75 Swann-Ganz, Edwards Life Sciences 
Ltd, Newbury, UK) was floated through an introducer sheath (Desivalve 
Catheter Introducer, Vygon, Cirencester UK) in the right internal jugular 
vein. Pulmonary arterial placement was confirmed by pressure wave 
monitoring (Propaq 106 EL, Dräger Medical AG &Co. Lübeck, Germany).  




Figure 7-2.  Neck and Head Access.  Displaying from left to right; sutures, Swann sheath, 
jugular vein and carotid artery access. Further to the right of that the endo-tracheal tube 







As previously discussed, in order to replicate more closely the human 
response to haemorrhage, the porcine spleen must be removed to disable 
the auto-transfusion capability this organ encompasses.  1ml 1:1000 
Epinephrine was dripped onto the surface and massaged onto the spleen.  
This contracted the smooth muscle, emptying the organ of most of its stored 
blood.  The splenic pedicle was then double ligated and divided.  The 
spleen was removed and weighed to estimate the retained blood volume. 
 
Open Suprapubic Cystostomy 
 
Two 2/0 Polyglactin 910 (Vicryl™, Ethicon, UK) purse-string sutures were 
placed on the anterior wall of the bladder.  A cystostomy was made with 
diathermy in the centre of the purse-string and a 14G Foley Catheter placed 
into the bladder (Bard Ltd, Crawley, UK).  The balloon was filled with 10ml 




The abdominal incision was closed en-mass with continuous size ‘0’ Nylon 
double-stranded sutures (PDS™, Ethicon, UK) and the Foley catheter were 
exteriorised without snagging.  The wound was dressed with thick black 
adhesive tape. 
 
Femoral Vessel Cannulation 
 
Approached through a left-sided groin incision the femoral vessels were 
distally ligated and cannulated with trimmed 8Fr Dog catheters (Arnolds®, 
Smiths Medical International Ltd. Hythe, UK). Three-way taps (Vyclic-Color, 
Vygon, Ecouen, France) were placed and the lines secured. The incision 





Once these procedures were complete a large van was used to transport 
the instrumented animal for the 15-minute journey from the operating 
theatre to the blast range located in close proximity to the Laboratory.  





7.9  Animal Assessment Methods 
 
Numerous parameters were measured either continuously (e.g. ETCO2 and 
ECG) or at certain intervals (e.g. urine output and blood samples).  Table 7-
2 illustrates the blood sampling protocol. 
 
 
7.9.1  Cardiovascular Measurements 
 
The animal’s arterial blood pressure was recorded via the carotid artery 
cannula.  Pulmonary arterial and central venous pressures were recorded 
via the flow-directed balloon tipped flotation catheter, which was also used 
to determine cardiac output as a 6 minute rolling average (Vigilance™ 
Volumetrics CEDV, Edwards Lifesciences™,USA).  Physiological pressure 
measurements were made using strain gauge manometers (SensoNor 840, 
SensoNor a.s., Norway): zero pressure for all transducers was set at heart 
level.  Core body temperature was measured by rectal probe (Propaq 106 
EL) and maintained at approximately 38°C using external heating/cooling 
and blankets as described previously.  All cardiovascular variables were 
recorded using a computerised data acquisition system (Maclab 8/s, 
ADInstruments, UK) and associated software (Chart v4.2.3, ADInstruments, 








Table 7-2.  Measurement parameter timeline.  Coloured box equates to time of sample.  
Full Blood Count (FBC); Thromboelastography tested with TEG ® (see section 7.10.4).  
 
 
7.9.2  Blood Gas Analysis 
 
Blood gas analysis was performed alongside cardiovascular measurements, 
but an extra set was taken immediately after blast exposure. Arterial and 
mixed venous blood samples were taken anaerobically into heparinised 
syringes from the carotid and pulmonary artery catheters respectively for 
blood gas, base excess and lactate analysis (Gem Premier 3000 Blood Gas 




7.9.3  Coagulation and Haematology  
 
Full blood counts were conducted using an ADVIA 120 (Bayer, Barmen, 
Germany).  Visco-elastic assessment was completed using 
thromboelastography (TEG).  A TEG® 5000 Hemostasis Analyser 
(Haemonetics Ltd., UK) was performed on fresh, un-citrated whole blood 
measuring R time (clot initiation), K time (clot dynamics) and Maximum 
Amplitude (MA; clot strength).  Arterial blood was taken from the femoral 
cannula and analysed immediately using dilute Innovin® (1:50887 dilution 
Dade® Innovin®, Dade Behring; marketed by System UK Ltd, UK) as the 
initiator (Sørensen 2010).  All TEG® analyses were performed in triplicate at 
37°C.  
 
Prothrombin and Activated Partial Thromboplastin Times (PT and aPTT) 
and Fibrinogen were measured from arterial blood samples.  These were 
taken into citrated vacutainers (9NC 0.105M Vacutainer 367691, Beckton 
Dickinson, UK) and centrifuged at 1500 x g for 10 min.  The plasma was 
separated and stored at -80°C for determination of PT and aPTT by 
turbidometry and fibrinogen concentration (Clauss method) using an ACL 
Elite analyser (Instrumentation Laboratories, Warrington, UK).  
 
 
7.9.4  Pre-injury Baseline Measurements 
 
Once at the blast range the animal was taken initially to the laboratory 
monitoring suite (Figure 7-3) where baseline measurements were taken 
(see Table 7-2 for details).  These measurement were made a minimum of 
one hour after completion of surgery.  The animal was then moved out to 










Figure 7-3.  Laboratory monitoring suite in close proximity to the Blast Arena.  This was the 
location for the remainder of the investigation.  From left to right: Monitoring (just out of 




7.10  Wounding Phase 
 
7.10.1  Blast Arena 
 
The anaesthetised animal was mounted supine onto the blast rig, with the 
right thorax nearest to the charge, and wrapped in a Kevlar® blanket to 
protect from any fragment injury.  Intravenous anaesthesia was maintained 
using a protected battery powered syringe driver.  A completely 
independent second syringe driver (which could be triggered remotely), and 
anaesthetic cannula, provided a redundant backup system.  The animals 
were monitored continuously throughout this phase and ECG and 
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respirometry were relayed to a laptop computer in a bunker.  Surgical 
anaesthesia was maintained throughout. 
 
             Animal in  





Figure 7-4.  Photograph of blast arena.  The explosive charge was secured to the 




7.10.2  Blast Exposure 
 
A stand-off of 2.15m was measured from the centre of the charge to the 
body wall at the level of the 8th rib.  This protocol was determined based on 
previous work performed by the Trauma and Biophysics Team at Dstl 
Porton Down, who have a broad experience in exposing large animal 
models to blast injury (Cooper 1996).  The same batch of 2.2kg uncased 
cylindrical high explosive EDC1S charges was used for all experiments in 
the series. 
 
After detonation of the charge and a safety check of the area, the surgical 
team quickly returned to the animal, always arriving within 120 seconds 
from charge detonation.   Airway patency, breathing and anaesthetic 
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delivery were confirmed.  Apnoeic animals were hand-ventilated until 
spontaneous respiration returned or were ventilated mechanically if they did 
not regain satisfactory spontaneous ventilation.  Concurrently, a blood 
sample was taken from the femoral arterial line for blood gas analysis.  The 
animal was recovered to the Laboratory (Figure 7-3) for the rest of the 
experiment.   Animals subjected to the sham blast were treated identically 
but not exposed to blast. 
 
 
7.10.3  Post-blast 
 
Immediately after the explosion the animal was taken to the Laboratory.  
The IV infusion of Alfaxan® was continued and was titrated to the depth of 
anaesthesia.  The animal was only ventilated (Evita 2, Dräger Medical) if its 
Arterial Blood Gas (ABG) showed a PaO2 < 7 KPa, or a PaCO2 > 6 KPa.  
Mechanical ventilation was discontinued if the animal showed signs of 
spontaneous breathing, (to determine if the animal had regained the 
capacity for adequate ventilation and gas exchange).  
 
 
7.10.4  Tissue Blunt Injury  
 
Ten minutes after blast (or sham blast), all animals were subjected to a 
controlled soft tissue injury using a blunt captive bolt pistol (CASH Special 
Knocker, Accles & Shelvoke, Sutton Coldfield, UK) delivering 4 standard 
impacts (using 2 Grain .25 cartridges) to the muscle of the right hindquarter.  
This resulted in widespread deep contusion in the underlying muscle but no 
fracture to bone.   
 
Serum myoglobin was measured to assess the impact of tissue injury in 
each animal, (AQT90 FLEX, Radiometer).  Creatine kinase (CK) is 
considered as a more clinically sensitive marker for muscle injury because 
myoglobin has a short half-life (2-3 hours), but in the context of this thesis 
myoglobin short half-life is a strength rather than a weakness.  CK can take 
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12 hours to show a rise, peaking at 1-3 days after injury (Huerta-Alardin 
2004), making it impractical for use in this investigation.  Myoglobin is 
released into plasma as a result of muscle damage, making a rise in serum 
myoglobin (normal 3-80 µg/l) a good indicator of muscle damage.  It rapidly 
returns to normal 1 to 6 hours after muscle injury due to rapid clearance of 
myoglobin by both renal excretion and metabolism to bilirubin (Poels 1993). 
 
A summary of measurements is displayed in Figure 7-5 for myoglobin levels 
at R60 (time of hospital “admission”, after 60 minutes of resuscitation).  
Baseline myoglobin levels were <42 µg/l in all animals.  At R60, all animals 
had a significantly raised myoglobin level illustrating significant muscle 
damage.  There was no difference between treatment groups in either 
strand: sham blast strand (P = 0.876), blast strand (P = 0.302; independent 
t-test based on log-transformed data in each case).  The mean for each 

















Figure 7-5.  Serum myoglobin at R60 for all groups.  Group 1 and 2; blast strand. Group 3 
and 4; sham blast strand.  Values are mean and upper and lower 95% confidence limits.  
Data were log transformed for analysis, and the resultant summary statistics detransformed 
for presentation.   
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7.10.5  Controlled Haemorrhage 
 
Five minutes after the tissue injury a haemorrhage of 35% of the estimated 
total blood volume was performed over 9 min 40 sec via the femoral arterial 
cannula, using a computer-controlled pump (Masterflex® L/S model 7550 –
17, Cole Palmer Instrument Company, Chicago, IL).  The rate of bleeding 
reduced exponentially as the haemorrhage progressed to mimic the rate of 
haemorrhage from a major arterial lesion.  For blood volume and bleeding 




7.11  Shock Phase  
 
Following haemorrhage, the animals underwent a 30 minute shock period 
during which a capped volume of 0.9% saline (500 mL maximum) was 
administered as necessary to maintain a target systolic arterial blood 
pressure (SBP) of 60 mmHg, reflecting an aspect of current clinical practice 
by Combat Medical Technicians.  Resuscitation infusions were warmed to 
37°C and administered at a rate of 200 mL/min (Belmont Rapid Infuser, 




7.12  Pre-Hospital Phase  
 
The next phase of the protocol represented a 60 min pre-hospital 
evacuation phase.  Warmed resuscitation fluid was administered according 
to the relevant protocol, with a final target SBP of 80 mmHg in each group.  
Group 1 and 3 were given aliquots of 0.9% saline (representing standard of 
care) to attain and maintain the target SBP, while Group 2 and 4 received 
Packed Red Blood Cells (PRBC) and Fresh Frozen Plasma (1:1 ratio, 
PRBC and FFP given simultaneously).  The volume of blood products in the 
pre-hospital phase was capped at 4 units (4x300 mL approximately) per 
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animal (2 units PRBC and 2 units FFP).  Once the maximum amount of 
blood product had been used resuscitation continued to the same pressure 
target using 0.9% saline for the reminder of the pre-hospital evacuation 




7.13  Early In-Hospital Phase.  
 
The in-hospital phase represented more aggressive resuscitation to a 
normotensive target (SBP 110 mmHg) using PRBC:FFP (1:1) in all groups. 
Supplementary oxygen (minimum FiO2 0.3) was given and titrated to attain 
an arterial oxygen saturation (SaO2) of 98%.  At the end of this phase (after 
30 minutes) the necessary blood test measurements were taken as this 




7.14  Late In-Hospital Phase 
 
This phase was a continuation of the Early In-Hospital Phase.  Due to the 
limitations of the blood bank the total amount of PRBC:FFP used in any one 
animal was capped at 6 units of each product (including the blood 
components used during the pre-hospital phase in Groups 2 and 4).  Once 
the total permissible amount of PRBC:FFP had been given resuscitation 
continued to the same pressure target using 0.9% saline in all groups.  In 










7.15  Study End 
 
At the end of the study, after 210 minutes of resuscitation (R210), the 
animals were killed humanely with an overdose of anaesthetic; 




7.15.1  Post-Mortem Examination 
 
An immediate post mortem examination was performed after animal death, 
confirmed by cessation of circulation and breathing.  The thoracic cavity 
was opened and the lungs and heart removed.  The lungs were examined 
for blast injury (contusion; Figure 7-7).  Froth or clots in the trachea were 






















7.16  Statistics 
 
Statistical analysis was carried out using a NCSS V11 statistical analysis 
package, and was conducted on data collected at pre-determined intervals, 
pre-treatment and post-treatment. 
 
A two-way Mixed Model repeated measures ANOVA using Treatment and 
Time as Main Factors was conducted on data recorded from critical 
measurement variables.  Identified baseline values for each treatment 
condition was entered into the model as a covariate term such that 
treatment effects could be observed as a function of the mean covariate 
baseline estimate.  For the period from initial baseline to the end of the 
shock phase the first baseline (B1, Figure 7.1) was used.  Post-treatment 
analysis utilised the last time point (end of shock phase, S30 Figure 7.1), 
immediately before the commencement of resuscitation as the covariate 
baseline. 
 
The distribution of variables was examined graphically and tested for 
Normality using the Anderson-Darling test procedure before being entered 
into the analysis model.  Data shown to be non-normal were transformed 
where appropriate.  Significant Treatment effects at critical time points 
indicated by the analysis model were tested using pre-planned contrast of 
Treatment means as follows:- 
 
- Group 1 v Group 2 in the Blast Condition (injury strand) 
 
- Group 3 v Group 4 in the Sham Blast Condition (injury strand) 
 
These contrasts were achieved using by a Fisher LSD t-test procedure at 
an alpha level of rejection of p ≤ 0.05 on the condition that the overall F 
value for the Main Treatment Effect of the ANOVA was p < 0.1. 
 
Measurement variables shown to be non-normal and resistant to transform 
were analysed at critical time points using a non-parametric one-way 
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Kruskall Wallis ANOVA followed by a Dunn’s post hoc comparison of 
contrast. Treatment medians were significant at an alpha level of rejection 
of p ≤ 0.05 
 
Single time point comparisons between two treatment groups were made 
with an independent t-test (parametric data) or Mann Whitney U test (non 





Chapter 8. Results 
 
 
8.1  Introduction 
 
This chapter is divided into two separate sub-chapters in order to describe 
the results of blast and sham blast injuries independently.  Each sub-
chapter is divided into 4 separate time periods corresponding to those 
illustrated in Figure 8-1: 
 - Baseline 
- Injury Period (consisting of Wounding and Shock 
Phases) ending at S30. 
- Primary Treatment Period (consisting of the 60 minutes 
of Pre-Hospital Phase and the 30 minutes of Early In-
Hospital Phase) ending at R90 (primary outcome point). 
- Final Treatment Period (consisting of the Late In-




8.2  Baseline Results – Sham Blast Groups 
 
All animals that survived to S30 (end of Injury Period) survived to the end of 
the investigation.  Baseline data is shown in Table 8-1.  There were no 
significant differences between groups in the majority of the parameters.  
Group 4 had a slightly prolonged TEG R time compared to Group 3 with the 
groups being within 15% of each other.  Mean arterial pressure (MAP) was 
within 10% of each other with no significant difference between the groups 
in systolic blood pressure (SBP).  Consequently blood pressure and mixed 
venous oxygen content (CvO2) differences were not physiologically or 























































Table 8-1. Initial animal data: Baseline and S30/R0 for SHAM blast injury groups. * Comparison performed using Mann-Whitney U test. Values are mean 
±SEM.   
	
	 201	
8.3  Injury Period – Sham Blast Groups 
 
The effect of blunt injury and haemorrhagic shock – Injury Period – ending 
at S30, is illustrated in Table 8-1. 
 
 
8.3.1  Coagulation – Injury Period (Sham Blast Groups) 
 
Injury and haemorrhagic shock led to significant temporal changes in R (P = 
0.034) and K times (P = 0.028) with a fall in both immediately after injury.  
This was followed by a rise by the end of the 30 minutes shock phase.  
There was no significant difference between groups (see Table 8-1 for P 
values and Figure 8-2).  PT and aPTT did not show an early fall immediately 
after injury but did rise during the shock phase.  These changes over time 
and between groups were significant for PT, but not aPTT.  However, by the 
end of the shock period it is important to note that there were no significant 
differences between groups in either PT or aPTT.  By contrast, MA showed 
no significant change over time or between groups (see Figure 8-3 and 
Table 8-1).  There was a small significant drop in fibrinogen observed in 
both groups, with no significant difference between groups (Table 8-1). 
 
Both groups therefore displayed a period of increased coagulation, 
assessed by TEG, immediately after tissue injury.  This increased clotting 
was not reflected in conventional laboratory measurements (PT, aPTT) and 
appeared to resolve spontaneously prior to any resuscitation attempts.  
Notwithstanding the temporary reductions in K and R time, the results 




8.3.2  Physiology – Injury Period (Sham Blast Groups) 
 
Blunt injury and haemorrhage produced a significant challenge to the 





















Figure 8-2.  Effects of blunt injury and haemorrhage on TEG R time (clot initiation), K time (clot dynamics) and MA (clot strength) in the SHAM blast injury 
groups, prior to resuscitation.  Time 0 corresponds to S30.  Group 3 - planned pre-hospital blood component resuscitation.  Group 4 - planned pre-hospital 






















Figure 8-3. Effects of blunt injury and haemorrhage on PT and aPTT in the SHAM blast injury groups, prior to resuscitation.  Time 0 corresponds to S30.  




















Figure 8-4. Effects of tissue injury and haemorrhagic shock on Systolic Blood Pressure, Heart Rate and Cardiac Output in the SHAM blast injury groups prior 





significant drop in systolic blood pressure (SBP) and cardiac output (CO) 
and a significant increase in heart rate ([HR]; P < 0.001; for all parameters 
changing over time; Table 8-1).  There was no significant difference in the 
cardiovascular response to haemorrhage between groups (see Table 8-1 
for P values and Figure 8-4). 
 
The degree of shock was evaluated by measuring changes in arterial base 
excess and lactate.  Both groups showed a marked clinical and statistically 
significant fall in arterial base excess and a rise in lactate (difference over 
time P < 0.001) with no difference between groups (P > 0.268 for all 















Figure 8-5. Effects of tissue injury and haemorrhagic shock on arterial base excess (ABE) 
and arterial lactate in the SHAM blast injury groups prior to resuscitation.  Group 3 - 
planned pre-hospital blood component resuscitation.  Group 4 - planned pre-hospital saline.  




All animals exhibited an increase in respiratory effort (respiratory rate and 
tidal volume, noted by simple observation) in response to injury, which 
resulted in a significant increase in arterial oxygen partial pressure (PaO2) 
and a significant decrease in arterial carbon dioxide partial pressure 
(PaCO2; P < 0.001 for change over time of both parameters).  There was no 
	
	 206	
difference between groups (P = 0.105), bar the single time point difference 
in PaO2 at S30/R0, which is probably of little physiological incidence (11.7 
compared to 12.8 kPa; see Table 8-1).    
 
Mixed venous oxygen content (CvO2) dropped significantly and the oxygen 
extraction ratio (OER) increased markedly for both groups (difference over 
time P < 0.001) with no difference between groups at S30 (P > 0.569 for 
both parameters; see Table 8-1 and Figure 8-6). 
 
By the end of the Injury Period, the injury and haemorrhage had caused 
equal physiological insult to the animals in both groups.  Both treatment 
groups displayed a cardiovascular response to haemorrhage (rise in HR 
and drop in BP) and the level of shock was reflected equally by a 















Figure 8-6. Effects of tissue injury and haemorrhagic shock on mixed venous oxygen 
content (CvO2) and oxygen extraction ratio (OER) in the SHAM blast injury groups prior to 
resuscitation.  Group 3 - planned pre-hospital blood component resuscitation.  Group 4 - 






8.3.3  Haematology – Injury Period (Sham Blast Groups) 
 
Haemoglobin and haematocrit levels both fell significantly during the injury 
and haemorrhage period (difference over time P < 0.001; Table 8-1 and 
Figure 8-7) with no difference between groups.  A small significant drop in 
platelet count was also observed; there was no difference between groups 
(see Table 8-1 for P values).  
 
 
Figure 8-7. Effects of tissue injury and haemorrhagic shock on haemoglobin and 
haematocrit in the SHAM blast injury groups prior to resuscitation.  Group 3 - planned pre-
hospital blood component resuscitation.  Group 4 - planned pre-hospital saline.  Mean 




8.3.4  Fluids – Injury Period (Sham Blast Groups) 
 
There was no significant difference between groups in the volume of fluid 
(0.9% saline) used in order to maintain a systolic blood pressure of 



















Figure 8-8.  Total volume of fluids given to each group during the Injury Period for SHAM 
blast injury groups.  Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-




8.3.5  Biochemistry – Injury Period (Sham Blast Groups) 
 
There was a small, but significant decrease in calcium levels in both groups 
(difference over time P < 0.001) with no difference between groups.  
However, the decrease was not clinically significant (1.3 to 1.2; Table 8-1). 
 
A significant rise in potassium levels was observed in both groups over the 
Injury Period (5.1 – 5.2 mM; Table 8-1 and Figure 8-9) with no difference 
between groups (P = 0.826).   
 
Blunt injury and haemorrhage caused a small reduction in calcium levels 
and a clinically significant rise in potassium levels to reach a level at the 























Figure 8-9.  Effects of tissue injury and haemorrhage on potassium levels in the SHAM 
blast injury groups.  Group 3 - planned pre-hospital blood component resuscitation.  Group 







8.4  Primary Treatment Period – Sham Blast Groups 
 
 
The effect of the two different pre-hospital treatment regimes on coagulation 
parameters is illustrated in Table 8-2.  It contains data for R60 (end of 60 
minutes pre-hospital phase) and R90 (additional 30 minutes in-hospital 
blood component resuscitation; the primary outcome time point and the end 
of the Primary Treatment Period).  All remaining parameters are illustrated 








8.4.1  Coagulation – Primary Treatment Period (Sham Blast Groups) 
 
Group 3, having received pre-hospital blood components in the pre-hospital 
evacuation phase, had minimal changes in TEG values by the end of the 
pre-hospital phase (R60) and by the end of the Primary Treatment Period 
(R90) (Table 8-2 and Figure 8-10).  
 
Group 4 however, having received only 0.9% saline in the pre-hospital 
phase, had a significantly elevated TEG R and K time compared to Group 3 
at R60 (Table 8-2 and Figure 8-10).  This difference persisted at R90, 
although K time was not significantly different between groups at this point.  
In contrast, TEG MA showed little change over time in either group and 
consequently there was no significant difference between them.  
 
In common with the TEG R and K times, the saline-treatment Group 4 
exhibited significant increases in both PT and aPTT over time, while Group 
3 showed minimal changes in these parameters throughout this period.  
Consequently PT and aPTT were significantly higher in Group 4 when 
compared to Group 3 by R90 (Table 8-2 and Figure 8-11).  
 
Fibrinogen levels for Group 4 (pre-hospital saline) at hospital admission 
(R60) and at R90 were significantly lower than Group 3 (P = 0.007 and 
0.050 respectively; Figure 8-11) with a significant difference observed in 
pattern over time between groups (P < 0.001).  The Fibrinogen levels at 
hospital admission (R60) in Group 4 dropped below 1.5 g/dl, which is 
markedly below the 95% reference range for this strain of pigs (1.77-3.36 
g/l)1.  Although this drop in fibrinogen can be explained to some extent by 




1	Data based on samples taken after minimal surgery in Large White pigs of similar age 
that contributed to this and other studies in our laboratory (n=147).  Data distribution was 











Table 8-2.  Animal data for coagulation parameters: R60 (end of Pre-Hospital Period) and R90 (primary outcome point) for SHAM blast injury groups.  





















Figure 8-10.  TEG R time (clot initiation), K time (clot dynamics) and MA (clot strength) in the SHAM blast injury groups, at end of 90 minutes of resuscitation 
(60 minutes pre-hospital and 30 minutes in-hospital).  Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-hospital saline resuscitation.   























Figure 8-11.  PT, aPTT and Fibrinogen in the SHAM blast injury groups during the Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-






The ratio of the proportional fall in fibrinogen levels from baseline, to the 
proportional fall in haematocrit from baseline, should be 1.0 if the reduction 
in fibrinogen levels is comparative to haemodilution.  This ratio would be 
less than 1.0 if there is additional fibrinogen loss.  The ratio at the end of the 
pre-hospital phase in Group 4 was 0.65 ± 0.03, suggesting there was loss of 
Fibrinogen over and above the effects of haemodilution. 
 
These results illustrate that after combined blunt injury and haemorrhagic 
shock Group 4 (receiving pre-hospital saline) developed a change in 
coagulation parameters, suggestive of coagulopathy.  By contrast the 
coagulation measured in the blood component treatment Group 3 changed 
little over the same period. 
 
 
8.4.2  Physiology – Primary Treatment Period (Sham Blast Groups) 
 
Systolic blood pressure (SBP) targets were maintained at the relevant level 
for each phase (80mmHg pre-hospital and 110 mmHg in-hospital) in both 
groups resulting in a significant elevation in SBP by R90 in both groups 
(Figure 8-12 and Table 8-3).  In contrast to there being no difference 
between groups in SBP, mean arterial pressure in Group 3, having received 
pre-hospital blood components, was significantly higher than Group 4.  
 
A corresponding rise in cardiac output (CO) was observed in both groups by 
R90.  Group 4 (pre-hospital saline) is observed to have a lower CO 
throughout the pre-hospital phase, but once that group received in-hospital 
blood components CO was observed to increase faster than the other group 
and at R90 Group 4 CO is significantly higher than Group 3 (P = 0.0019).  
Both groups had a small non-significant drop in heart rate (HR) throughout 
the primary treatment period.  Although there was no difference in HR at 
R90, it was noted that the pre-hospital saline group has a consistently lower 






Table 8-3.  Animal data: R90 (primary outcome point) for SHAM blast injury groups.      




The resuscitation goals (based exclusively on systolic blood pressure) were 
achieved for both groups in the pre-hospital and early in-hospital phases, 
and were associated with a rise in cardiac output by R90 in both groups. 
 
For both groups arterial base excess (ABE) continued to drop to its nadir 
and lactate rise to its peak at R60 - the end of the pre-hospital evacuation 




















Figure 8-12. Systolic Blood Pressure (BP), Heart Rate and Cardiac Output in the SHAM blast injury groups during the Primary Treatment Period (90 minutes 
of resuscitation; 60 minutes pre-hospital and 30 minutes in-hospital).  Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-hospital saline.  





Primary Treatment Period.  By R90 both groups had a lower ABE and 
higher lactate than at S30 (Table 8-3 and Figure 8-13).  There was a 
tendency for the pre-hospital blood component resuscitation group (Group 
3) to have a lesser level of shock, so that at R90 ABE for Group 3 was 
significantly less negative than the saline group (4; P = 0.012), although the 
difference in lactate did not attain statistical significance (P = 0.104). 
 
The saline-treatment Group 4 had a consistently significant lower PaCO2 (P 
= 0.045 at R90) throughout the Primary Treatment Period, with a slightly 
higher PaO2 that did not achieve significance at R90.   
 
Both groups had a significant increase in mixed venous oxygen (CvO2) and 
a significant drop in Oxygen Extraction Ratio (OER) by R60 so that at the 
end of the Primary Treatment Period (R90) both groups had a significantly 
higher CvO2 and lower OER.  There was no difference between groups 







Figure 8-13. Arterial base excess (ABE) and arterial lactate in the SHAM blast injury groups 
during the Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-hospital 
and 30 minutes in-hospital).  Group 3 - pre-hospital blood component resuscitation.  Group 


















Figure 8-14.  Mixed venous oxygen content (CvO2) and oxygen extraction ratio (OER) in 
the SHAM blast injury groups during the Primary Treatment Period (90 minutes of 
resuscitation; 60 minutes pre-hospital and 30 minutes in-hospital).  Group 3 - pre-hospital 
blood component resuscitation.  Group 4 - pre-hospital saline.  Mean values ± SEM. 
 
Pre-hospital and initial in-hospital resuscitation raised systolic blood 
pressure and cardiac output for both groups.   Pre-hospital resuscitation in 
both groups stopped the drop in base excess and rise in lactate, and this 
effect continued into the initial in-hospital phase.  Mixed venous content and 
oxygen extraction however, did not return toward baseline levels until the in-
hospital phase.  The pre-hospital saline group was noted to have a greater 
level of shock and lower PaCO2.   
 
 
8.4.3  Haematology – Primary Treatment Period (Sham Blast 
Groups) 
 
Group 3, receiving pre-hospital blood components, had minimal change to 
haematocrit by R90 (Table 8-3 and Figure 8-15).  Group 4, receiving pre-
hospital saline, had a significant decrease in haematocrit by the end of the 
















Figure 8-15.  Haematocrit and platelet count (109/l) in the SHAM blast injury groups during 
the Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-hospital and 30 
minutes in-hospital).  Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-
hospital saline.  Mean values ± SEM. 
 
 
Platelet count dropped significantly for both groups by R90 with no 
difference between groups (P = 0.056; Table 8-3 and Figure 8-15).   
 
At the end of the Primary Treatment Period, Group 3, receiving pre-hospital 
blood components had little change in haematocrit, in contrast to Group 4, 




8.4.4  Fluids – Primary Treatment Period (Sham Blast Groups) 
 
The fluid used in each group for the different phases of the Primary 
Treatment Period is illustrated in Figure 8-16 and 8-17; sub-divided into the 
pre-hospital and (early) in-hospital phases.  Compared to Group 3 (pre-
hospital PRBC:FFP), the other Group (4; pre-hospital saline) required a 
greater volume of fluids in the pre-hospital phase (P = 0.002; Figure 8-16) 

















Figure 8-16.  Total volume of fluids given to each group in the pre-hospital phase (between 

















Figure 8-17.  Total volume of fluids given to each group in the early in-hospital phase 
(between R60 and R90) for SHAM blast groups.  Group 3 - pre-hospital blood component 




















Figure 8-18.  Cumulative volume of fluids given to each SHAM blast group in the Primary 
Treatment Period; pre-hospital and early in-hospital phases combined (S30/R0 = 0 min; 
R60 = 60 min; R90 = 90min).  Group 3 - pre-hospital blood component resuscitation.  




8.4.5  Biochemistry – Primary Treatment Period (Sham Blast 
Groups) 
 
There was a reduction in calcium levels in both groups over time (P < 0.001) 
in the Primary Treatment Period with no difference between groups (P = 
0.267; Table 8-3 and Figure 8-19).  
 
Potassium levels however dropped from its previous high level in both 
groups by R60, with little change thereafter (Table 8-3).  At R90 there was 
no difference in potassium levels (4.2 mM) between groups.  
 
By R90, after the use of blood component resuscitation in both groups, 
calcium had dropped to the lower end of the normal range and potassium 














Figure 8-19.  Calcium levels in the SHAM blast injury groups during the Primary Treatment 
Period (90 minutes of resuscitation; 60 minutes pre-hospital and 30 minutes in-hospital).  
Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-hospital saline.  Mean 





8.5  Final Treatment Period – Sham Blast Groups 
 
The results for all parameters for the remaining (late) in-hospital phase is 




8.5.1  Coagulation – Final Treatment Period (Sham Blast Groups) 
 
The abnormal TEG values (R and K time) for the pre-hospital saline-
treatment Group 4 returned towards baseline levels so that by R210 there 
was little difference between groups (Table 8-4 and Figure 8-20).  Both 






Table 8-4.  Animal data; R210 (end of Late In-Hospital Phase and Final Treatment Period) 
for SHAM blast injury groups.  ° Comparison using logarithmic transformed data.  Values 




There is a significant difference between groups over the resuscitation 
period for R time (P = 0.040; Figure 8-22); which increased in the pre-
hospital saline group during the pre-hospital phase and remained high into 
the in-hospital phase.  K had a similar pattern in difference over the 
resuscitation period, which approached significance (P = 0.064; Figure 8-
23).   
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In similarity with other periods MA width did not change in either group in 
the Final Treatment Period (Figure 8-20).  The MA results at R210 were 
very similar to baseline levels and there was a significant difference in 
neither the MA result change over time (P =0.544), nor between groups (P = 
0.213). 
 
The aPTT times for Group 4 changed in a similar manner to the TEG K and 
R times with a trend towards returning to baseline levels by R210 (Table 8-4 
and Figure 8-21).  However in this case there was still a significant 
difference between groups (P < 0.001; Figure 8-24), as at R210 the pre-
hospital saline group did not recover to the same level as the other group. 
 
PT showed a different pattern of response over time in both groups (Figure 
8-21 and 8-25).  There was a significant rise in PT with the early (pre-
hospital) elevation being significantly greater in the saline group resulting in 
a significant difference between groups (P = 0.001 at R60; Table 8-2).  
However, unlike the other parameters PT did not return towards baseline in 
either group during the in-hospital phase although the rate of rise did 
decline.  The pre-hospital saline group (4) PT levels remained higher than 
Group 3 with a significant difference between the groups over the 
resuscitation period (P < 0.001).  These elevated PT results for both groups 
were, however, only just outside the 95% reference range for this strain of 
pigs (12.6 to 12.91).  The final results equate to an INR of approximately 1.1.   
 
Both groups showed a small elevation in fibrinogen levels back toward the 
normal range (Figure 8-21).  Over the whole resuscitation period there was 
a significant difference in change over time (P = 0.005; Figure 8-26) with a 
marked drop in fibrinogen levels in the pre-hospital period for the saline 
resuscitation group.  By R210 although the pre-hospital blood component 
group (3) had higher fibrinogen levels for the majority of the time, this 
difference did not reach significance (P = 0.113; Table 8-4 and Figure 8-26). 
																																																								
1	The 95% confidence limit based on samples taken after minimal surgery in Large White 




























Figure 8-20.  TEG R time (clot initiation), K time (clot dynamics) and MA (clot strength) in the SHAM blast injury groups for the Final Treatment Period.  Group 



























Figure 8-21.  PT, aPTT and fibrinogen in the SHAM blast injury groups during the Final Treatment Period.  Group 3 – pre-hospital blood component 

























Figure 8-22.  TEG R time (clot initiation) in the SHAM blast injury groups.  Group 3 – pre-
hospital blood component resuscitation.  Group 4 – pre-hospital saline resuscitation.   Mean 
















Figure 8-23.  TEG K time (clot dynamics) in the SHAM blast injury groups.  Group 3 - pre-
hospital blood component resuscitation.  Group 4 - pre-hospital saline resuscitation.   Mean 
















Figure 8-24.  aPTT in the SHAM blast injury groups.  Group 3 - pre-hospital blood 



















Figure 8-25.  PT in the SHAM blast injury groups.  Group 3 – pre-hospital blood component 




















Figure 8-26.  Fibrinogen in the SHAM blast injury groups.  Group 3 - pre-hospital blood 





Changes in clotting, suggestive of a coagulopathy – as measure by TEG R 
and K times, aPTT and fibrinogen – was developed by Group 4 (pre-
hospital saline) in the pre-hospital phase and lasted into the initial in-
hospital phase, resolving after 60 to 90 minutes of in-hospital blood 
component resuscitation (Figure 8-22 to 8-26).  These changes were 
significantly different from Group 3 and over time in the majority of these 
parameters.  If no significance was obtained, there was a trend to change 
and significance was only not obtained secondary to the size of error bars.  
Clotting in Group 3, as measured by these parameters, remained stable 







8.5.2  Physiology – Final Treatment Period (Sham Blast Groups) 
 
Systolic blood pressure (SBP) targets were maintained for the final period of 
the investigation with no difference between groups (P = 0.099; Table 8-4 
and Figure 8-27).  Mean arterial pressure mirrored the SBP and, with 
cardiac output, the results for these parameters plateaued during this 
period, remaining at similar levels as those at R90 with no difference 
between groups (P > 0.101; Table 8-3 and Figure 8-28).  There was a 
significant difference between groups in heart rate (HR) for the resuscitation 
period (P < 0.001; Figure 8-29) which, can be attributed to the lower HR 
observed for the majority of the Primary Treatment Period in the pre-



















Figure 8-27.  Systolic Blood Pressure in the SHAM blast injury groups.  Group 3 - pre-
hospital blood component resuscitation.  Group 4 - pre-hospital saline resuscitation.   Mean 














Figure 8-28.  Cardiac Output in the SHAM blast injury groups.  Group 3 - pre-hospital blood 















Figure 8-29.  Heart Rate in the SHAM blast injury groups.  Group 3 - pre-hospital blood 
component resuscitation.  Group 4 - pre-hospital saline resuscitation.   Mean values ± 
SEM. 
 
Throughout the remaining in-hospital phase Group 3’s (pre-hospital 
PRBC:FFP) trend for less shock endured (Figures 8-30 and 8-31).  For the 
duration of the resuscitation period the pre-hospital saline group (4) had a 
significantly more negative ABE (P < 0.001) and a significantly lower lactate 














Figure 8-30.  Arterial Base Excess in the SHAM blast injury groups.  Group 3 - pre-hospital 
















Figure 8-31.  Arterial Lactate in the SHAM blast injury groups.  Group 3 - pre-hospital blood 
component resuscitation.  Group 4 - pre-hospital saline resuscitation.   Mean values ± 
SEM. 
 
At R210 the values of PaO2 and PaCO2 were similar between both groups, 
however over the whole resuscitation period there was a statistically 
significant difference between the groups in both parameters (P < 0.023) 
despite similar patterns over time (P > 0.764; Table 8-4).  The majority of 
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this difference between groups occurred in the pre-hospital phase where 
Group 4 (pre-hospital saline) had a consistently higher PaO2 and lower 
PaCO2 (Figure 8-32).  The difference in PaCO2 persisted into the in-hospital 
phase and is probably caused by a degree of respiratory compensation in 







Figure 8-32.  Partial pressure of arterial oxygen (PaO2) and carbon dioxide (PaCO2) for the 
SHAM blast injury groups.  Group 3 - pre-hospital blood component resuscitation.  Group 4 
- pre-hospital saline resuscitation.   Mean values ± SEM. 
 
 
The OER and CvO2 levels remained similar to that at R90 throughout the 
Final Treatment Period.  Overall there was no difference between groups in 
OER (P = 0.110) with evidence of a difference in CvO2 secondary to slightly 
higher levels in the pre-hospital group throughout the in-hospital phase 
(Table 8-4). 
 
In-hospital blood component resuscitation to a normotensive goal, improved 
cardiac output and reduced the degree of shock.  The group receiving pre-
hospital saline displayed a greater degree of shock that although returned 
towards baseline levels remained greater than the other group throughout 
the remaining in-hospital period. 
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8.5.3  Haematology – Final Treatment Period (Sham Blast Groups) 
 
During the remaining in-hospital phase with both groups receiving blood 
component resuscitation, there was little change in haemoglobin (Hb) and 
haematocrit (Hct) from R90.  Both groups remained at a significantly lower 
level than baseline (P < 0.001, change over time) with a significant 
difference in pattern over time between groups (P < 0.001) secondary to the 
significant drop in both Hb and Hct in the pre-hospital phase for the saline 
resuscitated group (4).  This difference remained throughout the in-hospital 
phase despite blood component resuscitation (Table 8-4 and Figure 8-33). 
 
Platelet count remained lower than baseline in both groups (P < 0.001) with 
no difference between groups (P = 0.569; Table 8-4 and Figure 8-34). 
 
Haemodilution cause a comparatively larger drop in the pre-hospital saline 
group for haemoglobin and haematocrit.  Platelet count dropped steadily 
















Figure 8-33.  Haematocrit in the SHAM blast injury groups.  Group 3 - pre-hospital blood 



















Figure 8-34.  Platelet Count in the SHAM blast injury groups.  Group 3 - pre-hospital blood 






8.5.4  Fluids – Final Treatment Period (Sham Groups) 
 
The total fluids given in-hospital are illustrated in Figure 8-35 and the 
cumulative fluids given to each group are illustrated in Figure 8-36.  For the 
Final Treatment Period, there was no significant difference between the 
volumes of fluid each group received (P = 0.462).  For the whole 
resuscitation period the saline-treatment Group 4 received a significantly 
greater volume of fluids than Group 3 (P = 0.011), but the total volume of 
blood products received by both groups was similar (P = 0.172).   
 
Group 4 (pre-hospital saline) received a significantly greater volume of fluids 


















Figure 8-35.  Total volume of fluids given in the in-hospital early and late phases for SHAM 
blast injury groups.  Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-
















Figure 8-36.  Cumulative volume of fluids given to each group for SHAM blast injury 
groups.  Group 3 - pre-hospital blood component resuscitation.  Group 4 - pre-hospital 




8.5.5  Biochemistry – Final Treatment Period (Sham Groups) 
 
For the in-hospital phase Group 4 (pre-hospital saline) received blood 
components at a higher rate than the other group.  As a consequence that 
group had a significantly higher potassium level (P < 0.001) and a lower 
calcium level than the Group 3, however the calcium levels difference did 



















Figure 8-37.  Calcium levels in the SHAM blast injury groups.  Group 3 - pre-hospital blood 











8.6  Baseline Results – Blast Groups 
 
All animals that survived to S30 (end of Injury Period) survived to the end of 
the investigation.  Baseline data is shown in Table 8-5.  There were no 
significant differences between groups in the initial parameters. 
 
 
8.7  Injury Period – Blast Groups 
 
The effect of blast injury, blunt injury and haemorrhagic shock – Injury 
Period – ending at S30, is illustrated in Table 8-5. 
 
 
8.7.1  Coagulation – Injury Period (Blast Groups) 
 
At S30 the overall clotting picture was broadly similar to that shown in sham 
blast groups with an initial fall followed by a rise in both R and K times, and 
in contrast to sham blast, also aPTT (Figures 8-38 and 8-39).  Although the 
overall pattern of response during the injury/shock phase for R time was 
similar in the two treatment groups (P = 0.536), there was a significant 
difference in values by S30, although this appears to be of little 
physiological consequence.  
 
The consequence of the later rise in aPTT during the shock phase meant 
there was a significant difference between treatment groups and a 
significant difference in the pattern of response during the injury/shock 
phase in this parameter.  However, although the values of aPTT at the end 
of the shock phase showed a statistically significant difference, this was 
relatively small and is unlikely to be of clinical significance.  PT did not show 
the early fall immediately after injury, but did show the later rise. 
 
There was a small, statistically significant drop in fibrinogen observed in 













































Figure 8-38.  Effects of blast, tissue injury and haemorrhage on TEG R time (clot initiation), K time (clot dynamics) and MA (clot strength) in the BLAST injury 
groups, prior to resuscitation.  Time 0 corresponds to S30.  Group 1 - planned pre-hospital blood component resuscitation.  Group 2 - planned pre-hospital 
























Figure 8-39. Effects of blast, tissue injury and haemorrhage on PT, aPTT and Fibrinogen in the BLAST injury groups, prior to resuscitation.  Time 0 





Both groups therefore displayed a period of increased coagulation 
immediately after injury that appeared to resolve spontaneously prior to any 
resuscitation attempts.  
 
 
8.7.2  Physiology – Injury Period (Blast Groups) 
 
Blast injury, blunt injury and haemorrhage had a significant impact on the 
cardiovascular system in both groups.  There was a marked and statistically 
significant drop in systolic blood pressure (SBP) and cardiac output (CO) 
and a significant increase in heart rate ([HR]; P < 0.001; for all parameters 
changing over time; Table 8-5).  There was no significant difference in the 
cardiovascular response to haemorrhage between groups (see Table 8-5 
for P values and Figure 8-40). 
 
The degree of shock was evaluated by measuring changes in arterial base 
excess and lactate.  Both groups showed a marked clinical and statistically 
significant fall in in arterial base excess (ABE) and a rise in lactate (P < 
0.001).  There was a significant difference observed between the groups (P 
< 0.043 for both parameters) at this time point, with the saline group at a 
level some investigators would describe as evidence of hypoperfusion 
(Brohi 2007a, Curry 2012).  This difference is noted to be small when 
considering the over all change from the baseline (11mM compared to 
14mM for ABE; Table 8-5 and Figure 8-41).   
 
All animals exhibited an increase in respiratory effort (respiratory rate and 
tidal volume noted by simple observation) in response to injury, which 
resulted in a significant increase in arterial oxygen partial pressure (PaO2) 
and a significant decrease in arterial carbon dioxide partial pressure 
(PaCO2; P < 0.001 for change over time of both parameters).  There was no 





















Figure 8-40. Effects of blast, tissue injury and haemorrhagic shock on Mean Arterial Pressure, Heart Rate and Cardiac Output in the BLAST injury groups 









Figure 8-41. Effects of blast, tissue injury and haemorrhagic shock on arterial base excess 
(ABE) and arterial lactate in the BLAST injury groups prior to resuscitation.  Group 1 - 
planned pre-hospital blood component resuscitation.  Group 2 - planned pre-hospital saline.  
Mean values ± SEM 
 
 
Mixed venous oxygen content (CvO2) dropped significantly and the oxygen 
extraction ratio (OER) increased markedly for both groups with no 






Figure 8-42. Effects of blast, tissue injury and haemorrhagic shock on mixed venous 
oxygen content (CvO2) and oxygen extraction ratio (OER) in the BLAST injury groups prior 
to resuscitation.  Group 1 - planned pre-hospital blood component resuscitation.  Group 2 - 






By the end of the Injury Period, the injury and haemorrhage had caused 
equal physiological insult to the animals in both groups.  They displayed a 
cardiovascular response to haemorrhage (rise in HR and drop in BP) and 
the level of shock was reflected by a developing acidosis and a marked rise 
in the peripheral extraction of oxygen. 
 
 
8.7.3  Haematology – Injury Period (Blast Groups) 
 
Haemoglobin and haematocrit levels both fell significantly during the injury 
and haemorrhage period (P < 0.001; Table 8-5 and Figure 8-43) with no 
difference between groups.  A small drop in platelet count was also 







Figure 8-43. Effects of blast, tissue injury and haemorrhagic shock on Haemoglobin and 
Heamotocrit in the BLAST injury groups prior to resuscitation.  Group 1 - planned pre-
hospital blood component resuscitation.  Group 2 - planned pre-hospital saline.  Mean 




Both treatment groups showed a rapid drop in haemoglobin in response to 
haemorrhage with a small drop in platelet count. 
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8.7.4  Fluids – Injury Period (Blast Groups) 
 
There was no significant difference between groups in the volume of fluid 
(0.9% saline) used in order to maintain a systolic blood pressure of 











Figure 8-44.  Total volume of fluids given to each group during the Injury Period for BLAST 





8.7.5  Biochemistry – Injury Period (Blast Groups) 
 
No difference was detected in the calcium levels between groups (P = 
0.913) or over time in the Injury Period (P = 0.058; Table 8-5).  A significant 
rise in potassium levels was observed in both groups over the Injury Period 
(P < 0.001; Table 8-5 and Figure 8-45) with no difference between groups 
(P = 0.283).   
 
Blast, blunt injury and haemorrhage had no effect on calcium levels, but 















Figure 8-45.  Effects of blast, tissue injury and haemorrhage on Potassium levels in the 
BLAST injury groups.  Group 1 - planned pre-hospital blood component resuscitation.  





8.8  Primary Treatment Period – Blast Groups 
 
The effect of the two different pre-hospital treatment regimes on coagulation 
parameters is illustrated in Table 8-6.  It contains data for R60 (end of 60 
minutes pre-hospital phase) and R90 (additional 30 minutes in-hospital 
blood component resuscitation; the primary outcome time point and the end 
of the Primary Treatment Period).  All remaining parameters are illustrated 
in Table 8-7. 
 
 
8.8.1  Coagulation –Primary Treatment Period (Blast Groups) 
 
After the onset of resuscitation there were significant changes in clotting as 
assessed by R and K times (Table 8-6, Figure 8-46).  Both groups showed 
elevations in R and K times after the onset of resuscitation (Figure 8-46), in 
contrast to the situation in the sham blast injury strand (Figure 8-10) where 
only the saline-treatment strand displayed the elevation in R and K times.  
In the blast strand, the initial rate of rise of both R and K times appeared 









Table 8-6. Animal coagulation data; R60 (end of Pre-Hospital Period) and R90 (primary outcome point) for BLAST injury groups.  * Comparison performed 

























Figure 8-46.  TEG R time (clot initiation), K time (clot dynamics) and MA (clot strength) in the BLAST injury groups, at end of 90 minutes of resuscitation (60 
minutes pre-hospital and 30 minutes in-hospital).  Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-hospital saline resuscitation.  Mean 





















Figure 8-47.  PT, aPTT and Fibrinogen (g/dl) in the BLAST injury groups during the Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-








(Figure 8-46) although there was no statistically significant difference 
between treatment groups in the general pattern of response over time 
(Table 8-6).  Overall there was a trend for higher R and K times in the saline 
treated groups, but this did not attain statistical significance (Table 8-6).   
 
Consequently, at R90 there was no significant difference in the absolute 
values of the R and K times between groups.  This is probably explained by 
the small rise in these parameters in the blood treatment group (Group 1) 
and the wide variability in the saline group. 
 
In common with the Sham groups MA changed little during this phase with 
no difference between the groups. 
 
Conventional assessment of clotting (PT and aPTT) showed a similar 
overall picture to that seen for R and K times, although the difference 
between groups was statistically significant for PT, with the saline-treated 
Group 2 showing the greatest impairment in clotting.  By R90 both PT and 
aPTT were significantly higher in Group 2 compared to Group 1 (Figure 8-
47; P values in Table 8-6). 
 
Fibrinogen levels for Group 2 (pre-hospital saline) at hospital admission 
(R60) dropped below 1.5 g/dl, which is markedly below the 95% reference 
range for this strain of pigs (1.77-3.36 g/l, derived as described in section 
8.4.3).  This drop in fibrinogen is only partly explained to some extent by 
haemodilution (as measured by haematocrit), as the ratio of the proportional 
fall in fibrinogen levels from baseline, to the proportional fall in Haematocrit 
from baseline, in Group 2 was 0.67 ± 0.02, suggesting there was loss of 
fibrinogen over and above the effects of haemodilution.  Group 2 fibrinogen 
levels increased towards normal values by R90, however they remained 




A combined time-lapse example of the TEG trace for a subject in Group 2 is 
shown in Figure 8-48.  This figure illustrates the change in R and K time 








Figure 8-48.  Initial time lapse illustration of TEG changes in one subject from Group 2 
(receiving pre-hospital saline).  The initial shortening of R and K times are seen after injury 





These results illustrate that after combined blast and tissue injury with 
haemorrhagic shock Group 2 (receiving pre-hospital saline) developed a 
change in clotting suggestive of coagulopathy.  This clotting change was 
evident at the end of the pre-hospital period (R60) and persisted to R90 
having received 30 minutes of hospital based blood component 
resuscitation. The coagulation measured in Group 1 (receiving pre-hospital 








8.8.2  Physiology – Primary Treatment Period (Blast Groups) 
 
Systolic blood pressure (SBP) targets were maintained at the relevant level 
for each phase (80mmHg pre-hospital and 110 mmHg in-hospital) in both 
groups resulting in a significant elevation in SBP by R90 in both groups, 
with no difference between groups (P > 0.154; Figure 8-49 and Table 8-7). 
 
Resuscitation goals were therefore attained for both groups in the pre-




Table 8-7.  Animal data: R90 (primary outcome point) for BLAST injury groups.  



















Figure 8-49. Systolic Blood Pressure (BP), Heart Rate and Cardiac Output in the BLAST injury groups during the Primary Treatment Period (90 minutes of 
resuscitation; 60 minutes pre-hospital and 30 minutes in-hospital).  Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-hospital saline.  







A corresponding rise in cardiac output was observed in both groups by R90 
with both showing a small drop in heart rate, with no difference between 
groups in either parameter (P > 0.279).  
 
For both groups arterial base excess (ABE) continued to drop to its lowest 
point and lactate rise to its peak at R60 - the end of the pre-hospital 
evacuation phase - with both then plateauing during the remaining 30 
minutes of the Primary Treatment Period.  Group 2 (pre-hospital saline) 
ABE decreased to a lower level compared to Group 1 at R60 and remained 
below the other group up to R90.  The difference had reduced by R90 and 
so there was not a significant difference between them at this time point (P 













Figure 8-50. Arterial base excess (ABE) and arterial lactate in the BLAST injury groups 
during the Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-hospital 
and 30 minutes in-hospital).  Group 1 - pre-hospital blood component resuscitation.  Group 
2 - pre-hospital saline.  Mean values ± SEM. 
 
 
Group 2 (pre-hospital saline) had a consistently lower PaCO2 throughout the 
Primary Treatment Period.  The difference reduced at R90 and as a 
consequence there was not a statistical difference between treatment 
groups at this time point (Table 8-7 and Figure 8-51).  Both treatment 


















Figure 8-51.  Partial pressure of arterial carbon dioxide (PaCO2), mixed venous oxygen content (CvO2) and oxygen extraction ratio (OER) in the BLAST injury 
groups during the Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-hospital and 30 minutes in-hospital).  Group 1 - pre-hospital blood 






There was a significant increase in mixed venous oxygen (CvO2) and a 
significant drop in Oxygen Extraction Ratio (OER) after R60 so that at the 
end of the Primary Treatment Period (R90) both groups had a significantly 
higher CvO2 and lower OER compared to the pre-hospital phase.  There 
was no difference between groups (Table 8-7 and Figure 8-51).   
 
Pre-hospital and initial in-hospital resuscitation raised systolic blood 
pressure and cardiac output for both groups.   Pre-hospital resuscitation in 
both groups stopped the drop in base excess and rise in lactate, and this 
effect continued into the initial in-hospital phase.  The pre-hospital saline 
group displayed a greater acidosis than the pre-hospital blood component 
group during the pre-hospital phase, but this difference did not attain 
statistical significance.  Mixed venous content and oxygen extraction did not 
return toward baseline levels until the in-hospital phase. 
 
 
8.8.3  Haematology – Primary Treatment Period (Blast Groups) 
 
Group 1, receiving pre-hospital blood components, had a small drop in both 












Figure 8-52.  Haematocrit and platelet count (109/l) in the BLAST injury groups during the 
Primary Treatment Period (90 minutes of resuscitation; 60 minutes pre-hospital and 30 
minutes in-hospital).  Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-
hospital saline.  Mean values ± SEM. 
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The saline-treatment Group 2, had a significant decrease in haematocrit by 
the end of the pre-hospital phase (R60) compared to Group 1, and this 
difference persisted at R90 (P = 0.002).   
 
Platelet count dropped significantly for both groups by R90 with no 
difference between groups (P = 0.921; Table 8-7 and Figure 8-52).  At the 
end of the Initial Treatment Period Group 1 receiving pre-hospital blood 
components had little change in haematocrit in contrast to Group 2, which 
showed a significant drop. 
 
 
8.8.4  Fluids – Primary Treatment Period (Blast Groups) 
 
The fluid used in each group for the different phases of the Primary 
Treatment Period is illustrated in Figure 8-53 and 8-55; sub-divided into the 
pre-hospital and (early) in-hospital phases.  Compared to Group 1 (pre-
hospital PRBC:FFP), the other Group (2; pre-hospital saline) required a 
greater volume of fluid in the pre-hospital phase (P = 0.007; Figure 8-53) 














Figure 8-53.  Total volume of fluids given to each group in the pre-hospital phase (between 
S30 and R60) for BLAST groups.  Group 1 - pre-hospital blood component resuscitation.  













Figure 8-54.  Total volume of fluids given to each group in the early in-hospital phase 
(between R60 and R90) for BLAST groups.  Group 1 - pre-hospital blood component 



















Figure 8-55.  Cumulative volume of fluids given to each group in the Primary Treatment 
Period; pre-hospital and early in-hospital phases combined (S2 = 0 min; R60 = 60 min; R90 
= 90min) for BLAST groups.  Group 1 - pre-hospital blood component resuscitation.  Group 




8.8.5  Biochemistry – Primary Treatment Period (Blast Groups) 
 
There was a (significant) reduction in calcium levels in both groups over 
time in the Primary Treatment Period with no difference between groups (P 
= 0.454; Table 8-7 and Figure 8-56).  In the pre-hospital phase calcium 
dropped faster in Group 1 (pre-hospital blood components), with both 
groups illustrating a large drop once in the in-hospital phase (both receiving 
blood components; Figure 8-56).   
 
Potassium levels dropped slightly in both groups by R90 (Table 8-7 and 
Figure 8-56).  Both groups had potassium levels within the normal range, 
although there was a small but statistically significant difference between 
the groups.  
 
By R90, after the use of blood component resuscitation in both groups, 
calcium had dropped to the lower end of the normal range and potassium 







Figure 8-56.  Calcium and Potassium levels in the BLAST injury groups during the Primary 
Treatment Period (90 minutes of resuscitation; 60 minutes pre-hospital and 30 minutes in-
hospital).  Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-hospital 




8.9  Final Treatment Period – Blast Groups 
 
The results for all parameters for the remaining (late) in-hospital phase is 







Table 8-8.  Animal data; R210 (end of Late In Hospital Phase and Final Treatment Period) 






8.9.1  Coagulation – Final Treatment Period (Blast Groups) 
 
The abnormal clotting values for the saline-treatment Group 2 returned 
towards baseline levels by R210 (Table 8-8 and Figure 8-57 and 8-58).  
Higher times in the pre-hospital blood group for both K and R times at R210, 
meant that the difference between them was not significant secondary to 
one animal having an increase in both parameters in its last blood sample.  
That animal had achieved its targeted blood pressure and had recovered its 
acidosis and was not in receipt of a significant bolus of saline pre-blood 
sample, so this value cannot be easily explained.  Despite this result there 
was noted to be a significant difference in pattern between the groups in 
both parameters for the resuscitation period (P < 0.001; Table 8-8 and 
Figures 8-59 and 8-60), with the saline-treatment group having longer times 
in the Primary Treatment Period.  In similarity with other periods MA width 
did not change in either group (as per previous periods), with no difference 
between groups (P = 0.057).   
 
The aPTT times for Group 2 (pre-hospital saline) changed in a similar 
manner to the TEG K and R times with a trend towards returning to baseline 
levels by R210 (Table 8-8 and Figure 8-61).  In parallel with R and K times, 
although the levels in Group 2 were higher than Group 1 throughout, these 
differences did not achieve significance. 
 
PT showed a different pattern of response over time in both groups (Figure 
8-62).  There was a significant rise in PT with the early (pre-hospital) 
elevation being significantly greater in the saline group resulting in a 
significant difference between groups (P < 0.002) over time.  However, 
unlike the other parameters PT did not return towards baseline in either 
group during the in-hospital phase although the rate of rise did decline 
especially in the group previously treated with saline.  Similar to the sham 
groups, these elevated PT results were just outside the 95% reference 






















Figure 8-57.  TEG R time (clot initiation), K time (clot dynamics) and MA (clot strength)	in the BLAST injury groups for the Final Treatment Period.  Group 1 - 























Figure 8-58.  PT, aPTT and Fibrinogen in the BLAST injury groups during the Final Treatment Period.  Group 1 - pre-hospital blood component resuscitation.  






Group 1 (pre-hospital blood component resuscitation) had little change in 
fibrinogen throughout the final treatment period, in contrast to Group 2, 
which showed a small elevation in Fibrinogen levels back toward the normal 
range.  
 
Despite continued blood component resuscitation the pre-hospital saline 
Group 2 fibrinogen levels remained less than the other group throughout the 
investigation with a significant difference between the groups in all statistical 
parameters (P ≤ 0.050; Table 8-8 and Figure 8-63). 
 
The clotting changes - as measure by TEG R and K times, aPTT and 
fibrinogen - that were developed by Group 2 (pre-hospital saline) in the pre-
hospital phase and lasting into the initial in-hospital phase resolved after 60 
to 90 minutes of in-hospital blood component resuscitation.  These changes 
were significantly different from Group 1 as measured by difference in 




















Figure 8-59.  TEG R time (clot initiation) in the BLAST injury groups.  Group 1 - pre-hospital 

















Figure 8-60.  TEG K time (clot initiation) in the BLAST injury groups.  Group 1 - pre-hospital 



















Figure 8-61. aPTT in the BLAST injury groups.  Group 1 - pre-hospital blood component 

















Figure 8-62.  PT in the BLAST injury groups.  Group 1 - pre-hospital blood component 

















Figure 8-63.  Fibrinogen in the BLAST injury groups.  Group 1 - pre-hospital blood 




8.9.2  Physiology – Final Treatment Period (Blast Groups) 
 
Blood pressure targets were maintained for the final period of the 
investigation (Table 8-8 and Figure 8-64).  Despite being within 6mmHg of 
each other throughout the investigation, there was a statistically significant 
difference between the groups, which is probably not physiologically 
important.  The remaining cardiovascular physiology measurements 
plateaued during this period and remained at the same levels as those at 
R90.  There was a significant difference in heart rate (HR) for the 
resuscitation period (P = 0.013; Figure 8-65) which, can be attributed to the 
lower HR observed for the majority of the Primary Treatment Period in the 
pre-hospital saline group.  Group 2 having started to receive blood 
components in-hospital exhibited a surge in cardiac output at this transition 
and consequently there was significant difference between groups for 

















Figure 8-64.  Systolic Blood Pressure in the BLAST injury groups.  Group 1 - pre-hospital 



















Figure 8-65.  Heart Rate in the BLAST injury groups.  Group 1 - pre-hospital blood 


















Figure 8-66.  Cardiac Output in the SHAM injury groups.  Group 1 - pre-hospital blood 




Throughout the remaining in hospital phase the trend for less negative ABE 
in Group 1 (pre-hospital PRBC:FFP) endured as both groups returned 
towards baseline levels, although the difference was not enough to obtain 
statistical significance (see Table 8-8 for P values and Figure 8-67).  Lactate 
levels were significantly different, but not physiologically different for values 
with no statistical difference in the pattern between groups (P = 0.831; 
Figure 8-68). 
 
At R210 the values of PaO2 and PaCO2 were similar between both groups, 
however over the whole resuscitation period there was a statistically 
significant difference in patterns over time between the groups in PaCO2 (P 
< 0.003; Table 8-8).  The majority of this difference occurred in the pre-
hospital phase where the saline-treatment Group 2 had a consistently lower 
PaCO2 (Figure 8-69) probably caused by a greater respiratory 


















Figure 8-67.  Arterial Base Excess in the BLAST injury groups.  Group 1 - pre-hospital 



















Figure 8-68.  Arterial Lactate in the BLAST injury groups.  Group 1 - pre-hospital blood 


















Figure 8-69.  Partial pressure of arterial carbon dioxide (PaCO2) in the BLAST injury 
groups.  Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-hospital 
saline resuscitation.  Mean values ± SEM. 
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The OER and CvO2 levels remained similar to that at R90 throughout the 
Final Treatment Period with no difference between groups in either 




















Figure 8-70.  Oxygen Extraction Ratio in the BLAST injury groups.  Group 1 - pre-hospital 





In-hospital blood component resuscitation to a normotensive goal improved 
cardiac output and reduced the degree of shock.  The group receiving pre-
hospital saline displayed a greater degree of shock that then returned 






8.9.3  Haematology – Final Treatment Period (Blast Groups) 
 
During the remaining in hospital phase with both groups receiving blood 
component resuscitation, there was little change in haemoglobin (Hb) and 
haematocrit (Hct) from R90.  Both groups remained at a significantly lower 
level than baseline (P < 0.001, change over time) with a significant 
difference in pattern over time between groups (P < 0.001) secondary to the 
significant drop in both Hb and Hct in the pre-hospital phase for the saline 
resuscitated group (2).  This difference remained throughout the in-hospital 
phase despite blood component resuscitation (Figure 8-71).  
 
Platelet count remained lower than baseline in both groups (P < 0.001) with 



















Figure 8-71.  Haematocrit in the BLAST injury groups.  Group 1 - pre-hospital blood 



















Figure 8-72.  Platelet Count in the BLAST injury groups.  Group 1 - pre-hospital blood 




Throughout the investigation both groups showed a drop in haematocrit and 
haemoglobin with the pre-hospital saline group having lower levels of both 
parameters throughout, particularly in the pre-hospital phase.  Platelet count 
dropped steadily and similarly in both groups throughout the study period.  
 
 
8.9.4  Fluids – Final Treatment Period (Blast Groups) 
 
The total fluids given in hospital are illustrated in Figure 8-73 and the 
cumulative fluids given to each group are illustrated in Figure 8-74.   
 
For the Final Treatment Period, there was no significant difference between 
the volumes of fluid each group received (P = 0.215).  However, for the 
whole resuscitation period Group 2 (pre-hospital saline) received a 
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significantly greater volume of fluids than Group 1 (P < 0.001), but the total 













Figure 8-73.  Total volume of fluids given in the in-hospital early and late phases for BLAST 
injury groups.  Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-
















Figure 8-74.  Cumulative volume of fluids given to each group for BLAST injury groups.  
Group 1 - pre-hospital blood component resuscitation.  Group 2 - pre-hospital saline 




Group 2 (pre-hospital saline) received a significantly greater volume of fluids 
in total as a consequence of the significantly greater (P = 0.007) volume of 
saline received in the pre-hospital phase. 
 
 
8.9.5  Biochemistry – Final Treatment Period (Blast Groups) 
 
For the in-hospital phase Group 2 (pre-hospital saline) received blood 
components at a higher rate than the other group.  As a consequence that 
group had a significantly higher potassium level (P = 0.001) and a lower 
calcium level than the Group 1.  The difference in calcium levels did not 

















Figure 8-75.  Calcium levels in the BLAST injury groups.  Group 1 - pre-hospital blood 











This investigation produced an animal model of trauma coagulopathy in a 
severely injured, hypotensive casualty with evidence of shock that required 
pre-hospital resuscitation in order to sustain life on the way to the hospital.  
The injury sustained was a significant blunt tissue injury (representing a 
ballistic injury), controlled haemorrhage and haemorrhagic shock with or 
without a primary blast injury.  Resuscitation was carried out successfully to 
set, clinically relevant goals in separate pre-hospital and in-hospital phases, 
resulting in 100% survival in all groups. 
 
The principal finding of this study is that the use of blood components for 
pre-hospital resuscitation attenuates the coagulopathy developed by a 




9.1  Coagulation 
 
For severe injuries and haemorrhagic shock in the absence of blast, the 
pre-hospital blood component group developed no coagulopathy compared 
to the saline group as measured by viscoelastic techniques.  A full 60 to 90 
minutes of hospital based, aggressive, blood component resuscitation was 
required to return the coagulopathy developed by the pre-hospital saline 
group to normal.  In contrast these injuries plus an additional primary blast 
injury had a significant impact on both resuscitation groups, with the pre-
hospital blood component resuscitation group showing a tendency to a 
lesser coagulopathy.   
 
Overall the impact of blood products is qualitatively similar in both blast and 
sham strands; it attenuates the coagulopathy seen in the saline treated 
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group, although the difference after blast is somewhat less due to the 
greater impact of blast on coagulation.  
 
The coagulopathy developed was observed to be predominantly due to clot 
initiation and amplification (TEG R and K times) suggesting a potential 
deficiency in clotting factors and/or fibrinogen.  aPTT levels were raised at 
the same time points; indicating a reduced level of clotting factors (FII, FV, 
FVIII, FIX, FX, FXI, FXII) or fibrinogen.  A noticeable drop in fibrinogen was 
noted in all groups, with both pre-hospital saline groups having the greatest 
decline to a significantly lower sub-normal level.  The nadir of the fibrinogen 
levels mirrored the timings of the worst phase of the coagulopathy.    
 
In accordance with previous work on trauma coagulopathies, a reduction in 
fibrinogen is a consequence of the Acute Traumatic Coagulopathy (ATC) 
secondary to the actions of the activated protein C (APC) pathway (Brohi 
2008, Floccard 2012).  The lowest fibrinogen levels reached by the pre-
hospital saline group were similar to the levels found in previous human 
studies on fibrinogen and ATC where it was associated with increased 
mortality (Rourke 2012).   
 
The drop in fibrinogen levels and platelet counts observed in all groups 
approached clinically relevant levels by hospital admission and reinforces 
the guidance given in military (CGOs) and civilian (Rossaint 2016) 
resuscitation practice that both of these should be supplemented early in a 
trauma casualty’s in-hospital resuscitation, particularly if that patient has 
received pre-hospital saline.  There is a mounting argument for pre-hospital 
fibrinogen supplementation in severely injured patients.  
 
The raised aPTT observed is in all probability secondary to reduced 
fibrinogen levels, rather than consequent to a lack of clotting factors.  A 
factor deficiency would have been indicated by a change in both PT and 
aPTT.  Although PT did change, this was initially small.  A steady escalation 
in PT followed, reaching its maximum at the end of the investigation, when 
all groups’ coagulation as measured by all other parameters had returned to 
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normal.  If studied in isolation this would suggest there might have been a 
steady reduction in clotting factors in all groups, but this was not reflected in 
the other coagulation parameters.  Although this would be a trend requiring 
monitoring, this appears to be a clinically unexceptional finding in view of 
the fact that the PT remained within or very close to the normal range at all 
times.  As the continued rise in PT across the investigation period had no 
impact on the other coagulation parameters, this infers that if a clotting 
factor deficiency was present, its part in the coagulopathy was minor.  
 
More remarkable was the results of a parallel investigation in the same 
model using pre-hospital PRBC only (Watts 2015), where it was found that 
the use of PRBC alone in the pre-hospital phase was as effective as 
PRBC:FFP in avoiding a coagulopathy.  This finding is consistent with the 
concept that tissue hypoperfusion and reduced oxygen delivery cause an 
endotheliopathy, an early driver for Acute Traumatic Coagulopathy (Brohi 




9.2  Physiology 
 
Secondary, but related findings pertain to the physiological state of the 
animals.  All groups developed a significant degree of shock during the pre-
hospital phase as illustrated by a distinct drop in base excess and elevated 
lactate levels.  Oxygen extraction was maximal in all groups in the pre-
hospital phase with an equally high oxygen extraction ratio (OER) and low 
mixed venous oxygen content in all groups, suggesting the low blood flow 
state that occurs in pre-hospital resuscitation is the limiting factor for oxygen 
delivery, rather than blood oxygen content.  Again the parallel PRBC only 
investigation (Watts 2015) produced interesting results for non blast injuries 
where the shock burden was greater for PRBC only resuscitation compared 
to PRBC:FFP resuscitation; an ostensibly counter-intuitive result as the 
higher oxygen carrying capacity fluid was associated with a greater shock 
burden.  Although oxygen delivery to reduce the effects of hypoperfusion is 
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vital, it is not the only component involved in reversing the coagulopathy.  
Plasma may have a beneficial effect on the microvasculature, feasibly via 
an action on the endothelial glycocalyx (Pati 2010, Kozar 2011, Torres 
2013, 2014).  This function of plasma, independent of individual clotting 
factors appears to reduce the endothelial inflammatory response in trauma, 
possibly by limiting neutrophil adhesion and leading to a restored glycocalyx 
within hours of plasma transfusion (Barelli 2018), resulting in better 
microvascular flow and hence delivery of oxygen.  A recent study illustrating 
the mortality benefits of plasma only pre-hospital resuscitation (Sperry 
2018) further supports this theory. 
 
The results concur that both oxygen delivery and plasma derived 
endothelial protection is needed to reverse the Acute Traumatic 
Coagulopathy observed in severely injured patients.  Timings aside it 
transpires from this study’s results that both PRBC and FFP are essential 
and equal elements to damage control resuscitation in a 1:1 ratio.  This 
model shows that pre-hospital blood component in a 1:1 ratio resuscitation 
confers benefit extending into relevant in-hospital phases (surgical decision 
making point) even when aggressive resuscitation strategies are used from 
the outset in the in-hospital phase.   
 
Closer examination of the physiology data illustrates that in the absence of 
blast the effect of PRBC:FFP resuscitation has a long lasting effect, 
extending far beyond the coagulation benefit timelines.  The pre-hospital 
saline group continued to have a base deficit and higher lactate beyond the 
period coagulation had returned to normal, despite 2 hours of in-hospital 
blood component resuscitation.  The blast injury pre-hospital saline group 
again displayed a similar pattern in base deficit, but did not achieve 
statistical significance.   
 
Cardiovascular responses were appropriate for the injury challenges 
confronted by each animal.  At times mean arterial pressure (MAP) was 
significantly different between treatment groups despite no difference in 
systolic blood pressure (SBP).  This was most evident in the pre-hospital 
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phase when the sham pre-hospital saline group had a significantly lower 
MAP in in association with a lower cardiac output.  That group in receipt of a 
larger volume of fluid may have had a reduced arterial vasoconstriction 
response to haemorrhage, although if this hypothesis was correct peripheral 
perfusion should have been better within this group.  This was not the case 
as acidosis (arterial base excess) was worse in this group, unless there was 
a local microvascular disturbance present that was not necessarily reflected 
in gross haemodynamics.  The systolic blood pressure targets were 
achieved and the response in heart rate was largely appropriate.  Of interest 
was the significantly lower heart rate in both pre-hospital saline groups in 
the pre-hospital phase, despite similar or lower cardiac outputs.  The 
assumption is that this was secondary to the greater volume of fluid both 
saline groups received during this period.  
 
The sham pre-hospital saline group developed a greater shock burden 
compared to the blood component resuscitation group, the timing of which 
correlated with the coagulopathy.  The acidosis that developed in the pre-
hospital phase in all groups was also associated with a reduced carbon 
dioxide partial pressure (PaCO2).  This is a classic respiratory response to a 
metabolic acidosis: the acidosis stimulates the peripheral chemoreceptors, 
leading to increased ventilation and a reduced PaCO2, and consequently a 
partial respiratory compensation for the metabolic acidosis.  There was a 
significant difference in PaCO2 between treatment groups in both sham and 
blast strands.  Both pre-hospital saline groups had a comparatively lower 
PaCO2 in the pre-hospital phase, at a time associated with a comparatively 
higher level of acidosis in that group, which is consistent with the 
explanation given above.  In the sham strand the saline-treatment group’s 
greater acidosis persisted into the in-hospital phase and concurrent with 








9.3  Effect of Blast  
 
The effect of blast on trauma casualties is not only relevant to military 
physicians, but in an uncertain and increasingly high-risk terror related 
World it is a pertinent subject that civilian physicians need to be cognisant 
of.  The evidence from this study is that blast produces a patient that is 
considerably worse physiologically.  Despite clinically relevant blood 
pressure goals and the use of blood components, those animals exposed to 
blast were worse off, as measured by coagulation and physiological 
parameters.  Not only did this lead to an inability to observe a clear 
statistical difference between groups, but it does raise the question of what 
relevance does this have.  
 
It could be argued that because of the reduced difference between 
treatment groups, and the increased variability due to the blast element of 
the model, this aspect of the study was under-powered.  The obvious way to 
resolve this problem would have been to increase the group sizes in the 
blast strand of the study.  However, after a cost-benefit evaluation (cost in 
terms of animal use and benefit in terms of improving treatment of human 
casualties), it was decided that the additional use of animals was not 
justified.  This was because the effects of blood products in the blast strand 
were qualitatively similar to those seen in the sham blast strand (where a 
clear, statistically and clinically significant, effect was seen); after blast there 
was an indicative trend suggesting that blood products were beneficial in 
exactly the same way as that seen in the sham blast strand, and no 
suggestion of a detrimental effect.  Consequently, it is arguable that the 
current study, taken in its entirety, supports the necessity to give blast-
injured as well as non-blast injured patient groups blood components as 
early as possible.  This conclusion is emphasized by the clinical observation 
that the majority of blast-related casualties are more likely to be suffering 
penetrating ballistic injury from blast, rather than a primary blast injury.  
Unfortunately in the pre-hospital environment there is no way of 
distinguishing the two types of blast casualty except in the most severe of 
circumstances.  Giving blast casualties blood components early will at worst 
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bring with it either a minimal or, at best, clear beneficial consequence and 
as such it would be imprudent not to state that blood products should be 




9.4  Hypercoagulation 
 
One feature of our model was the presence of a self-resolving increased 
coagulation immediately after injury lasting for approximately 30 minutes.  
Hypercoagulability is well recognised in trauma, but normally only 
considered after 24 hours in humans (Selby 2009), although blunt trauma 
casualties have been found to have evidence of pro-coagulation at 2 hours 
(Park 2012).  Animal models have shown it is present after trauma, but 
again usually later in the injury model; 1 hour after injury (Riha 2013, Prat 
2015), 4 to 72 hours after injury (Mulier 2012).  One swine study did find 
similar findings to ours with a reduction in fibrinogen and reduced TEG R 
time within minutes of injury (Duan 2014).  This is an understandable 
reaction by the coagulation system in order to form an adequate clot rapidly 
in response to injury, but there is a suggestion that it may not be appropriate 
in all cases.  There is evidence that ballistic and blast casualties have a high 
incidence (9.3%) of abnormal pulmonary thrombus (Lundy 2013).  The 
incidence of later diagnosed Pulmonary Embolus is similar in certain 
populations (13% in military amputees; Palm 2012).  This study’s results 
suggest a foundation for this thrombo-embolic occurrence and so we must 
be wary of the pharmacological manipulation of the fibrinolytic system in 




9.5  Comparative Studies  
 
The results of our study are in agreement with a recent observational 
clinical study that compared pre-hospital transport platforms, one of which 
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used plasma and red cells in a 1:1 ratio, the other using crystalloids 
(Holcomb 2015a).  The patients receiving pre-hospital blood components 
had a statistically significantly improved physiological status (less base 
deficit) and a reduced volume of pre-hospital fluids required.  The 
investigators found no difference in coagulation status, as measured by 
TEG, however.  An explanation for this is the degree of shock their patients 
were in was not pronounced (ABE of -3 mM) and much less than in our 
study (-10 to -15) and less than that found in Helmand (-5 to -14; Morrison 
2013a).  
 
Equal ratios of plasma to red cells have been investigated in the hospital 
setting showing an improved 6-hour survival (PROMMTT – Prospective 
Observational Multicentre Major Trauma Transfusion; Holcomb 2013, del 
Junco 2013) and fewer deaths from exsanguination at 24 hours (PROPPR – 
Pragmatic Randomized Optimal Platelet and Plasma Ratio; Holcomb 
2015b), but evidence of clear longer term mortality benefits have been 
lacking in part due to trial constraints and timing of death in severe trauma.  
Our study did not investigate the longer-term mortality benefits, but 
concentrated on the early benefits of blood products and is therefore in 
agreement with these other studies findings and comments, despite them 
being from a civilian hospital setting. 
 
Military trauma casualties treated for a potentially prolonged time in the pre-
hospital space are arguably at greater risk of death.  This study was carried 
out to investigate a set pre-hospital time and challenges that can occur in 
this environment.  A more military relevant investigation has been 
completed recently, the findings of which are in agreement with our findings.  
It was a retrospective cohort study of pre-hospital blood product transfusion 
of over 500 military combat casualties in Afghanistan (Shackelford 2017) 
and therefore is the most relevant translational study associated with this 
animal study.  Timelines, capability, blood component or saline resuscitation 
and indeed treatment by MERT-E are all features of Shackelford’s study.  
By matching non-recipients of blood components to balance factors such as 
injury severity with recipients, they were able to show that pre-hospital blood 
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9.6  Model Limitations 
 
9.6.1  Coagulation Differences 
 
It is acknowledged that the coagulopathy observed in this model is not 
identical to that observed in humans.  There are key similarities with 
variation in R times and aPTT (and to some extent PT) in addition to a drop 
in fibrinogen.  Overt fibrinolysis was not observed, nor the reduction in MA 
width one would expect (despite a drop in fibrinogen) with Acute Traumatic 
Coagulopathy (ATC).  The greater proportion of similarities though suggest 
the model produced an abnormal coagulation state secondary to the 
trauma, rather than any other potential cause, such as dilution.  The 
resuscitation was conducted to meet defined, clinically relevant, 
hypotensive targets in the pre-hospital phases and limit the volume of fluid 
infused to a minimum required to sustain life.  During model development 
failure to provide this fluid was incompatible with survival.  Crystalloid was 
used in the immediate post-injury shock phase and in the control groups for 
the pre-hospital phase because this is still in widespread use.  This 
produced a degree of haemodilution (drop in haematocrit), which is valid, as 
it represents the dilution present in current pre-hospital crystalloid 
resuscitation regimes.  This dilution must be interpreted in context with other 
animal models.  In Group 3 (sham, pre-hospital saline) it amounted to 
approximately ⅔ of the remaining blood volume.  By contrast a recognised 
model published by Cho (2009) infused over 4 times the end haemorrhage 
blood volume.  The coagulopathy observed in this study may have an 
element of dilution, but comparatively it is not an all-consuming degree of 
dilution.  It is likely that the coagulopathy observed had a dilutional element 
present, but the volume of fluid given was kept to a minimum compatible 
with sustaining survival using relevant hypotensive resuscitation targets.  
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The results of this study are therefore relevant to a situation where a 
severely injured casualty demands limited resuscitation to sustain life prior 
to evacuation to a hospital and is therefore relevant to not only military 
battlefield casualties but also some civilian trauma victims.  
 
 
9.6.2  Biochemical Differences 
 
The biochemical changes that occurred in all groups did not reflect those 
commonly observed in damage control resuscitation.  Potassium was 
observed to rise after injury, but did not make significant changes with blood 
component resuscitation.  This difference from human clinical practice may 
be partly secondary to the short storage time for the blood used (48-72 
hours).  Calcium dropped steadily with resuscitation reaching levels of 
almost 1.0 mM by initial hospital admission.  The resultant rise in levels 
despite ongoing blood component resuscitation in all groups was 
unexpected.  It is possible porcine calcium homeostasis is more efficient 
than humans and the levels observed in this study were a reflection of rate 
of resuscitation and the resulting homeostatic balance of calcium levels.  
When confronted with a high level of infusion (end of pre-hospital and start 
of in-hospital phases), calcium levels dropped more rapidly.  Calcium levels 
rose again once infusion rates diminished again (remaining in-hospital 
phase).  The cause of calcium reduction in relation to pre-hospital saline 
resuscitation cannot be easily explained.  
 
 
9.6.3  Equipment Used  
 
In this investigation thromboelastography was the method of choice for 
clotting assessment for a number of reasons.  Viscoelastic testing is 
considered by many to be superior to conventional laboratory tests (PT, 
aPTT) in both pigs (Martini 2008) and humans (Veigas 2016, Roullet 2018) 
when investigating haemorrhagic shock and trauma related coagulation 
abnormalities.  The ROTEM®delta is the Defence Medical Services prime 
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choice in this role; its inflexibility of operation precludes ease of use in 
laboratory based research.  Thromboelastography fulfilled this role in our 
investigation facilitating the ability to investigate different activation 
compounds in the pilot study.  Reassuringly however aPTT gave a similar 




9.6.4  Animal Model 
 
There are limitations to the study described in this thesis.  It is animal-
based, and differences as well as similarities to the human response need 
to be acknowledged.  The hemodynamic response to trauma is broadly 
similar between humans and pigs and as such it is a widely acknowledged 
model for human trauma, with the porcine splenectomy removing the 
capacity to autotransfuse splenic blood.  Although there are similarities in 
clotting between pigs and humans, there are also important differences, 
e.g., uninjured pigs are hypercoagulable compared with humans.  These 
differences are important when evaluating some of the specific component 
therapies, but they do not exclude the general deductions that can be 
concluded regarding patterns of changes described in this report.  Caution 
must always be exercised when comparing between species; patterns of 
response rather than absolute numerical values should be compared.  It is 
notable in the present study that the coagulopathy was characterised on the 
basis of clot initiation and dynamics, but no change was seen in clot 
strength despite a fall in fibrinogen and a marked coagulopathy developing 
based on the other parameters.  The solution to these limitations of animal-
based studies is to triangulate results between species and always make 








9.7  Model Improvements 
 
The inability to find a significant difference between the different groups in 
the blast arm for coagulation parameters despite the saline resuscitation 
group showing a trend for a coagulopathy was unsatisfactory.  Data from 
one animal was missing as a consequence to equipment failure.  The 
impact of this missing data meant a lack of power in the statistical analysis 
and significance was not achieved.  Keeping the number of animals to the 
minimum number required in order to complete the study is a valid and 
ethical decision.  However the potential for equipment failure or other 
complications must be kept in mind and consideration of investigating 
additional animals to allow for this should be heeded.  
 
The coagulation parameters investigated could be enhanced so that specific 
aspects of Acute Traumatic Coagulopathy can be fully examined.  Use of 
ROTEM and its additional assays could provide additional information on 
fibrinogen (FIBTEM) and fibrinolysis (APTEM).  The addition of simple 
additional tests could elucidate further information on fibrinolysis such as 
fibrin degradation product (FDP) measurement.  Assessing specific clotting 
factors levels could assist in the determination of the specific causes of 




9.8  Future Studies 
 
There has been a recent change in military campaigning with a move away 
from sustained conflict by large numbers of troops to smaller Units 
deploying to more isolated locations.  The impact on medical care will be 
the need to care for severely injured casualties in a resource-constrained 
environment for prolonged periods.  Henceforth it is imperative to 
investigate how these patients can be resuscitated and their life sustained 
for prolonged periods prior to surgical intervention.  Can adequate pre-
hospital resuscitation take place for 3 or more hours with a severely injured 
	
	 289	
casualty and how can the medical team realistically monitor the 
effectiveness of their resuscitation strategy?  If logistical support is inhibited, 
the fluids and medications used in that resuscitation need to have a reduced 
logistical impact, being free from temperature constraints.  Resuscitation 
using only stable, easily stored compounds should be investigated; 
lyophilised plasma and fibrinogen concentrate with appropriate adjuncts 
such as tranexamic acid or rFVIIa.  Indeed a valid austere logistically 
contested study would be to look at the effects of using tranexamic acid and 
fibrinogen (Fibrinogen Concentrate) only as a resuscitation regime.  
In view of the current and increasing interest in its use in trauma, there 
should also be a place to investigate the use of fresh whole blood (FWB) as 
either an adjunct or as a sole resuscitation fluid.  There is no better storage 
medium for blood components than within the donor, and its use would 
result in the removal of a significant logistical burden. 
 
A follow up study should be performed using the animal model developed 
for this study and adapt it to encompass the effects of prolonged pre-
hospital timings, the use of basic markers to aid resuscitation (arterial base 
excess) and using resuscitation regimes that are purely lyophilised or use 
FWB as a sole resuscitation fluid, compared to PRBC and FFP in a 1:1 
ratio.  The potential investigation of inflammatory biomarkers may give an 
indication of subsequent complications related to the inflammatory system 




9.9  Summary 
 
The impact of blood products appears to be qualitatively similar in both blast 
and sham blast casualties in that it attenuates the coagulopathy observed in 
a saline treated ballistic injury group with the use of blood pre-hospital 
components.  The difference after blast is somewhat less due to the greater 




The findings of this study are relevant to civilian pre-hospital providers 
particularly if they can overcome the logistical challenges of providing blood 
components outside of the hospital environment.  In conclusion, this study 
provides evidence that the use of pre-hospital blood products (PRBC and 
FFP in a 1:1 ratio) confers an advantage compared with the old standard of 
care (limited crystalloid administration).  This resuscitation regime supports 
a treatment strategy that was started pragmatically by clinicians (MERT) in 
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